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Abstract 
Currently, there are no pre-clinical diagnostic tests to test for devil facial tumour disease 
(DFTD). This disease is a contagious cancer that has spread through the population of 
Tasmanian devils over 60 % of the island of Tasmania. The disease appears to always 
prove fatal and has decreased the overall population of Tasmanian devils by 84 %.  
This research investigated the potential of three mass spectrometry techniques to identify 
changes in the serum metabolome between DFTD and non-DFTD wild Tasmanian devils. 
Initially, a pilot study was conducted using a set of Tasmanian devil serum samples 
obtained from a total of 16 DFTD or non-DFTD devils to investigate the different mass 
spectrometry techniques. The serum was obtained from both males and females over the 
course of one year from locations in the Eastern half of Tasmania in known DFTD regions. 
One of these techniques examined the metabolites directly with mass spectrometry (MS) 
using electrospray ionisation - quadrupole – time of flight – mass spectrometry (ESI-MS). 
The other two techniques examined, capillary electrophoresis – mass spectrometry (CE-
MS) and gas chromatography – mass spectrometry (GC-MS), involved the separation of 
metabolites prior to MS detection. The CE-MS method was unable to detect as many 
compounds as the other two methods so only the ESI-MS and GC-MS techniques were 
investigated further.  
The ESI-MS and GC-MS techniques were used to examine the metabolites in three 
separate sets of samples obtained from wild Tasmanian devils that contained increasing 
amounts of sample variability using principal component analysis (PCA). Using the set 
with the least sample variability, both of the methods were successful at showing 
variability between all of the non-DFTD and all of the DFTD samples. Each of these two 
techniques was also able to classify devils with DFTD up to six months prior to visible 
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tumours and this ability to identify DFTD devils pre-clinically continued with the other 
sample sets.  
The ESI-MS method was used to analyse a set of ~100 samples obtained from male devils 
in the Forrester Peninsula. This method provided a sensitivity of 66 % and a specificity of 
80 %. The lower sensitivity was caused by uncertain classification of 6 of the DFTD 
samples and one DFTD sample incorrectly classified as non-DFTD. Unfortunately, 
because of the contagiousness of DFTD, all of the blinded samples in this sample set either 
had other diseases or developed DFTD within 12 months so the suitability of diagnosing 
healthy devils could not be determined.   
The final sample set examined included samples from both male and female devils 
obtained from locations throughout Tasmania. The results were improved by separating 
the samples according to gender. When the female samples were analysed, a sensitivity of 
95 % was obtained using both methods, with specificities of 80 and 72 % for the GC-MS 
and ESI-MS method respectively. The PCA results for the male samples were not as 
successful at showing variability between the DFTD and non-DFTD devils which may 
have been caused by the bias in the sampling locations of the male DFTD devils.    
The results showed the presence of changes in the serum metabolome of DFTD Tasmanian 
devils that appear prior to clinical signs of the disease. With the correct validation, these 
methods could be used to diagnosis DFTD up to at least 6 months prior to clinical signs.
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1 Introduction 
Early diagnosis of contagious diseases has the potential to reduce the universal impact of 
the disease by quarantining infected individuals to provide treatment; and limiting the 
spread of the disease [1, 2]. Devil facial tumour disease (DFTD) is a fatal contagious 
cancer that has dramatically reduced the population of Tasmanian devils [3]. This unique 
creature is endemic to Tasmania and its presence at the top of Tasmania’s food chain 
cements its ecological importance [4].  The low genetic diversity of Tasmanian devils [4] 
has allowed DFTD to develop into a contagious cancer that is spread by allograft transfer 
(cell-to-cell transfer between individuals of the same species) [5, 6]. A pre-clinical test for 
DFTD would allow for the isolation of DFTD-positive devils potentially before the tumour 
can spread to other individuals.  
The majority of devils affected by this devastating disease are in the wild since devils in 
captivity are generally not exposed to infected individuals. The choice of sample obtained 
for diagnosis, therefore, needs to be relatively easily obtained from wild devils. Blood 
samples from trapped wild Tasmanian devils can be routinely obtained via an ear prick to 
obtain blood serum irrespective of whether they have observable tumours. This relatively 
easily obtained sample then has the potential to be used to screen for DFTD biomarkers. 
The successful development of a diagnostic blood test that examines DFTD specific 
biomarkers could be used in two ways to aid in the survival of this iconic creature. Firstly 
it could be used to eliminate DFTD devils from a wild population to reduce the spread of 
DFTD, and secondly, devils that have been obtained for insurance populations could be 
tested to ensure that they do not have the disease before allowing interaction with other 
non-DFTD devils.  
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1.1 Biomarkers and Diagnostic tests 
Much research has been undertaken in biomarker discovery due to the potential for 
biomarkers to be used in the diagnosis of disease prior to other clinical signs [7-10]. 
Biomarkers are biological molecules that can show biological processes and pathological 
states of individual organisms. These biomarkers can then be used to determine if that 
individual is healthy, diseased [11] or pre-disposed [12] to a disease. In the case of disease 
diagnosis, biomarker profiles of body fluids may be used for diagnosis before the 
discernment of other clinical signs of the disease [13].  
Biomarkers consist of chemicals from a range of chemical types and include DNA, 
mRNA, proteins and metabolites [11, 14] and these biomolecules can be observed in a 
range of biological fluids. Fluids are generally selected by their ease of accessibility and 
practicality and can be obtained from serum, plasma, whole blood, urine, saliva, sweat, 
ascites fluid, cerebrospinal fluid (CSF), hair or faeces [11, 15, 16]. There are two different 
approaches that can be used in biomarker discovery: targeted and non-targeted. Targeted 
approaches look at specifically known biomolecules; sub-classes of biomolecules such as 
esters or amines; or the metabolites involved in a certain metabolomic cycle. Non-targeted 
approaches examine as many molecules as possible at once so that the complete 
metabolome can be observed [16] and allow for biomarker discovery without prior 
knowledge of the biological pathway of the disease [17]. In the case of metabolites, 
searching for biomarkers using a non-targeted approach requires universal methods that 
have the ability to simultaneously separate and detect metabolites from multiple chemical 
classes [17]. This can be difficult because of the range of physical and chemical properties 
of the different metabolites. One technique is, therefore, not suitable to examine all types 
of metabolites simultaneously [18, 19].  
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1.1.1 Requirements of Diagnostic Tests 
During the development of diagnostic tests there are many factors that need to be 
considered. It is important that the disease biomarker profile identified is specific to the 
disease; and has high specificity (ability to identify non-diseased individuals) and high 
sensitivity (ability to detect diseased individuals) to be useful [11]. The design of 
biomarker discovery studies must carefully consider other variations that can cause 
biomarker differences between individuals such as when the subject last consumed food, 
their diet, age, genetics, local environment, gender and reproductive cycle [16, 20, 21].  
These factors can all affect the presence, absence and even the concentration of 
metabolites and other biomolecules [11, 22]. Appropriate validation of biomarkers, 
therefore, requires a large number of samples that come from both diseased and healthy 
individuals to ensure that differences observed between individuals with and without the 
condition are being identified and not symptoms of another affect [11]. For example, 
studies looking for disease metabolite biomarkers in saliva, conducted by Sugimoto and 
colleagues showed some situations where race or gender could affect the differences 
observed between healthy and diseased samples [23]. Metabolites are often chosen for 
biomarker discovery studies because they show biological changes more readily than other 
biomolecules for example, proteins [24]. Changes in metabolite profiles have already been 
observed in ovarian cancer [7], breast cancer [23] and prostate cancer [10]. 
1.1.2 Metabolomics 
Metabolites are molecules of small molecular weight (generally less than 1500 Da) that are 
products from metabolic processes which occur as part of normal function, maintenance 
and growth of an organism [25, 26]. Metabolites include molecules from numerous 
chemical classes [24] and include sugars [27], carboxylic acids (including amino acids) 
[9], amines, esters [28], steroids [29], lipids and nucleotides [24]. They can vary greatly in 
6 
 
molecular weight, polarity and concentration [18], and often vary between 7-9 orders of 
magnitude [30]. Metabolomics is the study of the complete metabolome (the complete set 
of metabolites) [26]. Studies have been conducted on the metabolome of microbes [26], 
animals [26, 31], plants [26, 32] and humans [9] and they are similar across all species 
[21]. Unlike proteomics or genomics, metabolomics allows the study of changes in the 
phenotype of a subject [16] which provides the prospect of early cancer diagnostic tests 
because the metabolomic fingerprints for cancer cells are distinctive [16].  
1.2  Analytical Techniques 
In metabolomics, samples are most commonly analysed using nuclear magnetic resonance 
(NMR) or mass spectrometry (MS). These two methods can also be preceded with a 
separation technique such as liquid chromatography (LC), gas chromatography (GC) or 
capillary electrophoresis (CE) [25]. The majority of techniques that involve separation 
utilise MS detection rather than NMR.  
1.2.1 Nuclear Magnetic Resonance 
NMR is a popular technique for metabolite analysis that has been used since the early 
1970s and is commonly used to examine metabolic profiles of serum and urine samples 
[24, 33]. This technique is fast, non-destructive and requires minimal sample preparation. 
Its  shortfall is that it has poor spectral resolution [34] and low sensitivity when compared 
with MS [15, 35] with a limit of detection for 1H NMR metabolite analysis of around 100 
µM in tissue and biofluids [24]. Resolution and sensitivity in NMR can be improved by 
increasing the magnetic field strengths thus the majority of metabolomic studies are 
conducted at 11.7 Tesla. Resolution is often compromised especially when looking at cells 
or tissues because of the presence of macromolecules, the binding of small molecules in 
the sample and differences in sample composition [34]. NMR is highly reproducible and 
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suitable to directly analyse liquid and solid samples [24, 36]. In one dimensional 1H NMR, 
the technique is only suitable to distinguish between different functional groups that are 
present. For example, this technique is incapable of distinguishing between different sizes 
of lipids and is only able to determine the total amount of saturated lipids in a sample [24] 
but more specific information such as lipid sizes can be obtained when using two 
dimensional NMR [24]. NMR is useful to obtain qualitative data but quantitative data on 
the other hand can be difficult, especially in complex samples such as plasma because of 
overlapping signals from the different components in the sample. Quantitation can also be 
improved by using 2D heteronuclear NMR such as 1H-13C but the lack of natural 
abundance of 13C and poor signal-to-noise ratios, decreases the sensitivity that can be 
obtained using this type of analysis. Sensitivity can be improved using long scan times of 
around10 hours since NMR sensitivity is proportional to the squared-root of the number of 
scans [37]. To improve sensitivity, Gowda et al., developed a heteronuclear NMR method 
using 15N-13C that was able to examine 27 metabolites in plasma within 30 min [37].  
In one study, NMR was used to determine that serum lactate may be a biomarker for 
weight gain in postmenopausal women with breast cancer undergoing chemotherapy. This 
study was conducted because of the higher risk of breast cancer re-occurring in patients 
that increase in weight [38]. A number of NMR studies have also discovered metabolites 
that are significantly altered in breast cancer tumours when compared to healthy tissue 
[16]. Proton NMR (1H-NMR) has been used to identify disease metabolite biomarkers in 
brain tumours and one study has also compared histology results with magnetic resonance 
spectroscopy imaging (MRSI). This MRSI technique allows in vivo studies of metabolites 
without exposure to radiation by combining NMR and magnetic resonance imaging (MRI). 
The study suggested that this technique could be used to obtain more information to 
determine more suitable and precise positions for brain biopsy sites [16]. 
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1.2.2 Mass Spectrometry 
Mass spectrometry (MS) is a more sensitive technique than NMR and can thus provide 
quantitative information for a greater number of metabolites [37]. Mass spectrometry 
techniques have the ability to detect metabolites in the order of 100 nM whereas 1HNMR 
only has a limit of detection of 100 µM [24]. 
Many different types of ion sources and MS analysers have been used to look at 
metabolites [26]. Some of the ion sources provide soft ionisation which produces only a 
small amount of fragmentation which decrease the complexity of data when compared to 
other types of ionisation because the m/z ratio of the ionised compounds are generally 
detected rather than the fragmented compounds. These types of soft ionisation include 
atmospheric pressure chemical ionisation (APCI), chemical ionisation (CI) and 
electrospray ionisation (ESI). Types of ionisation sources that do produce mass fragments 
include, atmospheric pressure photo ionisation (APPI) and electron impact (EI) [26]. APCI 
is suitable for polar or semi-polar metabolites. To ionise the metabolites the solution (such 
as the eluent from prior LC analysis) is passed through a tube that is heated ≥ 500 ˚C. The 
solvent is present in excess and these molecules along with the metabolite molecules are 
vapourised within the tube prior to detection with a mass analyser [26]. Chemical 
ionisation involves bombarding the metabolites with gaseous substances such as methane 
or ammonia to transfer charge or ions to ionise the metabolites. Electrospray ionisation 
(ESI) involves passing the solution through a charged capillary (charged between 2-5kV) 
[26] and during this process the solvent evaporates and the droplets formed shrink, 
resulting in charged analytes which are then analysed by a mass detector [39]. Electrospray 
ionisation is suitable for detecting polar molecules but non-polar molecules are better 
examined using APCI [16]. APPI uses photons from UV lamps to inject electrons from 
non-polar molecules to form ions at atmospheric pressure [26]. Electron impact uses 
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electrons to produce positively charged ions at vacuum pressure. The resulting fragments 
from each analyte are very reproducible which aid in identification. This method is usually 
coupled to GC [26]. Another type of ion source is matrix assisted laser desorption 
ionisation (MALDI) [40] which is popular in protein or peptide studies but it has also been 
used to look at metabolites with high molecular weights such as phospholipids in 
mammalian tissue [41]. MALDI involves spotting the sample onto a plate along with a 
matrix solution. When the solvent evaporates the analytes crystallise with the matrix 
molecules. Once the MALDI plate is placed in the mass spectrometer, a laser excites the 
matrix which allows the molecules to partially vaporise which leads to the vaporisation of 
the analytes. In the vapour stage protons are exchanged between the matrix and analyte to 
produce both negative and positive ions. The presence of buffers and salts are less 
problematic when using MALDI compared to ESI. MALDI cannot be analysed on-line 
after chromatographic or electrophoretic separations like ESI can; although automatic 
fraction collections can be conducted after separation onto the MALDI plate prior to 
insertion into the mass spectrometer [39].  
There are also many different types of mass analysers including ion trap, time of flight 
(TOF), quadrupole (Q) and fourier transform ion cyclotron resonance (FTICR). Ion trap 
analysers have the ability to accumulate ions in the device by trapping the ions over time. 
This trapping ability was limited though until the development of linear ion trap 
instruments. Ion trap analysers have lower resolution capabilities than some other types of 
analysers but they do have the ability to conduct multiple-stage sequential MS-MS which 
allows for fragment ions to be further fragmented. This procedure is useful in determining 
post-translational modifications in proteins [42]. TOF analysers operate by measuring the 
time it takes for an ion to move through a tube of a specific length under vacuum. This 
time is then used to deduce the mass-to-charge ratio of the ion. TOF instruments can 
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provide mass accuracies of in the low parts per million range [42]. Another type of 
analyser, Quadropoles, cost less than the other analysers but they also have the lowest 
mass resolution. This instrument involves applying different potentials of direct current 
(DC) and radio frequency (RF) to four parallel rods. The ratio of DC and RF is always 
kept constant and the varying potential is used to select only the ions in the range of 
interest and the ions with a mass-to-charge ratio less or more than the range are not 
analysed by the MS [26]. FTICR has an accuracy of < 1 ppm and resolving power over 
1,000,000 but it has a lower limit of detection than the hybrid Q-TOF analysers [26, 40]. 
FTICR measure the orbital frequency of ions orbiting under ultra-high vacuum and high 
magnetic field strength. The orbital frequency of the ions is dependent upon their mass-to-
charge ratio. FTICR is the most accurate mass analyser currently available and 
consequently the most expensive. The high resolving power that can be obtained using 
FTICR allows for the ability to analyse more complex samples [26, 40].    
Hybrid instrumentation have also been developed that merge two mass analysers together 
such as quadrupole-time of flight (Q-TOF), or triple quadrupole (QQQ) [26]. The merging 
of analysers improves the resolution and accuracy of MS analysers [42]. In Q-TOF 
analysers, the ions are guided with the quadropole and then analysed with the TOF in MS 
mode. In MS-MS mode the ions selected in one quadropole, are fragmented in a second 
quadropole by collision-induced dissociation and then analysed in the TOF [42]. Another 
commercially available instrument which consists of multiple analysers is the triple 
quadropole (QQQ). This instrument is suitable for targeted analysis of metabolites and 
other analytes because knowledge of the analytes is required at the beginning of the 
experiment to determine which ions to fragment and monitor [26].  
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1.2.2.1 Direct Injection Mass Spectrometry 
Direct injection mass spectrometry (DIMS) allows for samples to be analysed in usually 
less than 5 min allowing for a large amount of samples to be analysed quickly [41, 43]. 
Direct injection mass spectrometry can also produce more reproducible results when 
compared to methods using prior separation such as LC-MS because degradation of 
columns can cause changes to retention times in subsequent runs [44]. However, one of the 
limitations of DIMS is that ionisation suppression can occur because of the production of 
droplets when using ESI for example. This phenomenon is caused when less volatile 
components in the sample cause evaporation difficulties which in turn reduce the 
efficiency of droplet formation. This drop in efficiency, reduces the amount of analytes 
that become charged which leads to reduced sensitivity because less ions reach the detector 
[45]. Part of the ionisation suppression can also be caused by components in the matrix 
which may ionise easier than the analytes. This effects and can be reduced using nano-
electrospray [41] or certain sample preparation techniques [46]. Lecchi et al. states that 
simple sample preparation techniques used to remove proteins from blood samples with 
organic solvents can also reduce the amount of inorganic salts and thus reduce the matrix 
affects causing ionisation suppression [47]. Han et al. also showed that sample dilution can 
decrease ionisation suppression and found a 1:100 dilution of mouse serum to be the 
optimum in their FTICR-MS studies to allow quantitative comparison of non-targeted 
metabolite spectrums from mouse serum [43].  
FTICR has also been used to detect over 10,000 components in a petrochemical sample 
which suggests that this technique is well equipped to simultaneously analyse all of the 
mammalian metabolome which is estimated to contain approximately 3000 components. 
The high accuracy allows for more accurate molecular identification because of the precise 
mass to charge ratio that can be obtained [40].  Han et al. used isotopically-labelled 
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internal standards to quantify metabolites from human plasma using non-tandem MS and 
formulas generated from Bruker Daltonics Data AnalysisTM software using the Generate 
Molecular Formula tool. This group also conducted non-targeted metabolite analysis on 
serum obtained from 49 inbred mice involved in an alcohol study. They were able to 
analyse all of these samples in both positive and negative ion mode three times in 
approximately 24 hours. During this study they found 298 metabolites in positive ion 
mode and 133 metabolites in the negative ion mode. If prior sample separation was 
conducted before MS detection this number of samples would have required a number of 
days to analyse [43]. Ritchie et al. used ESI or APCI-FTICR-MS to conduct a non-targeted 
metabolomics search for markers for colorectal cancer using three independent sets of 
serum samples. These sets of samples were obtained from the USA and Japan. The 
researchers identified 44 different metabolites that were capable of distinguishing between 
serum samples from controls and colorectal cancer patients. This shows that metabolite 
disease biomarkers can be indentified when the samples are obtained from different 
geographical areas [48]. This result may not have been as promising if these researchers 
had looked at all three sets together instead of independently, using a subset of the 
complete sample to use as a “training set” for identifying the metabolite differences 
between the controls and cancer patients. Using the complete set of samples though may 
have helped to eliminate changes that occur from other variables such as sampling location 
and diet etc.  
1.2.3 Advantages of Separation Techniques Prior to NMR or MS Detection 
Detection of metabolites using NMR or MS can be improved when an additional technique 
is also employed that looks at different physiochemical properties. This can be done by 
initially utilising a separation technique such as liquid chromatography (LC), gas 
chromatography (GC) or capillary electrophoresis (CE) prior to detection [49]. Further 
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separation using other physiochemical properties can be conducted by analysing with 
multidimensional separation techniques such as GCxGC-MS or LCxLC-MS. This is 
conducted by using separation columns with different types of stationary phases that 
contain different ratios of alkyl groups [26]. All of these techniques can provide 
complementary or further information on metabolites from a range of types of samples 
[15]. 
Improvements with ion suppression can also be achieved with utilisation of 
chromatography or electrophoresis techniques prior to MS analysis by separating the 
components of interest so that they are not eluted at the same time as the less volatile 
components in the sample [25, 45]. 
1.2.3.1 Gas Chromatography – Mass Spectrometry 
Gas chromatography (GC) is a technique that separates volatile compounds according to 
their interaction with the stationary phase (column) and the mobile gas phase [26]. Gas-
chromatography-mass spectrometry (GC-MS) is a very well developed technique which 
was published as early as the 1950s [26] and is now one of the most commonly used 
techniques for metabolite analysis. GC-MS provides good separation efficiency with the 
use of capillary columns and high sensitivity by using MS detectors [41]. 
GC columns can have non-polar or polar stationary phases and the differences in the 
stationary phases of the column determine how the analytes are separated. The analytes are 
primarily separated by the boiling point of the compound when a non-polar stationary 
phase is used but when a polar stationary phase is used the compounds are mainly 
separated by the polarity of the compound [41]. The analytes in the sample interact with 
the column (liquid stationary phase) and the gas mobile phase as the column is heated and 
allows the separation of species in the sample [26].  
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In metabolomic studies GC-MS can also be used in targeted and non-targeted approaches 
[50] and metabolites up to at least 350 Da can be observed [26]. However, a key 
requirement of metabolomics by GC-MS is that the samples need to undergo sample pre-
treatment prior to injection into the GC. One approach is to use solid phase 
microextraction (SPME) which is an equilibrium processes to extract analytes from a 
sample but using SPME for multiple samples carries a high risk of sample carryover. To 
desorb the sample from the SPME syringe into the GC column cryofocusing is required 
because the analysis needs to start at low temperatures to give enough time for the sample 
to enter the column. To successfully use this technique with samples such as plasma, the 
majority of proteins need to be removed and the analytes of interest must be highly 
volatile. The presence of polymers, for example proteins, and non-volatile analytes not 
present at high concentrations are not suitable for SPME [51]. An alternative approach to 
remove proteins and matrix ions from a sample off-line is via protein precipitation with 
organic solvents [52, 53]. 
Many metabolites are not volatile and these can be analysed by GC with prior chemical 
derivatisation. This is generally performed using alkoxyamines and N-methyl-N-
trimethylsilyltrifluoroacetamide (MSTFA). Alkoxyamine stabilises sugars by converting 
the carbonyl groups to oximes in the open-chain conformation. The alkoxyamine is also 
used to prevent decarboxylation in α-ketoacids. The alkoxyamine reaction is conducted 
first so that the active hydrogens from acids, alcohols and amines are substituted with a 
trimethylsilyl group via a silylation agent such as MSTFA in a subsequent derivatisation 
reaction [41]. This type of two step derivatisation procedure allows for many types of 
metabolites to be analysed such as amino acids, sugars, sterols, carboxylic acids (such as 
fatty acids), lipids, phosphates and alcohols [26]. There are limitations to detect large polar 
molecules with GC-MS even with the chemical derivatisation because steric difficulties 
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make it difficult to modify all of the functional groups with the silylation agent [30]. The 
requirement for derivatisation prior to analysis increases analysis time and cost for this 
method [16] but when compared to SPME, derivatisation of the metabolites has several 
advantages. This method is not disadvantaged if some protein still remains in the sample 
and it allows for an increase in the number of analytes that can be analysed because many 
of the low volatile metabolites become volatile.       
Nishiumi and colleagues examined serum metabolites with GC-MS to determine 
differences between 9 healthy volunteers and 21 patients with pancreatic cancer. The 
development of a diagnostic test for early stage pancreatic cancer could save many lives 
since 96 % of patients experience mortality within a year of diagnosis because the cancer 
is often diagnosed when it is in an incurable stage. A metabolite library obtained 
commercially from Shimadzu was then used to identify some of the metabolites seen in the 
chromatograms and the researchers were able to identify 60 metabolites. From these 60 
identified metabolites they found 18 to be significantly different using Student’s t-test 
between samples from pancreatic cancer patients and those from the healthy control group. 
Using partial least squares discriminant analysis (PLS-DA), Nishiumi et al. were not only 
able to successfully separate the patients from the healthy samples but they could also 
distinguish between the different stages of pancreatic cancer. They concluded that their 
research showed that metabolites could be used to develop an early stage diagnostic test 
for pancreatic cancer and thus increase the chance of curing the disease in many patents 
but further trials will need to be conducted with a larger sample group [9].  
To increase the number of metabolites that can be identified, methods have been 
developed that use two-dimensional GC with a MS detector (GCxGC-MS) [49]. GCxGC 
is used to increase the peak capacity by using two columns with differing polarities to 
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separate compounds that co-elute when only one column is used which increases the 
number of metabolites that are identifiable [41, 49]. In a study conducted by Welthagen et 
al. 1200 components were seen when using GCxGC-MS but only 500 components when 
they used GC-MS. Increased detection sensitivity can also be obtained using GCxGC-MS 
which allows for smaller amounts of sample to be injected into the system [49].  
It can be difficult to identify all metabolites detected in non-targeted metabolite studies 
because of the number of metabolites that are observed [30]. Part of this complication 
stems from difficulty in obtaining some metabolite standards [30]. Commercial metabolite 
identification libraries can be obtained for GC-MS which makes the technique more 
suitable than others such as CE-MS and LC-MS since libraries for these latter two 
techniques are not yet as widely available [26]. To identify the metabolites without 
commercial libraries, metabolite standards need to be obtained to compare the retention 
time and mass spectrum of the standard with that observed experimentally. When 
metabolite standards cannot be obtained, identification can only be determined by 
manually deciphering the mass spectrum of the analyte. Identification can be difficult if 
the peaks are not well resolved because of the presence of additional peaks in the mass 
spectrum from co-eluting analytes.   
1.2.3.2 Liquid Chromatography – Mass Spectrometry 
Liquid chromatography (LC) is a separation technique that separates analytes according to 
physiochemical properties which are determined by the type of column that is used. Size 
exclusion chromatography uses a column that separates the analytes according to size; and 
ion-exchange chromatography (IC) separates the analytes according to the charge of the 
molecule. Other LC columns such as those used in reverse phase liquid chromatography 
(RPLC) or hydrophilic interaction liquid chromatography (HILIC) separates the analytes 
17 
 
according to how hydrophobic or hydrophilic the analytes are respectively [54, 55]. The 
mode that will be discussed here is RPLC.  
Techniques to examine metabolites using liquid chromatography – mass spectrometry 
(LC-MS) have only recently been developed [16]. Although LC-MS is slower and has 
limited commercial metabolite libraries when compared to GC-MS, it has the ability to 
look at analytes with a greater range of molecular weight and polarity than GC-MS [56] 
without prior chemical derivatisation [15]. However, it can be difficult to separate small 
hydrophilic peptides by LC [56].  
LC when coupled to mass spectrometry (MS) is normally operated in the reverse phase 
(RP) mode because mobile phases used with (RPLC) are suitable at atmospheric pressure 
for ionisation in the MS [57]. Other practical issues to consider when looking at 
biomolecules with LC-MS are that the samples generally require preliminary sample 
preparation prior to analysis by the instrument. The amounts of organic modifier and salt 
also need to be kept low. Excess in organic modifier can cause the samples to be trapped 
on the column and excess salt can cause blockages in the column [56]. Metabolites from 
biological fluids can be difficult to separate by RPLC because many of these compounds 
are very polar and ionic. To counteract these issues HILIC columns have been developed 
which are more apt than RPLC at separating polar compounds [15, 55].  
Yang and colleagues used a non-targeted metabolite approach to discover biomarkers for 
hepatitis B in humans by examining serum metabolites from 50 controls and 37 hepatitis B 
patients. After peak alignment and removal of noise, the peaks were analysed by partial 
least squares discriminant anlaysis (PLS-DA) and this plot was able to clearly separate the 
healthy samples from the diseased. Potential biomarkers were then determined by using a 
formula to determine the Variable Importance in the Projection (VIP) and then examining 
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which of the top 20 analytes determined with this formula were significantly different (p < 
0.05) using Student’s t-test. Examination of the mass spectra data led to the identification 
of 5 metabolites which are also involved in liver function. Further study was required to 
ensure the metabolites identified are biomarkers specific to hepatitis B [18].  
1.2.3.3 Capillary Electrophoresis – Mass Spectrometry 
Capillary electrophoresis (CE) separates components via the mass to charge ratio and is 
therefore suitable to separate polar and ionic compounds which includes many of the 
compounds found in biological fluids [15]. This technique is cheaper and more 
environmentally friendly than other techniques such as LC-MS. The reasons for this 
include limited or no use of organic solvents; using fused silica columns which are 
considerably cheaper than LC columns; and the requirement of very low samples volumes 
(nanolitres) [15]. Greater resolution is obtained in CE when compared to LC when 
electroosmotic flow (EOF) is present because EOF may help to focus the analyte bands 
[41]. The use of low sample volumes and capillaries with a narrow internal diameter 
provides very low pathlengths when detecting with UV which leads to poor detection 
sensitivity when compared to LC. Sensitivity in detection can be improved through the use 
of MS detection and/or using pre-concentration techniques inside the separation capillary 
[15]. There are many different modes of CE that are used to separate components in 
different ways such as capillary isoelectric focusing (cIEF), capillary zone electrophoresis 
(CZE), micellar electrokinetic capillary chromatography (MEKC), or capillary gel 
electrophoresis (CGE). Many of these can be interfaced via ESI to MS but the presence of 
surfactants and polymers in MEKC and CGE are not suitable for connection to MS 
detectors [39]. CZE is the most popular method for analysing metabolites [15] and is the 
most popular method used with CE-MS [39]. The sharp peak profiles that are obtained 
with CE and low sample volume require high-scan-speed mass spectrometers to obtain 
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adequate detection sensitivity. This lack of sensitivity is also intensified further by the 
requirement of sheath flow in CE-ESI-MS which dilutes the analytes further prior to 
detection [19, 41]. 
CE is generally coupled to MS via ESI. The buffers that can be used in CE-ESI-MS need 
to be volatile and are therefore restricted to those comprising chemicals such as acetic acid, 
formic acid, ammonium acetate or ammonium formate. The ionic strength of the buffers 
also needs to be limited when analysing by ESI-MS to limit ionisation (ion) suppression 
[58, 59]. This limitation can cause CE-ESI-MS separations to lack the resolution that is 
seen in CE runs that are conducted with optical detectors [59] since the optimal buffers for 
separation cannot always be used.  
CE-MS has been used to test various metabolites in a range of cases. Sugimoto et al. used 
CE-MS to determine saliva metabolites that could distinguish between oral cancer; 
pancreatic cancer; breast cancer; individuals with periodontal disease; and healthy 
individuals. This study looked at 69 patients with oral cancer, 30 with breast cancer 18 
with prostate cancer, 11 with periodontal diseases and 87 healthy controls. They found 57 
metabolites that were significantly different between the samples from the patients (cancer 
and periodontal disease) and the healthy individuals to the 5 % confidence level using the 
Steel-Dwass test. However, the metabolites that were found to be statistically different 
between breast cancer patients and healthy individuals were not found to be specific to 
breast cancer [23]. Baidoo et al. used pH-mediated stacking to improve sensitivity so that 
the higher-resolution and more accurate FT-ICR MS could be used to detect amino acids 
after CE separation. They tested their developed method by injecting a bacterial lysate 
from the species Desulfovibrio vulgaris and identified 27 metabolites from their mass-to-
charge ratios and chemical standards [19]. A method has also been developed to screen for 
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amino acids and acylcarnitines in dried blood spots for inborn errors of metabolism (IEM). 
Online desalting and sample pre-concentration was conducted through electrophoresis 
since the strong electrolytes migrated thorough the capillary faster than the metabolites of 
interest. These researchers developed a method that allowed for a 1:1 methanol:water 
extraction of the proteins rather than a 100 % methanol extraction to isolate the 
metabolites in the supernatant. When using other techniques such as direct injection ESI-
MS or LC-MS, internal isotope standards or chemical derivatisation are used which are not 
required when analysing by CE-ESI-MS. The absence of isotope standards and chemical 
derivatisation, along with the ability to remove unwanted salts reduces the ion suppression. 
This along with a reduction in solvent consumption reduces the cost of analysis of the 
dried blood spots using this method [60].     
When compared with GC-MS or LC-MS, CE-MS is more appropriate for looking at 
phosphorylated or sulphated small molecules but less suitable for secondary metabolites 
[49]. The small sample volumes and high resolution of CE can decrease the sensitivity of 
MS detection especially when high-scan speed MS instrumentation are not used but low 
solvent volumes and separation of analytes in relatively cheap fused silica capillary makes 
this considerably cheaper than chromatographic methods.  
1.2.3.4 Comparisons of Techniques 
All of the techniques mentioned above are complimentary as they use different 
mechanisms to analyse the analytes in a sample. DIMS provides the quickest method to 
analyse metabolites. This method would be suitable for a quick screening test that could be 
later confirmed with one of the separation methods. Identification of the metabolites with 
DIMS is difficult because information such as retention time provided when separating the 
analytes prior to detection is not obtained. Migration or retention times can provide further 
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information on the structure and type of the chemical, cannot be used to aid in 
identification of metabolites that may have the same mass-to-charge ratio. Peaks of interest 
in DIMS could be further analysed with tandem mass spectrometry which would allow for 
manual identification of the metabolites.  
The availability of commercial libraries and the ability to derivatise non-volatile 
metabolites with GC-MS advocates the advantages that this method has over the other 
methods. Although the relative migration times of analytes is quite reproducible with CE-
MS actual migration times can vary. In non-targeted metabolites it is possible to observe 
10-100’s of peaks. To efficiently analyse the data it is beneficial to produce peak tables 
that allow for automatic integration of peaks. When migration times change, this can be 
difficult.  
These three separation techniques separate analytes using different mechanisms for 
separation so the chemical classes that each are apt at examining differs. When choosing a 
method for metabolomics the method of choice depends on the goal of the study and 
whether or not a specific class of metabolites is being examined. Liquid methods such as 
LC and CE are more suitable when looking at large polar molecules where as GC is more 
suitable to look at the smaller metabolites such as amino acids, other organic acids and 
sugars. Each method will provide different information and in many cases utilising two 
methods will be more beneficial in obtaining the information required for the study being 
conducted. 
A comparison of these three techniques, CE-MS, GC-MS and LC-MS, was conducted by 
Büscher et al. when looking at 75 different metabolites involved in central carbon and 
energy metabolism pathways. The majority of metabolites were polar and there were 
isomers of 16 of the metabolites in addition to the 75 in the sample. As can be observed in 
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Figure 1.1 approximately a third of the metabolites were observed in all methods and only 
three were not observed with any. The two liquid based methods (CE and LC) showed the 
most overlap in respect to the metabolites that were observed with these methods. This is 
likely to be because these methods are suitable to analyse non-volatile components. They 
were all found to have similar sensitivity and ability to examine isomers. The authors of 
this paper showed that LC and CE methods take between 20-60 min to analyse each 
sample but because of the need for chemical derivitisation of metabolites, GC takes 
between approximately 45-90 minutes. Overall the authors suggested that LC was the 
superior technique for the analytes they were studing and could be used complementary 
with GC-MS. This was suggested because CE was less robust and provided similar 
information to the LC methods [30].   
 
Figure 1.1: Distribution of the identification of 75 metabolties involved in central carbon and energy 
pathways using GC-TOF-MS, CE-TOF-MS and LC-TOF-MS. Figure taken from [30]. 
1.3 Sample Preparation for Metabolomic Studies 
Prior to metabolite analysis there are numerous ways that samples can be collected, stored, 
and prepared for metabolite extraction. All of these procedures have the potential to 
modify the structure of the metabolites and can therefore affect the results and 
reproducibility of the analysis [16, 53].  
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Serum or plasma can be isolated from blood for metabolite analysis depending on how the 
blood is first stored immediately after collection. Plasma is obtained from blood samples 
that have been added to tubes containing anticoagulants or additives which allows the 
samples to be analysed quickly since there is no need to wait for the blood to clot. The 
types of chemicals used with blood to obtain plasma include EDTA, heparin, sodium 
fluoride/potassium oxalate or citrate. Serum is obtained from blood that has been allowed 
to clot naturally. Dettmer et al. showed in a study that compared serum verses EDTA-
plasma that differences in the concentration of some analytes can occur between these two 
types of samples [52]. It is, therefore, important to ensure that all of the samples are either 
plasma or serum in metabolomic biomarker discovery projects.  
Sample storage is known to influence the abundance of metabolites and in some instances 
metabolomic reactions can still occur if the samples are not immediately frozen at -80 ˚C 
or lower. The length of sample storage and number of freeze/thaw cycles has the potential 
to increase variability even more than what is observed with proteins or RNA. This can be 
more of an issue with target metabolomics than non-targeted metabolomics since the small 
amount of changes can generally be counteracted in non-targeted metabolomics if large 
sample sizes are utilised [53].    
Potential interferants need to be removed prior to analysis by isolating the type of 
biomolecules that are being examined as potential biomarkers. In metabolomic studies, 
proteins are often extracted using solvent extraction [61]. The process of extraction can 
also affect how the metabolites are separated or detected during anlaysis [60]. Metabolites 
can be extracted from biological fluids using solid phase extraction, liquid-liquid 
extraction [40] or more commonly by precipitation (using either certain types of acids; 
salts or water-miscible organic solvents [40, 62]. When using the common method of using 
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organic solvents to precipitate and remove the proteins from the sample, the supernatant 
(which contain the metabolites) is collected and used for further analysis. If the correct 
ratios of solvent to sample are used the majority of metabolites of interest remain in the 
supernatant. There is a risk of losing important metabolites when using liquid-liquid 
extraction or solid phase extraction [40, 43].  
In mass spectrometry analyses, the presence of involatile salts can cause ion suppression 
and the use of methanol extraction can help reduce the amount of involatile salts in a 
sample [60]. It is also sometimes beneficial to reduce the presence of phospholipids which 
are ionic species that can increase ion suppression during MS detection [62]. A study by 
Alzweiri et al., examined the suitability of four organic solvents to extract metabolites 
from biological fluids. The dielectric constants and viscosity of solvents affects the 
efficiency of protein precipitation and thus the extent of protein removal from the sample. 
Alzweiri et al. suggest that acetone and acetonitrile are more apt at protein removal than 
methanol or ethanol [62]. Different extraction methods can be tailored to improve the 
efficiency of extracting certain chemical classes of metabolites. For example, amino acid 
extraction can be improved by using a 1:1 MeOH/H2O extraction [60]. This increases the 
solubility of the amino acids since some of these acids are hydrophobic and some are 
hydrophilic [63]. 
Overall samples need to be obtained, stored and prepared in a consistent way to reduce 
changes in the metabolite composition between samples after collection. Different 
procedures to isolate the metabolites should be tested to obtain optimum results.   
1.4 Data Analysis 
The development of pre-clinical diagnostic tests using NMR or MS techniques can 
produce extensive amounts of data. To obtain meaningful information, chemometric 
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techniques are used to determine disease biomarkers. When using hyphenated techniques 
such as GC-MS, CE-MS or LC-MS, the data needs to be tabulated so that all of the peaks 
from each sample are correctly aligned with the other samples [64].   
After the results are tabulated feature selection can be conducted to decrease the 
complexity of the data by removing redundant features so that further analysis can be 
conducted to determine biomarkers of the disease [65, 66]. Levner believes that this step is 
necessary to obtain the full potential of mass spectrometry techniques in discovering 
biomarkers for disease diagnosis [65]. Feature selection can be conducted using a range of 
statistical techniques including Student’s t-test [61, 67], Kolmogorov-Smirnov test (KS-
test) [65], ANOVA[61, 68] or Fisher test [69]. The feature selection step is then followed 
by multivariate analysis such as principal component analysis (PCA), partial least-squares 
(PLS) [64] hierarchical clustering [70] or linear discriminant analysis (LDA) [32]. Using 
techniques such as PCA and PLS allows the visualisation of complex data which can show 
differences in different groups of data according to patterns of analytes rather than a single 
analyte [71, 72]. This would be useful in biomarker studies because it can show if the 
presence and/or relative variance of different sample groups such as healthy and diseased 
according to a selection of biomarkers rather than a select few.  
Feature selection and multivariate analysis can be conducted on a subset of the total data 
(training set or test set) and the resulting algorithm is then used to classify the samples that 
were not included in the training set. Stentiford et al found the use of Student’s t-test as a 
feature selection step prior to hierarchical cluster analysis was required to show differences 
between fish with and without liver cancer. If the feature selection step was excluded the 
differences between the diseased and non-diseased fish were not observed [8].  
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The number of samples in the training set is important as work has shown that decreasing 
the number of the samples in the training set can decrease the accuracy of the algorithm to 
classify the samples [65]. Biomarker identification can be conducted at a later stage [66] or 
by using libraries that help to identify the biomarkers from mass fragments and retention 
times [9]. 
The identification of metabolites can involve some difficulties and generally require 
chemical standards. Identification can be obtained using a commercial library of the 
chemical standards along with retention indices [26]. The metabolites identified in this 
way must still be manually checked to ensure the library spectrum is a good match for the 
experimentally obtained spectrum. Non identified spectrums can also manually be 
identified. When this is done losses of water or sodium ions must be considered so that the 
assumed quassi-molecular ion is correct. In some circumstances, it may be difficult to 
determine the correct isomer for a selected metabolite especially if a standard is difficult to 
obtain and cannot be observed separately. Prior to identifying the metabolite as a potential 
disease biomarker, the biological function of the identified metabolite must also be 
examined to ensure that the metabolite identified is potentially associated with the disease 
being examined [18].  
1.5 The Effect of Devil Facial Tumour Disease on Tasmanian Devils 
1.5.1 Tasmanian Devils 
Tasmanian devils (Sarcophilus Harrisii), once prominent throughout Australia, are now 
endemic to Australia’s island state of Tasmania. The devil has been the world’s largest 
living carnivorous marsupial [73] since the death of another iconic Tasmanian creature - 
the Tasmanian tiger (thylacine). The Tasmanian tiger was declared extinct in 1986 [74] 
though the last known Tasmanian tiger died at Hobart zoo in 1936 [75]. Tasmanian devils 
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are nocturnal [76], non-territorial creatures that generally reside in areas of greater than 10 
km2 although  they have been known to travel 50 km in one day [73].  Tasmanian devils 
have an overall low genetic diversity but there is still a distinct genetic difference between 
devils from eastern Tasmania and those from north-western Tasmania [4, 77]. A study of 
the genetic diversity of Tasmanian devils conducted by Jones et al. examined the 
variability between devils of the same subpopulation and different subpopulations. Jones 
and colleagues observed very low genetic diversity within all sub-populations of these 
creatures. The greatest difference between populations was observed between the well-
connected populations in the eastern half of Tasmania and those of north-western 
Tasmania. The terrain between these two locations in Tasmania is uninhabitable for 
Tasmanian devils so there is limited dispersal of devils between these two populations. 
This observation was collaborated with model-based clustering anlaysis. The north-
western population of devils is smaller than the population found in eastern Tasmania [4]. 
Historically, there have also appeared to be declines in Tasmanian devil populations 
around 1909 and 1950 [76] which could have contributed to a decrease in the genetic 
diversity of this species.  
Although devils are considered to be solitary animals, recent work published by Hamede et 
al. showed that a certain wild population of devils had broad contact networks. This study 
examined the interaction between 27 devils at Narawntapu National Park, Tasmania and 
showed that all devils had some contact with each other either directly or via another 
individual in the testing group. The study also found that interactions between different 
devils differed between mating and non-mating season. During mating season the most 
common interactions occurred between male and female devils. These interactions also 
appear to occur more frequently with the same individuals as a pair. In non-mating season 
the most common interactions occur between females. Interestingly, there were not many 
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male to male interactions in either season [2]. This knowledge could now shed light on 
how a contagious disease can spread though an entire devil population.  
Tasmanian devils are scavengers and predators and consume all types of meat including 
fish, insects, birds and mammals (both marsupials and domesticated animals), generally as 
carrion which more than one devil often feeds upon. Their sharp teeth allow them to 
consume all of the carcass including the skull [76]. Devils are dimorphic in size, the 
females grow to 4.5-9 kg in size and the males grow to a size of 7.5-13 kg. They normally 
reach maturity at two years of age although since at least 1970 females have been known 
to breed from the age of one [73, 78]. Originally it was noted that less than 10 % of one 
year old female devils reproduced [73] but more female devils are now breeding earlier in 
regions where devil facial tumour disease (DFTD) is well established [78, 79]. Tasmanian 
devils only breed once a year which generally results in a total of four times during their 
lifetime if they survive until the age of 6. It is possible to breed captive devils but this can 
be difficult [80, 81]. Mating occurs in underground burrows [2] generally between March 
and April. The female does not ovulate until a few days after mating which is followed by 
a gestational period of between 14-22 days. Overall the mother gives birth 28-31 days after 
mating [2] to around 20 young at a time. The young then travel up to the pouch and the 
first to find one of the four teats are the only ones to survive. These three or four young 
devils (called imps) continuously stay hold of the teats until they leave the pouch to 
prevent them from falling out [74]. A female devil will lactate for 30 weeks with the imps 
living in the pouch for 15 of those weeks [76]. In the wild Tasmanian devils can live to 
five-six years of age [73]. Each female, therefore, can produce around 16-20 offspring in 
their lifetime but this is dramatically reduced if they die from disease and only reproduce 
once or twice in their lifetime.   
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1.5.2 Devil Facial Tumour Disease 
Devil Facial Tumour Disease (DFTD) is a contagious cancer that forms in the facial area 
of Tasmanian devils but can metastasise throughout their body [3, 82].  As at December 
2010, the disease had been observed in over 60 % of the island of Tasmania and had 
decreased the total population of devils to 20 % of what it was in 1996 when the DFTD 
was first observed. The disease still has not been observed on the west coast of Tasmania 
[83]. 
DFTD was first witnessed at Mt William National Park in Tasmanian’s north east when a 
Tasmanian devil was noted to have tumours on their face. Even though there appears to be 
less male-male contact between devils and pre-dominantly female-female contact between 
devils in non-mating seasons [2], DFTD appears to have no gender bias [3, 84, 85] and 
does not appear to be present in juvenile devils. This disease had not been observed 
previously by the six biologists who had been trapping devils between 1964-1995 [73] 
although there is anecdotal evidence from people that saw devils with facial tumours as 
early as the 1950’s [74]. In 1999, 3 years after the disease had been observed in 
Tasmania’s far north-east, Jones, another Tasmanian biologist, observed tumours at Little 
Swanport on Tasmania’s east coast, 250km south of Mt William National Park [74]. The 
disease was not publicly announced until September 2003. Even at this time very little was 
known about the disease. Work was conducted to determine if the cancer was spread by a 
retrovirus or if it had been initially caused by certain chemicals such as 1080 [74] but no 
chemicals were determined to cause the cancer. Biopsies from DFTD tumours were also 
examined for six viruses that are known to be involved in cancer and no evidence was 
gained to support the hypothesis that the etiology of this disease was caused by a virus [6]. 
Other research suggested that the cancer was spread by allograft [5] and a considerable 
amount of evidence has been obtained to support this theory [6] which is discussed more 
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completely below. Since then, further research has shown that DFTD is a cancer that easily 
metastasises by spreading hematogenously [86]. Tasmanian devils are prone to developing 
cancers but none of these are similar to DFTD [82]. DFTD cells have been shown to be of 
neuroendocrine in origin and also similar to Schwann cells which was supported from 
miRNA studies and the fact that DFTD cells also express Schwann cell markers [82]. 
DFTD microRNA (miRNA) profiles were shown by Murchison et al. using Pearson’s 
correlation statistics, to be more similar to brain tissue than the nine other tissues that were 
tested (heart, testis, kidney, pancreas, spleen, bone marrow, lymph node, skin and liver) 
[82].  This cancer has also been shown to be neuroendocrine in origin by Loh et al.’s [77] 
using imunohistochemistry with cells that were histologically DFTD according to the 
diagnostic method published by Loh et al. [85] as well as positive and negative controls. 
As well as suggesting that the cancer was most probably neuroendocrine in origin their 
work also showed that devils from a range of geographical areas were affected with the 
same disease [77].  
DFTD has been monitored in a range of geographical areas around Tasmania. Although 
DFTD is spreading west, the population of devils in western Tasmania is still majorly 
DFTD free [83] which could be partially because of genetic differences as well as the 
uninhabitable terrain between the northwest and eastern devils. Further research has also 
been conducted on the diversity on a class of proteins called major histocompatibility 
complex (MHC). MHC are antigens that are present on cell walls. The genetic diversity of 
MHC informs an individual’s immune system if the cell is foreign or not. In humans only 
identical twins are likely to have the same MHC. Lack of diversity in the MHC between 
devils has been hypothesised to allow for allograft transmission of DFTD cells [87, 88] 
[89]. Siddle et al. observed genetic differences in MHC between the north-western and 
eastern Tasmanian devils. Tasmanian devils in eastern Tasmanian have low genetic 
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diversity in MHC although not all have the same MHC as DFTD cells. The low diversity 
in eastern devils and the differences between the north-western devils could contribute to 
the slower rate of transmission of DFTD in the north-western populations [88].  
1.5.2.1 A Contagious Cancer 
DFTD is a highly contagious disease; appears to always prove to be fatal after contact 
between devils [3, 76]; and is one of only a few known contagious cancers. Another 
example of a contagious cancer is canine transmissible venereal sarcoma (CTVS) which is 
sexually transmitted in dogs [90]. The transmission of DFTD appears to occur via allograft 
and the most plausible theory is that this occurs when the devils are bitting and fighting 
each other. The spread of this disease could also occur via cannibalism [86] and there is a 
possibility that healthy devils could be infected by DFTD cells that are left on carrion by 
DFTD positive devils [84]. There does not appear to be any vertical transmission between 
mothers and their young [86]. The allograft theory has been supported by results from 
chromosomal tests [5, 6], Amplified Fragment Length Polymorphism (AFLP) [6] and 
transmission trial [6] studies. Early chromosomal studies showed that all DFTD tumours 
from different animals had identical chromosomal abnormalities. This was shown with 
Pearse and Swift’s work that looked at samples from 11 different DFTD-positive devils 
that had been obtained from different areas around eastern Tasmania. They saw that 
whereas normal devil cells contain 14 chromosomes (including the sex chromosomes), 
DFTD cells only contain 13 chromosomes. There were also abnormalities within the 
remaining chromosomes. Some of the chromosomes were decreased in size; four of the 13 
chromosomes that are present in DFTD cells are not observed in normal Tasmanian devil 
cells; and neither of the sex chromosomes were observed in DFTD cells (see Figure 1.2). 
Although chromosomal changes occur in other types of tumours the fact that these 
abnormalities are identical in multiple devils suggested something more than conventional 
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cancer and the possibility that the cancer was contagious and spread by allograft [5]. This 
allograft theory was further supported in transmission trial studies [6], and research that 
was conducted by Siddle et al. that showed that Tasmanian devils have low major 
histocompatibility complex (MHC) diversity [87].  The low MHC diversity seen in devils 
allows for the allograft transmission of this disease because the MHC on the tumour cells 
does not differ from the host Tasmanian devil and are therefore not destroyed by the 
Tasmanian devil’s immune system [87]. If DFTD cells have originated from Schwann 
cells this could also have contributed to this disease being transmissible since Schwann 
cells are involved in the immune response in the peripheral nervous system [82]. 
 
Figure 1.2: Comparison of a healthy male Tasmanian devil set of chromosomes (a) and the profile of 
chromosomes from DFTD cells (b) that were observed in 11 individual devils.  The DFTD karotype 
shows an enlarged chromosome 1; the removal of both chromosome 2’s, one of the chromosome 6’s 
and both sex chromosomes; and the presence of four extra chromosomes that are not present in 
healthy cells (labelled M1-M4). This figure is reproduced from [5]. 
At present DFTD is tested for by taking a biopsy from a suspected tumour and undertaking 
a time consuming histological examination [73]. This does not allow for devils where no 
suspected tumours are seen to be tested for the disease, since no tumour biopsy can be 
taken. At present there are no methods to test for DFTD before the tumours are seen [91].  
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1.5.2.2 An Endangered Species 
In the past, infectious diseases have not been considered to be a major driving force for 
species extinction [92]. Although a number of population declines in mammals have been 
caused by infectious diseases, one study has shown that only 8 % of endangered animal 
and plant species including approximately 1 % of endangered mammals are listed as 
endangered because of infectious diseases. DFTD gives us an example of how devastating 
a highly contagious disease can be to a species [92]. Low genetic diversity of wild species 
increases the chance that an infectious disease will put the species at risk of extinction 
[93]. This has likely been a major contributor to the devastation that DFTD has had on the 
Tasmanian devil population [87]. In DFTD areas most devils succumb to the disease by 
the age of two or three which is resulting in some females only breeding once [94]. This 
would also contribute to a reduction in the population of Tasmanian devils. In the early 
1990s it was estimated that there was a population of 150,000 devils [95] but since the 
disease was first seen in 1996 there has been an 80 % decline in the total wild population 
of this species [83]. This decline in population led to the Tasmanian devil being listed as 
endangered under the Tasmanian Governments Threatened Species Protection Act 1995 in 
May 2008 [96] as well as the Commonwealth Environment Protection and Biodiversity 
Protection Act 1999 in May 2009 [97]. There is a high risk that the devil will be extinct in 
the wild from this disease in the next 20-30 years [98]. Local extinction in some areas is 
also possible within 5 years [78]. As is the case with all species, the extinction of the 
Tasmanian devil will alter the Tasmanian ecosystem which in turn will affect other species 
that reside in Tasmania. The loss of Tasmanian devils will reduce the competition at the 
top of Tasmania’s food chain and it is feared that this could lead to increased establishment 
of foxes in Tasmania which could be detrimental to Tasmania’s livestock industry.   
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1.5.2.3 Suppression Trials 
Disease suppression in contagious wild animal diseases is often conducted by trapping and 
removing the diseased animals to limit the spread of the disease. A suppression trial for 
Tasmanian devils was set up at the Forestier and Tasman Peninsulas (see Figure 1.3) 
encompassing a total area of 360 km2. To decrease the spread of DFTD all positive DFTD 
devils that were trapped were removed. This area was chosen since the only land contact 
between the peninsulas and mainland Tasmania is via the Dunalley Bridge at Dunalley. 
The initial suppression trial study occurred between June 2004 to June 2005 and then an 
intensive study commenced in January 2006. The suppression trial was conducted by 
removing and euthanizing all devils that either had DFTD or characteristic signs that were 
considered to show that they would develop DFTD. Devils were chosen this way since the 
only available diagnostic test is to histologically test visible tumours. The devils were 
removed during 10 day trapping trips that occurred four to five times per year in an area of 
the Forestier Peninsula that included an area known have DFTD devils as well as a buffer 
zone. The initial suppression trial showed good preliminary results with a decrease in the 
number of devils with late stage tumours (tumours larger than 4 cm in size) and no 
noticeable decrease in the population. The results from the suppression trial were 
compared to a similar site at the Freycinet Peninsula (see Figure 1.3). Whereas there was 
no noticeable decrease in devil population in the suppression trial area the population 
density of devils at the Freycinet Peninsula decreased from 0.9 to 0.6 devils per km2 in a 
similar time frame to the 12 month initial suppression trial. In December 2009, the trial 
still had not succeeded in producing a DFTD free population but it had not been 
completely unsuccessful though since the population of devils in this area has not 
decreased since the start of the suppression trial and DFTD has also not spread to other 
places around the peninsulas. There are two possible reasons why DFTD had not been 
35 
 
eradicated. Firstly, it had been observed using hair samples that around 25 % of the 
population were not being trapped. This population could contain DFTD-positive devils 
that are spreading the disease to other devils. The second reason the disease may still be 
present is because DFTD-positive devils are not being removed soon enough to prevent 
them from spreading the cancer to other devils. The development of the preclinical test 
discussed in this work would aid in removing the devils before they can spread the disease 
[99]. Successful implantation of this suppression trial will allow for DFTD-free devils to 
be obtained from an eastern Tasmanian devil population which will allow for increased 
genetic diversity as part of insurance populations [86].  
 
Figure 1.3: Map of Tasmania showing the Freycinet and Forestier Peninsulas where DFTD research is 
being conducted. 
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1.5.2.4 Insurance Populations 
To try and prevent the extinction of this species the highest priority at present is the 
development of insurance populations in wildlife parks and zoos across Australia [100]. 
These insurance populations were developed to ensure that there was a DFTD-free 
population of devils that could be used to repopulate mainland Tasmania in the case that 
the species becomes extinct in the wild [98]. The Tasmanian devil population is known to 
have low genetic diversity so the purpose of the insurance population was also to maintain 
as much of this genetic diversity as possible. The best way to maintain genetic diversity in 
the insurance populations would be to conduct managed breeding. Managed breeding 
would require less captive devils but it could also cause problems of re-introducing the 
population into the wild because the living conditions of the captive devils in this situation 
would not be representative of the wild. To increase genetic diversity it is also possible to 
transplant devils from one population into other populations [98].  The initial Insurance 
population strategy [98] suggested that 150 DFTD-free devils that varied in as much 
genetic diversity as possible, would be bred to a population of 1500 devils (if breeding was 
managed) or 5000 devils (if breeding was not managed) or at a relative number if both 
these type of population groups exists. These numbers were considered as an “effective 
population” which is very close to the actual population when the gender numbers are 
identical and all animals are breeding at an equal rate.  
At present, since there is no pre-clinical diagnostic test to determine if a devil has the 
disease before tumours are seen and the latent period of the tumour is also unknown [78], 
Tasmanian devils for the insurance population are maintained in quarantine for two years 
[86].  
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1.5.2.5 DFTD Diagnostic Tests 
Currently DFTD is diagnosed histologically by examining biopsies of suspected tumours. 
The cells from the biopsies were considered to be DFTD if the neoplastic cells had been 
derived from dermis or subcutaneous tissue and were round to spindle-shaped [85]. DFTD 
cells can also be identified karotypically since the chromosomes from DFTD cells differ 
from those of the host in a distinct way as seen in Figure 1.2, page 32 [5].  
This type of diagnosis may not be appropriate for biopsies obtained from non-facial DFTD 
tumours or metastasis of DFTD tumours. To aid in diagnosing these abnormal DFTD 
tumour biopsies, another diagnostic test was developed by Murchison et al. This 
diagnostic test involves staining suspected DFTD cells with an antibody for periaxin 
(PRX) a Schwann cell-specific myelin protein. This stain was able to correctly diagnose 20 
DFTD tumours plus an additional 10 DFTD metastases from different types of organs. It 
could also correctly identify the nine non-DFTD biopsies that were tested [82].  
All of these methods require a biopsy of the suspected tumour so at present there are no 
methods to test for DFTD before the tumours are seen [3, 91]. The availability of a pre-
clinical diagnostic test will aid in the managing the spread of DFTD [2]. The development 
of this diagnostic test could be used to aid in two of the major projects that are currently 
being conducted to ensure that a healthy population of Tasmanian devils is maintained. 
Firstly this test could be used to ensure that only DFTD free devils enter into insurance 
populations. Having a pre-clinical test for DFTD would allow healthy Tasmanian devils to 
enter into the insurance population straight away allowing breeding to occur earlier. This is 
desirable since Tasmanian devils only have a lifespan of around six years [80, 81]. The 
insurance populations need to maintain as much genetic diversity as possible. To do this, 
devils will need to be included from eastern and western Tasmania since there are distinct 
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genetic diversities between these two groups of devils. Unfortunately almost all Tasmanian 
devils eventually develop DFTD in eastern Tasmania so to include these devils, an 
accurate pre-clinical test is required to ensure that these devils do not all ready have DFTD 
which could spread to the other individuals in the insurance population. The ability to 
determine DFTD pre-clinically will also allow a decrease in the time required for 
quarantine since the latent period for DFTD is uncertain and could be anywhere up to 12 
months.  
The availability of a diagnostic test would also aid in the suppression trial. Pre-clinically 
diagnosing DFTD would allow for the removal of DFTD devils potentially before the 
tumour cells could transfer and infect another devil.  
For use in the suppression trial or to aid in ensuring a DFTD-free population in the 
insurance trial, a diagnostic test would be required to have the ability to test all Tasmanian 
devils with and without the presence of tumours in the wild. This means that a test that 
diagnoses the disease by a biopsy is not suitable. A biological sample is therefore needed 
that is easy to obtain from wild trapped devils. Blood is easier to collect than urine or other 
biological fluids when collection is taking place out in the field. A serum blood test is 
suitable since blood can be collected into clean tubes without additives in the field; 
allowed to clot; spun down at the end of the day in a portable centrifuge to remove the 
cells; and stored in a freezer prior to transportation back to the laboratory for testing. 
1.6 Project Aims 
The purpose of this work was to search for biomarkers for DFTD that could be used in the 
development of a pre-clinical diagnostic test to aid in the survival of Tasmanian devils. 
There have not been many if any diagnostic tests developed for diseases of wild animals 
where other factors affecting biomolecules are not controlled. Hines et al. though actually 
39 
 
noted less metabolite variability from mussels (Mytilus galloprovincialis) that had been 
sampled straight from the field compared to when mussels collected at the same location, 
were first stabilised in the laboratory for 60 hours prior to analysis [22]. This suggests that 
obtaining samples for biomarker determination from wild animals is not unfeasible. Wild 
fish have also been studied to try and determine biomarkers for liver cancer in flatfish 
(Limanda limanda) found in waters surrounding the United Kingdom. The researchers 
involved in this study looked at healthy and cancerous liver tissue which showed greater 
variability between individuals than between healthy and diseased tissue [8]. They also 
looked at peptides in wild flatfish plasma but their results showed greater difference 
between the location that the fish was caught and the age of the fish rather than the liver 
cancer status of the fish. Even removing these effects the researchers were still unable to 
completely distinguish between healthy and diseased fish. The results were only able to 
determine 7 out of the 10 fish that had liver tumours [101].  
Although previous disease biomarker work on wild animals has not been as successful as 
hoped, the low genetic diversity of Tasmanian devils may aid in the discovery of DFTD 
specific metabolites for a diagnostic test. As a small blood sample obtained through an ear 
prick is the easiest sample to obtain from a wild devil, this work focused on the use of 
various types of mass spectrometry techniques with and without prior sample separation to 
examine serum metabolites obtained from non-DFTD and DFTD devils. The techniques, 
CE-ESI-MS, GC-MS and ESI-MS, were used in collaboration with multivariate analysis to 
discover differences in Tasmanian devil serum that are observed in DFTD positive 
individuals but not in non-DFTD devils to use as potential disease biomarkers for DFTD. 
Their applicability to be used for routine screening of samples to diagnose DFTD is also 
discussed.    
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2 Method Development 
2.1 Introduction 
As discussed in the introduction (see section 1.2), there are numerous well established 
instrumentation and methods that are suitable to study metabolomics based on NMR or 
MS detection [25, 102]. Mass spectrometry is a more sensitive technique which allows 
quantitative data to be obtained for a greater number of metabolites [37]. This work 
involved the investigation of three different mass spectrometry (MS) methods to 
distinguish differences in the metabolome between devil facial tumour disease (DFTD) 
and non-DFTD Tasmanian devils. One of the methods, electrospray ionisation – mass 
spectrometry (ESI-MS), had no separation step prior to MS detection. The other two 
methods, gas chromatography – mass spectrometry (GC-MS) and capillary electrophoresis 
– mass spectrometry (CE-MS) separated the metabolites prior to MS detection. GC-MS 
and CE-MS were both investigated because each technique a) provides a different process 
of separation; b) requires different types of sample preparation prior to analysis [15, 26, 
41]; and c) different chemical classes of metabolites are better observed with different 
separation techniques [30].  These methods were examined to determine appropriate 
approaches to mine for specific metabolite changes that occur with DFTD. 
2.2 Experimental 
2.2.1 Samples 
An initial pilot set of Tasmanian devil serum samples was obtained from 16 devils 
(including males and females) caught in the eastern half of Tasmania in 2004 (see Table 
2.1) collected by the Department of Primary Industries, Parks, Water and the Environment 
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(DPIPWE), Mount Pleasant, Tasmania. All of the devils came from areas in which DFTD 
was known to be present. A pooled rat serum sample was obtained from female Sprague 
Dawley rats and a pooled mouse serum sample was prepared from serum obtained from 
non-obese diabetic-severe combined immunodeficient (NOD/SCID) mice.  
Table 2.1: List of serum samples used for the pilot study with information on DFTD status, sampling 
location, gender and age. Further details can be observed in Appendix 1, Table A 1. 
Sample # Location DFTD status Sex   Age 
04/0560 Bronte Park DFTD 69 days later M 3 
04/0603 Bronte Park Non-DFTD F 3 
04/0605 Bronte Park DFTD F 3 
04/0735 Bronte Park DFTD M 3 
04/0960 National Park Non-DFTD M 3 
04/1021 National Park Non-DFTD F 4 
04/2058 Mount William DFTD F 3 
04/2062 Mount William Non-DFTD M 1 
04/2064 Mount William DFTD M 4 
04/2065 Mount William Non-DFTD F 3 
04/3000 Fentonbury DFTD F ? 
04/3003 Fentonbury Non-DFTD F 4 
04/3008 Fentonbury DFTD M 4 
04/3011 Fentonbury Non-DFTD M 4 
04/3176 St Helens Non-DFTD F 3 
04/3201 St Helens Non-DFTD M 3 
 
2.2.2 Reagents 
Water was purified with a Millipore Milli-Q water purification system (North Ryde, 
Australia). Methanol (> 99.7 %, isocratic HPLC grade (254nm)) was obtained from 
Scharlau Chemie S.A. Methylhydroxylamine hydrochloride and formic acid (98 %) were 
obtained from Fluka. Poly(sodium 4-styrene-sulfonate 70kDa was obtained from Aldrich, 
St Louis, USA; HPLC grade acetonitrile; very low molecular weight 
Poly(diallyldimethylammonium chloride), polybrene (≥ 95 %); N-Methyl-N-
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(trimethylsilyl)trifluoroacetamide (MSTFA); pyridine (≥ 99.0 %) and sodium hydroxide 
(99.99 %) were obtained from Sigma Aldrich. 
2.2.3 GC-MS 
Proteins were removed from serum using a crude methanol extraction by precipitation. The 
serum (15 µL) was added to 500 µL of cold methanol. The mixtures were vortexed (Ratek 
VM1 vortex mixer) for 5-10 s to mix and then incubated at 4 ˚C for over 20 min. After 
incubation the samples were centrifuged at 14,000 rpm (Eppendorf bench top centrifuge 
5424) for 5 min. A 200 µL aliquot of the supernatant was transferred into a glass sample 
vial which were then covered with parafilm and pierced. The samples were dried in a 
vacuum oven at 55 ˚C.  
On the day of analysis the metabolites were derivatised using a method described 
elsewhere [103] using 20 µL of 40 mg/mL methylhydroxylamine hydrochloride in 
pyridine and 80 µL of N-Methyl-N-(trimethylsilyl)trifluoroacetamide. The solutions were 
then vortexed to mix and left at room temperature for 90 min.  
After derivatisation, the samples were analysed using a Shimadzu QP2010-plus GC-MS 
fitted with a BPX-35 capillary column (30.0 m or 15.0 m in length, film thickness 0.25 µm 
and an internal diameter of 0.22 µm). The separation method for the 30 m column was as 
follows: 1 µL of sample was injected using splitless injection for 45 s at 230 ˚C. The 
temperature program was set to hold the column at 55.0 ˚C for 2 min and then increased at 
15 ˚C/min until it reached 330 oC. The column was kept at this temperature for a further 6 
min. The column pressure was kept constant at 88.6 kPa with an initial carrier gas (helium) 
flow rate of 0.88 mL/min. The temperature of the mass spectrometer ion source and 
interface was 200 ˚C and 250 ˚C respectively. The detector voltage was set to 0.88 kV. 
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Spectra were obtained from 6.5 min into each run between 85-500 m/z with a scan speed 
of 5000 amu/s.  
The timing for the temperature program for the 15 m column was modified from the 30 m 
program to take into consideration the decrease in column length using Method 
Translation software (Agilent) as follows: 1 µL of sample was injected using splitless 
injection for 30 s at 230 ˚C. A temperature program consisted of holding the column at 
55.0 ˚C for 0.7 min. The temperature was then increased at 42.4 ˚C/min until it reached 
330 oC. The column was then kept at this temperature for a further 2.10 min. The column 
pressure was kept constant at 33.2 kPa with an initial carrier gas (helium) flow rate of 0.88 
mL/min. The temperature of the mass spectrometer ion source and interface was 200 ˚C 
and 250 ˚C respectively. The detector voltage was set to 0.84 kV. Spectra were obtained 
from 2.2 min into each run between 85-501 m/z with a scan speed of 10,000 amu/s.  
Data analysis was performed using the GCMS solutions software (Version 2.50SU1, 
Shimadzu 1999-2006). Integration was done with two different processes in GCMS 
Postrun Analysis,GCMS Solution Version 2.50 SU1, © 1999-2006 Shimadzu Corporation. 
For each metabolite peak, the base peak was determined and the total area for this ion was 
calculated to more accurately determine peak areas for overlapping peaks. The first 
process involved manual integration of the peaks. The second process used the 
Quantitative Parameters Peak Integration option in the program. For the second process, 
initially the main ion for each peak was determined and the list of m/z and retention times 
were inputted into the parameters table. The quantitative parameters were then adjusted to 
obtain the parameters that most efficiently integrated the peaks. Each peak was manually 
checked to ensure that the peak had been correctly identified. The peak table was then 
analysed using Microsoft Excel 2007 and XLSTAT (Addinsoft 1995-2010).  
2.2.4 ESI-MS 
Dilution Study: Two extraction methods were used to isolate the serum metabolites of 
interest from proteins and other large molecules. In the first instance 15 µL of Tasmanian 
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devil serum was added to 500 µL of cold method (sample M1) and the second method 
involved the addition of 30 µL of Tasmanian devil serum 500 µL cold methanol (sample 
M2). Both of the mixtures were vortexed to mix and then incubated at 4 ˚C for over 20 
min. After incubation the samples were centrifuged at 14,000 rpm (Eppendorf bench top 
centrifuge 5424) for 5 min. Further dilutions of M1 were prepared before injection into the 
instrument with methanol to give final dilutions shown in Table 2.2. Sample M2 was not 
diluted further and had an overall dilution of the serum of 17.7 times (See Table 2.2). Each 
sample was acidified with addition of 10 % v/v aqueous formic acid to give an overall 
formic acid concentration of 0.1 % v/v.  
Table 2.2: Description of serum sample dilutions for ESI-MS method development. 
Sample # Mixture V(of 
prepared 
sample) (µL) 
V(10 % 
Formic acid) 
(µL) 
V(MeOH) 
(µL) 
Total vol 
(µL) 
Overall serum 
dilution 
1 M1 198 2 0 200 1:34.7 
2 M1 20 2 178 200 1:347 
3 M1 2 2 196 200 1:3468 
4 M1 100 2 98 200 1:68.7 
5 M1 50 2 148 200 1:137.3 
6 M2 198 2 0 200 1:17.8 
7 - - 2 198 200 N/A (blank) 
The analysis of the samples was conducted on a Bruker micrOTOF-Q II instrument 
(Bruker Daltonics) as follows: The sample was infused into the instrument for 2-3 min via 
a syringe pump at a constant flow rate of 180 µL/hr (kd Scientific syringe pump with a 
0.10 mL Gastight #1710 syringe, Hamilton Co, Reno, Nevada, USA). Spectra were 
collected between 50-1200 m/z in positive ion mode. The capillary voltage was set to -
4500 V, nebulizer pressure was 0.3 bar, the flow rate and temperature of the dry gas was 
4.0 L/min and 180 ˚C respectively. The energy of the Collision cell was 10.0 eV with a 
transfer time of 110.0 µsec. For further analysis the average spectrum was obtained 
between 1.0-2.0 min after the sample was injected into the instrument. Mass spectra were 
collected using MS software Compass 1.3 for micrOTOF-SR 1 micrOTOF control version 
3.0 © 2002-2009 Bruker Daltonik Gmbh and analysed using MS software Compass 1.3 for 
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micrOTOF Sr 1 micrOTOF- SR 1 DataAnalysis version 4.0 SP 1 © 1992-2009 Bruker 
Daltonik Gmbh.  
Quality control samples: A sample of rat serum was used as a quality control (QC) sample. 
The quality control samples were prepared by placing 15 µL of serum in 500 µL of cold 
methanol. The samples were vortexed to mix followed by a 4 ˚C incubation for at least 20 
min. The mixtures were then centrifuged at 14,000 rpm for 5 min. Two 100 µL aliquots of 
the supernatant were then obtained and each aliquot was diluted by the addition of 98 µL 
of methanol and acidified by the addition of 2 µL of 10 % v/v aqueous formic acid. 
Generally each day two quality control samples were prepared to obtain a total of four 
aliquots of the quality control. Prior to the analysis of samples two reagent blanks were run 
followed by a quality control. Another reagent blank and quality control sample were run 
after every ten samples. The QC samples were run in alternating order to determine if 
outliers were caused by errors with the instrument or during sample preparation. 
2.2.5 CE-MS 
Instrumentation: Analysis was conducted with an Agilent CE-ESI-Iontrap MS system 
using an Agilent 3D capillary electrophoresis system connected to an Agilent 6320 Ion 
Trap LC/MS with the aid of an Agilent 1200 Series pump. The CE was controlled with 
Agilent ChemStation software and the MS was controlled with 6300 Ion Trap Control 
software (Waldbronn, Germany). Mass parameters were set as in Ramautar et al. [33] 
where the dry gas temperature was set to 180 ˚C, 4 L/min N2, 7.3 psi nebulizer pressure 
and an ESI capillary voltage of - 4500 V. Spectra were collected between 70 – 400 m/z.    
Separation and sheath buffers: 1 M formic acid was used for the background electrolyte 
(BGE). The sheath liquid consisted of 1 % v/v formic acid in 1:1 methanol:water and was 
used at a flow rate of 4 µL/min. 
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Polybrene-PSSS coated capillaries: Capillaries were coated using a Harvard apparatus 
PHD 2000 infuse/withdraw syringe pump and Hamilton gastight #1725 syringe with a 
flow rate of 300 µL/hr. The capillary was rinsed with Milli Q water for 15 min followed by 
15 min with NaOH. Water was then passed through the capillary until the flow through 
was neutral. The capillary was then flushed with polybrene (10% w/v in water) for 30 min, 
water for 5 min, PSSS (5% w/v in water) for 30 min and finally water for a further 5 min.   
PDDMAC-PSSS coated capillaries: Capillaries were coated using a Harvard apparatus 
PHD 2000 infuse/withdraw syringe pump and Hamilton gastight #1725 syringe with a 
flow rate of 300 µL/hr. The capillaries were rinsed for 5 min with Milli-Q water, 15 min 
with 1 M NaOH, more water until the flow through was neutral, 30 min with 0.1 % 
PDDMAC/0.5 M NaCl, 3 min with water, 30 min with 5 % w/v PSSS, 3 min water, 30 
min with 0.1 % PDDMAC/0.5M NaCl, 3 min with water, 30 min with 5 % w/v PSSS, and 
finally 5 min water. At the beginning of each day the capillary was reconditioned by 
removing the outlet from the mass spectrometer and flushing for 5 min with 5 % PSSS, 5 
min with water and 10 min with BGE to maintain capillary stability. This type of coating 
still allowed for EOF but eliminated the coating of analytes onto the capillary wall which 
reduces reproducibility by increasing migration times in subsequent runs. 
Sample preparation: The organic solvent study was conducted by placing one volume of 
serum to two volumes of acetonitrile or methanol. The mixtures were vortexed to mix and 
incubated at 4 ˚C for greater than 20 min. After the incubation the samples were 
centrifuged at 14,000 rpm (Eppendorf bench top centrifuge 5424) for 5 min. The 
supernatant was injected into the instrument without further sample treatment. Prior to 
injection a 73.8 cm PDDMAC-PSSS coated capillary was conditioned for 5 min with 1 M 
formic acid as the BGE. The supernatant from the protein precipitation step was injected 
47 
 
into the capillary at 50 mbar for 120 s. Prior to sample separation, a sample plug of Milli Q 
water was injected into the capillary for 5 s at 50 mbar. 25 kV was applied to the column 
to separate the metabolites along with 30 mbar pressure to aid in moving the analytes 
through the sheath. The sheath fluid consisted of 1 % v/v formic acid in a solution of 1:1 
methanol:water. Instrument and mass spectrometry parameters were used as stated above. 
To determine the ultimate ratio of solvent to serum, equivalent of one volume of 
Tasmanian devil serum was added to one, two and three volumes of acetonitrile. The 
samples were prepared and analysed by CE-MS in the same way as the organic solvent 
study.   
Sample injection study: The sample injection study looked at rat serum samples. In both 
instances serum metabolites were collected by the addition of serum 1:1 with acetonitrile 
according to the method described under sample preparation. The samples were then 
injected 75, 90 and 120 s at 50 mbar followed by a 5 sec 50 mbar injection of water. A 
voltage of 20 kV and a pressure of 30 mbar was applied to the capillary during separation. 
Sample separation: The optimum separation voltage was determined by the injection of rat 
serum metabolites using the same method as the sample injection study. Prior to injection 
the 80cm 50µm id PDDMAC-PSSS capillary was conditioned for 5 min with BGE. The 
rat serum metabolites were injected for 120 s at 50 mbar. A plug of water was then 
injected into the capillary for 5 s at 50 mbar. Analyte separation was conducted at a 
pressure of 30 mbar and separation voltages of either 15, 20 or 25 kV.  
2.2.6 Analysis of quality controls 
To ensure that the quality controls were reproducible the samples were analysed using the 
Grubbs test. Samples were considered to be an outlier if some of the variables (analytes) 
were outside of the range calculated by the formula: ݂ሺݔሻേ ൌ ݔҧ േ  ሺܩ௡ୀ௫ ൈ ߪሻ for each 
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analyte. Where Gn=x was dependent upon the number of quality controls with a 
significance of 2.5 % [104].  
2.3 Results and Discussion 
2.3.1 GC-MS 
Comparisons of the same sample between runs: Samples were analysed in duplicate and 
using two different column sizes (30 and 15 m). The shorter capillary size was investigated 
to determine if similar results could be obtained in a considerably shorter run time. Having 
a shorter run time could dramatically increase the sample output if the method was used to 
screen a large number of devils for DFTD.  
Initially these samples were prepared and run in duplicate using the 30 m column. 
Overlaying the chromatograms showed good reproducibility which suggested that there 
was limited variability in the sample preparation and separation steps (see overlay of 
replicates in Figure 2.1). Because of the good reproducibility, preparing and running the 
samples in duplicate was not continued.  
Originally these samples were analysed with the 30 m BPX35 column over 26.3 min. The 
same samples were later analysed on the same column cut to 15 m in length. The method 
times were modified according to Blumberg and Klee [105] with Method Translation 
software (Agilent) to take into consideration the shorter column, and the separation was 
completed 9.3 min after sample injection. The chromatograms of the serum metabolites 
obtained from a male DFTD positive devil (sample 04/0735) separated in the 30 m and the 
15 m column can be viewed in Figure 2.2. 
The shorter column was translated to provide a similar separation according to Blumberg 
and Klee [105] as would be expected, the reduction of plate numbers reduced the 
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Figure 2.1: Reproducibility of samples: This figure shows the overlay of two chromatograms from the 
separation of serum metabolites from a DFTD male devil run in duplicate by GC-MS as follows: The 
samples were injected into the GC using a splitless injection for 0.75 min at 230 ˚C into a 30 m BPX-35 
column. The temperature of the column was held at 55 ˚C for 2 min and then ramped to 330 ˚C at a 
rate of 15 ˚C/min. The column was held at 330 ˚C for 6 min. The acquisition of data was initiated 6.5 
min into the run. 
separation efficiency in the shorter column. The majority of peaks that were observed in 
the longer 30 m column could still be observed in the 15 m column. The relative intensity 
of the peaks though did differ between these two runs. An example of this can be observed 
by comparing the relative intensities of the cholesterol peak with the two dominant sugar 
peaks in the two chromatograms. In the 30 m column separation, the cholesterol peak is 
approximately half as intense as the small of the two large sugar peaks where as in the 15 
m separation the intensity of the cholesterol peak is on par with the intensities of the two 
abundant sugar peaks. This change in relative intensity of the cholesterol peak was also 
observed with the other samples run. The change in peak height was mirrored when the 
peak areas were also examined (in the longer column the areas were 3 and 7 times higher 
than for cholesterol and in the shorter 15 m column the areas were approximately 4 and 5 
times that of the cholesterol peak). Longer separation time increases diffusion of the 
analyte in the column so the peak of intensity for cholesterol is likely lower in the longer 
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Figure 2.2: Comparison of the separation of serum metabolites from a male DFTD devil in a 30 m and 
15 m column: In part A the sample was analysed by GC-MS as follows: The samples were injected into 
the GC using a splitless injection for 0.75 min at 230 ˚C. The temperature of the column was held at 55 
˚C for 2 min and then ramped to 330 ˚C at a rate of 15 ˚C/min. The column was held at 330 ˚C for 6 
min. The acquisition of data was initiated 6.5 min into the run. In part B the sample was analysed by 
GC-MS as follows: The samples were injected into the GC using a splitless injection for 0.50 min at 
230 ˚C. The temperature of the column was held at 55 ˚C for 0.70 min and then ramped to 330 ˚C at a 
rate of 42.40 ˚C/min. The column was held at 330 ˚C for 2.10 min. The acquisition of data was initiated 
2.20 min into the run. 
column because of peak broadening. The number of peaks observed in the shorter column 
was 105, around half the 215 peaks that were observed in the longer column for this 
sample. Although there were changes in peak intensity of the peaks compared to the 30 
and 15 m columns, the shorter column allowed for at least twice as many samples to be 
analysed in the same time frame and was still able to provide enough information to 
discriminate between DFTD and non-DFTD samples to be observed by PCA (see chapter 
3). The 15 m column was therefore used in future analysis. 
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2.3.2 ESI-MS 
Electrospray ionisation (ESI) is known to be affected by ion suppression. Ion suppression 
is caused by the presence of less volatile components present in the solution. These ions 
can decrease the efficiency of droplet formation and evaporation which then affects the 
amount of analyte that becomes charged in the gas phase which reduces the amount of 
analyte that is then detected by the MS [45]. There are a number of processes that can be 
undertaken to decrease the effect of ion suppression in ESI-MS as discussed in section 
1.2.2.1. The methods discussed here used the precipitation of proteins using organic 
solvents and sample dilution to reduce ion suppression. To do this, serum proteins were 
removed from a Tasmanian devil serum sample using methanol and various dilutions of 
the serum metabolites were prepared and injected into the ESI-MS (see Table 2.2). The 
resulting spectra were examined to determine the best dilution to use in further 
experiments (see Figure 2.3).  
The spectra showed that lower dilutions (17.8 to 137.3 times dilutions) were more 
applicable when looking at the higher molecular weight ions (> 500 m/z) but higher 
dilutions (347 and 3468 times dilutions) gave better intensity for the lower molecular 
weight ions (< 500 m/z). Higher molecular weight ions have also previously been shown 
by Sterner et al. to decrease the intensity of lower molecular weight ions [106]. Taking 
into consideration the differences in intensity of the high and low molecular weight ions it 
was determined that the best dilution factor to use for further runs was 68.7 which showed 
good responses for both the low and high molecular weight ions. This was comparable to a 
study conducted by Han et al. which analysed mouse serum diluted 100 times by ESI-MS 
[43]. 
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Figure 2.3. Mass spectra of a devil sample prepared with various amounts of dilutions (see right hand 
side legend) prior to injection into the ESI-MS. 
Quality controls: The reproducibility of this method was shown by using a rat serum 
quality control which was used with a set of samples over three consecutive days and again 
with another set of data run one day approximately six weeks later (see Figure 2.4 for 
spectra). A total of 10 aliquots (see experimental) of this quality control were run with the 
initial set of samples and 4 were run in the second set. In the second set only 3 samples 
could be analysed because one of the samples had a corrupt file. The reproducibility of the 
initial 10 aliquots of the control sample were analysed using the Grubbs test as explained 
above in section 2.2.6. Quality controls on each day were within the outer ranges 
determined by the formula: ݂ሺݔሻേ ൌ ݔҧ േ ሺܩ௡ୀ௫ ൈ ߪሻ; where G was 2.29 (n=10); and 2.46 
(n=13).  
The three QC that could be analysed from the runs conducted six weeks later were 
analysed using the same formula (n=13) with all of the initial QC’s. These three QCs were 
all within the range determined by the Grubbs test. This shows that this test is reproducible 
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over time. It would therefore be suitable for continued analysis of samples over a range of 
time such as what would be required to continually test Tasmanian devil serum for DFTD. 
 
Figure 2.4: Showing the reproducibility of the rat quality control sample analysed of three consecutive 
days and again 6 weeks later using ESI-MS 
2.3.3 CE-MS 
Capillary coating: Fused silica columns are cheap and provide EOF which can aid in 
separation in metabolite studies, but separation and migration time can be affected by the 
binding of amino acids and peptides to the capillary wall which can also affect the 
separation in subsequent runs. These effects can be reduced or eliminated by coating the 
capillary. In the case of proteins, linear polyacrylamide capillaries are often used to 
prevent the proteins binding to the walls which also eliminates EOF [107]. In this work, a 
coating method based on Ramautar et al. was used to non-covalently coat the capillary 
with a bilayer of polymers consisting of an anionic and a cationic polymer [33] which 
would not eliminate EOF [108]. Ramautar et al. used a polybrene - polyvinylsulfonate 
coated capillary. Initially because of compound availability the polyvinylsulfonate 
polymer was replaced with another anionic polymer, poly (sodium 4-styrene-sulphonate) 
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(PSSS). Capillaries were also coated with another cationic polymer, poly 
(diallyldimethylammonium chloride) (PDDMAC) that was used instead of polybrene. The 
two different capillary coatings were compared for the separation of metabolites obtained 
with a 1:1 acetonitrile protein precipitation (see Figure 2.5). In both instances additional 
flushes of PSSS were required to maintain reproducibility between runs. The PB-PSSS 
capillary showed better separation between peaks than the PDDMAC-PSSS capillary but 
very few peaks were observed between 20 and 25 min. By observation, it appeared that the 
PDDMAC-PSSS capillary separated a similar number of metabolites in a third or the time 
of the PB-PSSS capillary without the observed peak free area, so PDDMAC-PSSS coated 
capillary was chosen for future work.  
 
Figure 2.5: Comparison of two different capillary coating methods PDDMAC-PSSS and PB-PSSS. In 
both instances samples were prepared by obtaining the supernatant of a 1:1 mixture of pooled rat 
serum and acetonitrile. Prior to injection the capillaries were flushed for 3 min with BGE (1 M formic 
acid). Samples were injected for 120 s at 50 mbar followed by a 5 s 50 mbar water injection. The 
metabolites were then separated at 25 kV and 30 mbar in an 80 cm 50 µm i.d. capillary coated with 
either PDDMAC-PSSS or PB-PSSS.  
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Sample reproducibility: To test the reproducibility of CE-MS, samples of Tasmanian devil 
serum metabolites were run over the course of three days along with rat serum metabolites 
obtained from a pooled rat sample to use as a quality control. The rat quality controls in 
this sample set showed variation in migration time up to 5 min. Shifts in migration time 
changes and peak resolution were also observed between the devil samples. The capillary 
was re-coated with PSSS after approximately every 10 runs. When examining the quality 
controls, the migration time reproducibility was optimum when comparing runs that were 
conducted immediately after PSSS re-coating (see Figure 2.6). This was observed when 
comparing the electropherogram of the QC run immediately after PSSS re-coating and 13 
runs after PSSS re-coating (see QC 5 and QC 7 respectively in Figure 2.7). As shown in 
Figure 2.7 the migration times increased with subsequent runs. This suggested that the 
capillary wall was being modified by either the metabolites coating the capillary or the 
PSSS polymer was being removed during runs. The removal of the PSSS polymer would 
expose the underling PDDMAC polymer and reverse the EOF because of the change in the 
charge of the capillary wall [108]. The modification in the capillary wall was affecting 
subsequent runs by changing the EOF or increasing analyte-capillary interaction during the 
run and thus increasing the migration times of subsequent runs. This result shown in 
Figure 2.7 suggests that the capillary should have been re-coated with PSSS more 
regularly to obtain greater reproducibility. In general capillaries can be re-coated in CE as 
part of the method which allows for continue analysis of subsequent samples when using 
an autosampler. Automated PSSS re-coating could not be conducted as part of the method 
in this case because the capillary outlet needed to be unconnected from the MS to prevent 
the large polymer from contaminating the MS. This method could be improved by coating 
before each run but this would increase analysis time and would prevent running samples 
overnight unless a device could be developed which allowed for the outlet to go to waste 
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during re-coating. It would be beneficial to determine a more robust capillary coating 
method that did not require frequent recoating.  
 
Figure 2.6: Showing the reproducibility of this CE-MS method. Samples were prepared by obtaining 
the supernatant of a 1:1 mixture of pooled rat serum and acetonitrile. Prior to injection the capillaries 
were flushed for 5 min with BGE (1 M formic acid). Samples were injected for 120 s at 50 mbar 
followed by a 5 s 50 mbar water injection. The metabolites were then separated at 20 kV and 30 mbar 
in an 80 cm 50 µm i.d. capillary coated with PDDMAC-PSSS. 
Sample preparation: To determine the optimum conditions for metabolite isolation, two 
different organic solvents, methanol and acetonitrile (ACN) were investigated with 
different ratios of serum-to-solvent for protein precipitation. To determine the optimum 
organic solvent the proteins from a Tasmanian devil serum sample were precipitated by the 
addition of 1 volume of serum to two volumes of organic solvent (1:2). The 
electropherograms showed superior peak shapes and separation with the ACN protein 
precipitation (see Figure 2.8) thus different ratios of ACN to Tasmanian devil serum were 
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examined (see Figure 2.9). The electropherograms showing the separation of devil serum 
metabolites prepared with the 1:1 and 1:2 ACN ratios showed the most optimum and 
similar separations. The 1:1 ratio of ACN to serum was chosen since ACN provided better 
metabolite separation than the methanol preparation method and this ratio of solvent to 
sample, introduced less organic solvent during injection which could affect the ionic 
strength within the injection plug. 
 
Figure 2.7: Showing the change in migration time that occurs between a run conducted immediately 
after a PSSS re-coating (bottom electropherogram) and 13 runs after a PSSS re-coating (top 
electropherogram. Samples were prepared by obtaining the supernatant of a 1:1 mixture of pooled rat 
serum and acetonitrile. Prior to injection the capillaries were flushed for 5 min with BGE (1 M formic 
acid). Samples were injected for 120 s at 50 mbar followed by a 5 s 50 mbar water injection. The 
metabolites were then separated at 20 kV and 30 mbar in an 80cm 50 µm i.d. capillary coated with 
PDDMAC-PSSS. 
Sample injection study: To determine the optimum amount for sample injection, rat serum 
metabolites were injected into a PDDMAC-PSSS capillary for 75, 90 and 120 s and 
separated at 20 kV and 3 mbar. A longer injection of 120 s was considered to be optimum 
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since the electropherogram showed a higher number of separated peaks that were sharper 
and showed greater sensitivity (see Figure 2.10). 
 
Figure 2.8: Comparison of acetonitrile and methanol protein precipitation sample preparation steps. 
In both instances samples were prepared by obtaining the supernatant of a 1:2 mixture of Tasmanian 
devil serum and acetonitrile (top) or methanol (bottom). Prior to injection the capillaries were flushed 
for 5 min with BGE (1 M formic acid). Samples were injected for 90 s at 50 mbar followed by a 5 s 50 
mbar water injection. The metabolites were then separated at 20 kV and 30 mbar in a 73.8 cm 50µm 
i.d. capillary coated with PDDMAC-PSSS. 
Separation voltage: Separation of rat serum metabolites (with a 120 s 50 mbar injection) 
were investigated with voltages of 15, 20 and 25 kV with a constant separation pressure of 
30 mbar (see Figure 2.11). The 15 kV separation was not completed within 30 min which 
was around three times slower than the 20 kV and 25 kV separations. Although there was 
considerably greater resolution between peaks when separating at 15 kV there was also 
substantial peak broadening. On the other hand the 25 kV separation had very low 
resolution so 20 kV separations were conducted for further work. 
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Figure 2.9: Comparisons of different ratios of acetonitrile to serum for protein precipitation. In all 
instances samples were prepared by obtaining the supernatant of a 1:1, 1:2 or 1:3 mixture of 
Tasmanian devil serum and acetonitrile. Prior to injection the capillaries were flushed for 5 min with 
BGE (1 M formic acid). Samples were injected for 120 s at 50 mbar followed by a 5 s 50 mbar water 
injection. The metabolites were then separated at 25 kV and 30 mbar in an 80 cm 50µm i.d. capillary 
coated with PDDMAC-PSSS. 
 
Figure 2.10: Comparison of different injection times. In all instances samples were prepared by 
obtaining the supernatant of a 1:1 mixture of rat serum and acetonitrile. Prior to injection the 
capillaries were flushed for 5 min with BGE (1 M formic acid). Samples were injected for 75, 90 or 120 
s at 50 mbar followed by a 5 s 50 mbar water injection. The metabolites were then separated at 20 kV 
and 30 mbar in an 80 cm 50 µm i.d. capillary coated with PDDMAC-PSSS. 
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Figure 2.11: Examination of different separation voltages. In all instances samples were prepared by 
obtaining the supernatant of a 1:1 mixture of rat serum and acetonitrile. Prior to injection the 
capillaries were flushed for 5 min with BGE (1 M formic acid). Samples were injected for 120 s at 50 
mbar followed by a 5 s 50 mbar water injection. The metabolites were then separated at 15, 20 and 25 
kV (as stated) and 30 mbar in an 80 cm 50 µm i.d. capillary coated with PDDMAC-PSSS. 
2.4 Data Processing 
2.4.1 Gas Chromatography 
Peak Normalisation and Feature Selection: The serum metabolites were analysed by GC-
MS as stated in section 2.2.3. The data for each full chromatogram was tabulated 
according to retention time and the peak area of the base peak (most intense peak) ion for 
each metabolite. PCA was selected for the analysis of the data to allow for easy 
visualisation of the potential variance between DFTD and non-DFTD samples [71]. 
Initially PCA was conducted using all of the peaks without prior normalisation or feature 
selection (see Figure 2.12). Although the majority of DFTD and non-DFTD samples could 
be separated in this PCA, there were three non-DFTD samples (04/3011, 04/3003 and 
04/0560) that clustered with the DFTD samples. Two of these non-DFTD devils had been 
obtained from Fentonbury and the remaining sample, 04/0560 was obtained at Bronte Park 
61 
 
which is approximately 100 km north of Fentonbury.  Biases of gender and sampling 
location could be observed with samples 04/3000, 04/3003, 04/3008 and 04/3011. These 
four samples were obtained at Fentonbury from four different devils (see microchip 
numbers in Table A 1). It was observed that the two samples obtained from Fentonbury 
female devils, samples 04/3000 and 04/3003 clustered close together near the majority of 
the DFTD samples. The other two samples from Fentonbury, samples 04/3008 and 
04/3011, also clustered close together near the majority of the non-DFTD samples. The 
second principal component showed a general gender bias in this plot which was shown by 
the majority of the male samples clustering in the bottom half of the plot. This showed that 
the variability of the samples was not only affected by the presence of DFTD but 
potentially gender and sampling location as well. Gender, disease and sampling location 
[8, 10, 20, 21, 109] have all been previously shown to affect the presence and abundance 
of metabolites in biological samples. Various procedures, such as normalisation were then 
conducted to observe further variability between DFTD and non-DFTD samples. 
To remove any potential bias between samples a normalisation step is recommended when 
analysing biological samples such as urine, blood or tissue [110, 111]. There were a 
number of potential normalisation steps that could be investigated which included the 
addition of an internal standard [30, 112], normalising to a metabolite already present in 
the samples or by obtaining the ratio of each peak to the total area [32, 110]. Internal 
standards can also be added to the sample prior to sample injection and used to normalise 
the response for each metabolite. An internal standard would be required to not interact in 
any way; be absent in the sample and also elute away from the other components. One 
possibility is the use of labelled isotopes [30]. Since serum metabolite samples are already 
quite complex, an internal standard was not considered to be a viable option. 
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Initially all of the metabolites were normalised to the area of the cholesterol peak, a 
metabolite observed in all samples that elutes at the end of the chromatogram away from 
other metabolites. After the metabolites were normalised all the metabolite peaks were 
analysed using PCA and three clusters of samples were observed. One cluster contained  
 
Figure 2.12: PCA of the first and second principal components showing the variability of devil serum 
metabolites without any peak normalisation or feature selection. The samples came from 16 male and 
female devils that were trapped in 2004 in known DFTD areas around the eastern half of Tasmania. 
The samples were analysed by GC-MS. The samples were injected into the GC using a splitless 
injection for 0.75 min at 230 ˚C into a 15 m BPX-35 column. The temperature of the column was held 
at 55 ˚C for 2 min and then ramped to 330 ˚C at a rate of 15 ˚C/min. The column was held at 330 ˚C 
for 6 min. The acquisition of data was initiated 6.5 min into the run.  
just healthy samples, another contained a mixture of healthy and DFTD-positive samples 
and the third cluster contained two samples obtained from two different DFTD-positive 
male devils. This third cluster was positioned a considerable distance away from the other 
samples. The chromatograms for the two samples in the third cluster were examined 
further and it was found that the cholesterol peak was considerably smaller in these 
samples than in the other samples. The samples in the third cluster also had a decreased 
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abundance of glucose. Cholesterol levels in blood are increased by dietary intake of animal 
fat [113]. Animal fat would be digested by Tasmanian devils when they feed on carcases 
and other meat since they consume the whole carcass including the skeleton [76]. When 
DFTD becomes advanced, the position of the tumours could make it difficult for the devil 
to eat. If these samples came from devils with advanced disease this could explain the 
decrease in serum cholesterol and glucose. Other diseased or injured devils may also find it 
difficult to obtain food and would thus also show decreased serum cholesterol and glucose 
levels so this observation is not necessarily a good predictor for DFTD. The separation of 
samples in the PCA plot in Figure 2.13 did not appear to be separated according to other 
known parameters such as gender and/or sampling location. These results suggest that 
normalisation did aid in removing these biases but cholesterol was not an appropriate 
metabolite to normalise to. A feature selection step though can help to remove variables 
that are not dependent upon the disease or other criteria that is being explored.   
Feature selection is often conducted to decrease the complexity of data that is further 
analysed with PCA [65, 66]. As the number of samples is increased in the sample set the 
amount of information also increases and it is best to try and decrease the information prior 
to multivariate analysis. A feature selection step pre-selects the variables (in this case 
metabolite peaks) that have the highest chance of showing a difference between different 
classes of samples such as non-DFTD and DFTD. Two ways to do this is by ANOVA and 
Student’s t-test [68, 69]. Since only two groups were being investigated here (non-DFTD 
and DFTD) and ANOVA is used to analyse 3 or more groups, t-test was used in this 
instance [114]. Using the data normalised to cholesterol, a feature selection was conducted 
using Student’s t-test to obtain a list of metabolite peaks that were significantly different 
between the DFTD and non-DFTD samples to the 95 % confidence level (p ≤ 0.05). There 
were 15 peaks that were found to be significantly different and these peaks were further 
64 
 
analysed via PCA (see Figure 2.14). The PCA showed that there was variability between 
the DFTD and non-DFTD samples. In this analysis all of the non-DFTD samples were 
separated from the DFTD samples. This is logical since the variables that are not affected 
by the presence of DFTD are not involved in the analysis which removes variability of the 
samples that are caused by factors other than the presence of DFTD. 
 
Figure 2.13: Identifying variability between samples normalised to cholesterol: This PCA plot shows 
the separation from the first and second principal components. The samples came from 16 male and 
female devils that were trapped in 2004 in known DFTD areas around the eastern half of Tasmania. 
The samples were run by GC-MS and injected into the GC using a splitless injection for 0.75 min at 
230 ˚C into a 30 m BPX-35 column. The temperature of the column was held at 55 ˚C for 2 min and 
then ramped to 330 ˚C at a rate of 15 ˚C/min. The column was held at 330 ˚C for 6 min. The 
acquisition of data was initiated 6.5 min into the run. Each metabolite peak was normalised to 
cholesterol and all the peaks were analysed by PCA without prior feature selection. 
Another pre-selection process that can be used prior to PCA analysis is the Fisher test [31] 
and this process was also investigated for use as a feature selection step. The metabolite 
peaks determined to have a Fisher value of greater than one were further analysed with 
PCA where, ܨ ൌ  ሾఙሺ௔௟௟ ௦௔௠௣௟௘௦ሻሿమሾఙ ሺ஽ி்஽ ௦௔௠௣௟௘௦ሻሿమ. There were 68 metabolites where F >1 and the second 
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and third principal components showed the best separation between the non-DFTD and 
DFTD samples (see Figure 2.15). Since the Student’s t-test selected metabolites that were 
more apt at showing the variances between DFTD and non-DFTD this method of feature 
selection was used in future data analysis.  
Although the addition of a feature selection step did allow for the separation of non-DFTD 
and DFTD samples, cholesterol was not viewed as suitable for peak normalisation because 
diet can affect the concentration of cholesterol levels in the blood and this may affect the 
prediction of other DFTD and non-DFTD samples that are analysed since DFTD is not the 
only reason that a devil may have a decrease of food intake. Further normalisation 
procedures were therefore investigated. 
An alternate process used to normalise the data was to divide the response of each peak by 
the total sum of all peak areas [32, 110, 115]. Before calculating the sum of all peaks, 
peaks that were not observed in 80 % of the samples were removed. Previous work with 
normalising to cholesterol had shown improvement when a feature selection step was 
added to the analysing process so future analysis was conducted using a feature selection 
step. This method of analysis was able to show variability between non-DFTD and DFTD 
samples (see Figure 2.16). Two of the non-DFTD samples (04/0560 and 04/3003) were 
still positioned on the same side as the other non-DFTD samples but they clustered lower 
in the plot. These two samples also clustered with the DFTD samples in Figure 2.12. The 
other non-DFTD sample that had plotted with the DFTD samples in Figure 2.12 actually 
plotted with the non-DFTD samples well away from the DFTD samples. Overall though 
this plot generally separated the DFTD and non-DFTD samples. 
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Figure 2.14: PCA plot of the first and second principal components of metabolites that were 
normalised to cholesterol and reduced via a feature selection step using Student’s t-test. The samples 
came from 16 male and female devils that were trapped in 2004 in known DFTD areas around the 
eastern half of Tasmania. The samples were run by GC-MS. The samples were injected into the GC 
using a splitless injection for 0.75 min at 230 ˚C. The temperature of the column was held at 55 ˚C for 
2 min and then ramped to 330 ˚C at a rate of 15 ˚C/min. The column was held at 330 ˚C for 6 min. The 
acquisition of data was initiated 6.5 min into the run. Each metabolite peak was normalised to 
cholesterol and a feature selection was conducted using Student’s t-test. The 15 peaks with p ≤ 0.05 
were analysed by PCA. 
To confirm that a feature selection step was still required when the data was normalised to 
total area, a PCA using all of the identified metabolite peaks was conducted. The variables 
with the greatest loadings were not identical to those identified using Student’s t-test 
although many of the t-test peaks still had significant loadings in the loadings plot (see 
Error! Reference source not found. for the list of significant peaks determined using 
Student’s t-test and Figure 2.18 for the loadings plot). The first four principal components 
were examined but none were suitable at clustering the non-DFTD samples away from the 
DFTD samples (see Figure 2.17) which showed that a feature selection step is required to 
efficiently show differences between DFTD and non-DFTD samples using PCA. 
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Figure 2.15: PCA plot of the second and third principal components of metabolites that were 
normalised to cholesterol and reduced via a feature selection step using the Fisher test. The samples 
came from 16 male and female devils that were trapped in 2004 in known DFTD areas around the 
eastern half of Tasmania. The samples were run by GC-MS. The samples were injected into the GC 
using a splitless injection for 0.75 min at 230 ˚C. The temperature of the column was held at 55 ˚C for 
2 min and then ramped to 330 ˚C at a rate of 15 ˚C/min. The column was held at 330 ˚C for 6 min. The 
acquisition of data was initiated 6.5 min into the run. Each metabolite peak was normalised to 
cholesterol and a feature selection was conducted using the Fisher test. The 68 peaks with F > 1 were 
analysed by PCA. 
Although some good results were obtained when normalising to cholesterol, analysis of all 
future samples was normalised to total area to eliminate possible differences caused by 
food intake. When the data was analysed after normalising to total area of all peaks, and 
conducting a feature selection using Student’s t-test, the samples were efficiently separated 
between DFTD and non-DFTD samples using PCA analysis. Rather than continued 
exploration of the numerous types of chemometric analysis available, further analysis of 
data was therefore conducted using Student’s t-test for feature selection following by PCA. 
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Table 2.3: The list of peaks identified to be significantly different between DFTD and non-DFTD 
samples analysed by GC-MS and normalised to total peak area according to Student’s t-test. 
Peak # 
Retention 
time m/z p-value 
9 7.44 142 0.0117 
10 7.48 134 0.0273 
14 7.72 131 0.0143 
16 7.78 168 0.0440 
26 8.27 209 0.0204 
79 11.55 155 0.0043 
87 12.15 156 0.0043 
88 12.38 147 0.0475 
90 12.73 217 0.0003 
102 13.46 147 0.0428 
105 13.68 156 0.0215 
107 13.93 147 0.0114 
110 14.44 147 0.0434 
120 15.7 147 0.0229 
127 16.14 149 0.0474 
133 16.65 117 0.0020 
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Figure 2.16: PCA plot of the first and second principal components after normalisation to the sum of the total area. The samples came from 16 male and female 
devils that were trapped in 2004 in known DFTD areas around the eastern half of Tasmania. The samples were run by GC-MS. The samples were injected into the 
GC using a splitless injection for 0.75 min at 230 ˚C. The temperature of the column was held at 55 ˚C for 2 min and then ramped to 330 ˚C at a rate of 15 ˚C/min. 
The column was held at 330 ˚C for 6 min. The acquisition of data was initiated 6.5 min into the run. Each metabolite peak was normalised to the sum of the total 
area of each individual sample and a feature selection was conducted using Student’s t-test. The 16 peaks with p ≤ 0.05 were analysed by PCA. 
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Figure 2.17: PCA of the first and second principal components showing the variability of devil serum metabolites normalisation to total peak area with no feature 
selection. The samples came from 16 male and female devils that were trapped in 2004 in known DFTD areas around the eastern half of Tasmania. The samples 
were analysed by GC-MS. The samples were injected into the GC using a splitless injection for 0.75 min at 230 ˚C into a 15 m BPX-35 column. The temperature of 
the column was held at 55 ˚C for 2 min and then ramped to 330 ˚C at a rate of 15 ˚C/min. The column was held at 330 ˚C for 6 min. The acquisition of data was 
initiated 6.5 min into the run. 
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Figure 2.18: The plot of variables (metabolites) analysed for the PCA after normalisation to total area but without prior feature selection. 
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Figure 2.19: PCA analysis showing the variability of samples using the automated integration method. 
This PCA plot shows the variability determined using the first and second principal components. The 
samples came from 16 male and female devils that were trapped in 2004 in known DFTD areas around 
the eastern half of Tasmania. The samples were run by GC-MS. The samples were injected into the 
GC using a splitless injection for 0.75 min at 230 ˚C. The temperature of the column was held at 55 ˚C 
for 2 min and then ramped to 330 ˚C at a rate of 15 ˚C/min. The column was held at 330 ˚C for 6 min. 
The acquisition of data was initiated 6.5 min into the run. Each metabolite peak was automatically 
integrated as discussed above, normalised to the sum of the total area of each individual sample and a 
feature selection was conducted using Student’s t-test. The 11 peaks with p ≤ 0.05 were analysed by 
PCA. 
Peak Integration: During the pilot study of this research the peaks present in the gas 
chromatogram were integrated by both manual and automatic integration methods as 
discussed in section 2.2.3. Both of these processes involved determining the area of the 
most abundant mass peak for each peak in the chromatogram. Automatic integration was 
conducted using the same chromatograms used in Figure 2.16. The metabolite peaks were   
then analysed the same way by normalising each peak to the total peak area for each 
sample; conducting a feature selection using Student’s t-test to determine the peaks to the 
95 % confidence level and analysing by PCA (see Figure 2.19). Although the PCA plot 
that was obtained when the metabolite peaks were integrated manually (see Figure 2.16) 
was more able to separate all of the DFTD samples from the non-DFTD samples the 
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automatic integration process (Figure 2.19) greatly reduced the amount of time required to 
process the data and was therefore preferential. The PCA for the automatic integrated 
peaks included more of the sample variability in the first two components than the manual 
peak integration method which is desirable. Only sample 04/0605 in Figure 2.19 was not 
clustered with the correct samples. This sample in Figure 2.16, which used data that was 
manually integrated, clustered close to the DFTD samples. The analysis of future sample 
sets used the automatic integration process because of the dramatic reduction in analysis 
time. Using this method still provided good results for samples obtained from devils with 
DFTD were efficiently separated from the samples obtained from non-DFTD devils. 
2.4.2 ESI-MS 
No normalisation was required for the ESI-MS data since the data exported from the 
DataAnalysis (Bruker Daltonics) software was already normalised. In a similar way to the 
GC-MS data, a feature selection step was employed as a data reduction step using 
Student’s t-test. The variables (metabolite peaks) that were significantly different (p ≤ 0.1 
or p ≤ 0.05) were analysed further with PCA. This method of analysis as with GC-MS was 
found to successfully show variability between the DFTD and non-DFTD samples 
analysed by ESI-MS (shown in chapters 3, 4 and 5). 
2.5 Comparison of the different techniques 
The three methods discussed here (CE-MS, GC-MS and ESI-MS) required different 
sample preparation steps; used different types of MS analysers and involved different 
separation mechanisms. The techniques thus required varying analysis times and provided 
different degrees of analyte sensitivity.   
The CE-MS method could identify 36 distinct mass responses in the separation that were 
observed in the majority of devil samples compared to 107 and 142 peaks observed in 80 
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% of samples with the GC-MS and ESI-MS method respectively (Figure 2.20 shows the 
separation of serum metabolites from a DFTD and a non-DFTD Tasmanian devil using the 
CE-MS method). Capillary electrophoresis is known for the analysis of small sample 
volumes [15] which can reduce analyte sensitivity. The CE-MS method used an injection 
volume of just under 130 nL and taking into consideration the dilution factor of the 
samples prior to sample injection this injection was equivalent to 65 nL of serum. This was 
close to the equivalent amounts of serum that was analysed from the GC-MS and ESI-MS 
methods investigated which was 60 nL (from a 1 µL injection) with the GC-MS method 
and 45 nL with the ESI-MS method (taking an average spectrum between 1 to 2 min into  
 
Figure 2.20: Typical electropherograms showing the separation of serum metabolites from a non-
DFTD (top) and DFTD (below) Tasmanian devil. In all instances samples were prepared by obtaining 
the supernatant of a 1:1 mixture of non-DFTD or DFTD devil serum (as stated) and acetonitrile. Prior 
to injection the capillaries were flushed for 5 min with BGE (1 M formic acid). Samples were injected 
for 120 s at 50 mbar followed by a 5 s 50 mbar water injection. The metabolites were then separated at 
20 kV and 30 mbar in an 80 cm 50µm i.d. capillary coated with PDDMAC-PSSS. 
75 
 
the injection which was equivalent to 3 µL of sample). This suggests that the low sample 
volume was not the cause for the decrease in the number of metabolites observed with CE-
MS. The sensitivity of CE-MS is also reduced because of the need to dilute the sample 
further with the addition of sheath fluid [116]. Unlike the ESI-MS method, CE-MS 
requires additional sheath fluid because normal capillary flow does not provide efficient 
solute for electrospray ionisation [25, 39]. Extra fluid is not required with GC-MS since 
the analytes are all ready present in the gas phase and were ionised by an electron impact 
mass analyser.  
Each of these methods used a different type of mass spectrometer. Whereas an iontrap 
analyser was used with the CE-MS approach, a QTOF was utilised in the ESI-MS 
approach and a quadrupole was employed after electron impact with the GC-MS method 
which all have different amounts of mass resolution which can affect the number of 
metabolites observed [26]. Different mass analysers also provide different degrees of mass 
accuracy which is important for accurate determination of the elemental composition of 
the analyte and metabolite identification [117].  Iontraps and quadrupoles both do not 
provide the resolution that can be observed with other mass analysers [26, 42]. The most 
accurate MS analyser used in this work was the QTOF using for the ESI-MS method [42]. 
The sensitivity of MS detection when electrospray ionisation is utilised can also be 
reduced by the presence of salts in the sample. The first broad peak observed in the CE-
MS electropherogram (generally between 4-6 min in both the rat and devil samples) 
showed a pronounced peak consisting of sodium formate clusters. The large injection time 
required to show good analyte sensitivity had the fall back of also introducing a lot of 
sodium chloride into the capillary which can then react with the formic acid to form the 
sodium formate clusters. The presence of this cluster would contribute to ion suppression 
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which could be hiding the presence of metabolites that might co-elute with the sodium 
formate clusters. 
Small sample injections in CE can lead to poor analyte sensitivity so stacking techniques 
are commonly used in CE to improve detection ability [116].  Shihabi used acetonitrile 
precipitation to remove the proteins from plasma and as a stacking technique to examine 
peptides and drugs. The acetonitrile also allowed for increased sample injections up to 50 
% of the total capillary volume where as conventional CE uses injection volumes equal to 
0.5-2 % of the total capillary volume. Shihabi’s method though was only suitable to 
quantify drugs present in the body with concentrations in the range of mg/L [116]. This 
low sensitivity was also shown in the work discussed in this chapter (see section 2.3.3) 
where it appears that only the abundant metabolites were observed in the electropherogram 
when an injection equal to ~10 % of the capillary volume was used. Another process for 
sample stacking is to prepare the sample in buffer at a concentration 10 x less than the 
BGE. During this procedure a longer sample injection is used and the analytes move faster 
in the area of low ionic strength and then slow down as they enter regions of the full 
strength BGE. Injecting the sample electrokinetically can also improve analyte sensitivity 
by reducing the amount of solvent that is injected into the capillary [116]. This process of 
stacking could have been used by evaporating the solvent in the metabolite sample and 
resuspending the metabolites in dilute BGE.  
When comparing the two methods that involved the separation of metabolites prior to MS 
detection the GC-MS method was superior to the CE-MS method. The CE-MS method, 
given time, could have been improved via the investigation of different types of stacking; 
using different types of MS analysers; or testing other capillary coatings. The GC-MS 
method without extensive method development provided better separation efficiency than 
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CE-MS and improved sensitivity. This could be explained by the fact that the analytes 
were all ready in the gas phase and did not need to be diluted with a sheath liquid to be 
analysed by the MS. The GC-MS and ESI-MS methods also provided consistently 
reproducible chromatograms / spectrums. The GC-ME and ESI-MS method were therefore 
used in further work as the CE-MS method required further method development to obtain 
appropriate sensitivity and reproducibility. 
2.6 Summary 
The pilot sample set examined with GC-MS showed variability between the DFTD and 
non-DFTD samples when the correct normalisation procedure was implemented. In the 
development of the appropriate data analysis procedures though variability had been 
observed to be correlated with gender and sampling location (see section 2.4.1 and Figure 
2.12). The purpose of this study was to discover differences in the serum metabolome of 
DFTD devils prior to the manifestation of visible tumours. To aid in this discovery the 
sample variability was reduced to include samples obtained from male devils caught in the 
one location over the course of one year. These samples were analysed using both GC-MS 
and ESI-MS.  
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3 Comparison of ESI-MS and GC-MS Methods to 
Isolate Pre-Clinical Devil Facial Tumour Disease 
Biomarkers 
3.1 Introduction 
The work discussed in chapter 2 suggested that GC-MS and ESI-MS may be appropriate 
analytical techniques to study serum metabolites. This was shown when considering 
sample throughput and the sensitivity and selectivity of identifying non-DFTD and DFTD 
Tasmanian devils. In this chapter, these two mass spectrometry techniques are compared 
using non-targeted metabolite approaches to determine differences in the serum 
metabolome between non-DFTD and DFTD devils. The first method, GC-MS provided 
prior separation of metabolites before MS detection and the second method used MS 
detection without prior separation of metabolites. Low volumes of serum were obtained 
from DFTD and non-DFTD male wild devils trapped in eastern Tasmanian during 2004. 
This sample set was chosen to remove biases of sample storage times, gender, and genetics 
since devils from western Tasmania (which are yet to develop DFTD) are genetically 
different from eastern devils [4]. This chapter discusses the potential of identifying 
variability between DFTD and non-DFTD samples that is capable of diagnosing DFTD 
prior to clinical signs of the disease.  
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3.2 Methods 
3.2.1 Samples 
Tasmanian devil serum collected in 2004 was obtained in 2007 from the Tasmanian 
Department of Primary Industries, Parks, Water and the Environment (DPIPWE), Mount 
Pleasant, Tasmania; and stored at -80 ˚C (see Table 3.1).  
Table 3.1: List of samples obtained from male devils at Bronte Park with the addition of the male 
samples part of the pilot study (see chapter 2). Further details on these samples can be observed in 
Table A 1 and Table A 2 in the appendix. 
Accession 
number 
Graph 
sample ID 
DFTD 
status 
Sampling 
Location 
04/0276 1 Non-DFTD Bronte Park 
04/0284 2 DFTD Bronte Park 
04/0446 3 DFTD Bronte Park 
04/0448 4 Pre-clinical Bronte Park 
04/0451 5 DFTD Bronte Park 
04/0560 6 Pre-clinical Bronte Park 
04/0602 7 DFTD Bronte Park 
04/0720 8 DFTD Bronte Park 
04/0722 9 Non-DFTD Bronte Park 
04/0725 10 DFTD Bronte Park 
04/0728 11 Non-DFTD Bronte Park 
04/0731 12 Non-DFTD Bronte Park 
04/0735 13 DFTD Bronte Park 
04/1167 14 Non-DFTD Bronte Park 
04/1769 15 DFTD Bronte Park 
04/1771 16 Non-DFTD Bronte Park 
04/1849 17 Non-DFTD Bronte Park 
04/1852 18 Non-DFTD Bronte Park 
04/1853 19 DFTD Bronte Park 
Additional Samples from the Pilot Set 
04/2062 20 Non-DFTD Mount William 
04/2064 21 DFTD Mount William 
04/3008 22 DFTD Fentonbury 
04/3011 23 Non-DFTD Fentonbury 
04/3201 24 Non-DFTD St Helens 
04/0960 25 Non-DFTD National Park 
80 
 
These 25 samples had been collected from wild male Tasmanian devils in the eastern half 
of Tasmania, Australia. DFTD status, sampling location and other information on the 
sample can be seen in Table 3.1. Pooled mouse serum was used as a quality control. 
3.2.2 Reagents 
Methanol (> 99.7 %, isocratic HPLC grade (254nm), was obtained from Scharlau Chemie 
S.A., European Union); Milli-Q water (Millipore);≥ 98 % o-methylhyrodxylamine 
hydrochloride and 98 % Formic acid were obtained from Fluka; N-Methyl-N-
(trimethylsilyl)trifluoroacetamide (MSTFA) and pyridine (≥ 99.0 %) were obtained from 
Sigma Aldrich. 
3.2.3 Sample Preparation 
Proteins were removed from the serum by precipitation with methanol by the addition of 
15 µL of serum to 500 µL of cold methanol as stated in section 2.2.3. The supernatant was 
analysed using two complementary mass spectrometric techniques, gas chromatography-
mass spectrometry (GC-MS) and electrospray ionisation-mass spectrometry (ESI-MS).  
Gas chromatography - mass spectrometry: Samples were prepared by evaporating 200 µL 
of the supernatant to complete dryness under vacuum and derivatising the metabolites with 
methylhydroxylamine hydrochloride and MSTFA as described in section 2.2.3. 
Electrospray ionisation – mass spectrometry: A 100 µL aliquot of supernatant for each 
sample and mouse quality control was placed into a tube with 2 µL of a 10 % v/v formic 
acid (in milli-Q water) and 98 µL of methanol to give a 0.1 % acidified solution. Reagent 
blanks were prepared by adding 2 µL of a 10 % v/v formic acid (in milli-Q water) to 198 
µL of methanol. 
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3.2.4 Instrumentation 
Gas chromatography - mass spectrometry: The samples were analysed using a Shimadzu 
QP2010-plus GC-MS fitted with a 15 m BPX-35 capillary column as described for the 15 
m column in section 2.2.3. 
Electrospray ionisation – mass spectrometry: These experiments were conducted by 
electrospray ionisation quadropole – time of flight- mass spectrometer (ESI-QTOF-MS) 
with a Bruker micrOTOF-Q II instrument. The prepared sample was infused into the 
instrument into the same way as stated in section 2.2.4 and analysed using the same 
parameters. Prior to every 10 samples a reagent blank and quality control sample was run. 
All analyses were performed on the same day. The average spectrum obtained between 
1.0-2.0 min was then used for further analysis and collected using the same software 
according to section 2.2.4. 
3.2.5 Data Analysis 
Gas chromatography – mass spectrometry: Data interrogation initially involved obtaining 
the total area of the base peak for each chromatographic signal. The response for each peak 
was normalised to the total response of all the peaks. Automated data reduction was 
performed across the entire data set to locate sample class-differentiating metabolites by 
using two-tailed t-tests to determine differences between the DFTD and non-DFTD 
conditions. A p-value less than 0.05 or 0.10 (as stated) was considered statistically 
significant. The significant peaks were then analysed with PCA using XLSTAT (version 
2010.2.01 Copyright Addinsoft 1995-2009). 
Electrospray ionisation – mass spectrometry: Data interrogation was performed by 
chemometric analysis of the extracted spectra (50-1200 m/z). First a feature selection was 
performed using a series of Student’s t-tests to extract ion responses that were significantly 
different (p < 0.1 or p < 0.05) between the DFTD and non-DFTD samples. The 
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significantly different ion responses were then analysed further using PCA (XLSTAT 
Version 2010.2.01 Copyright Addinsoft 1995-2009). 
3.3 Results and Discussion 
From the 19 samples obtained at Bronte Park, 9 samples were obtained from animals that 
exhibited visible DFTD tumours, 10 were apparently disease-free although 2 of these 
animals were later found to have showed signs of DFTD in a subsequent trapping trip. 
These two samples came from devils that were confirmed to have DFTD when they were 
captured 35 and 69 days afterwards (samples 4 and 6 respectively). The only variables that 
were controlled were sample storage time, gender and the requirement for the serum to 
have come from locations known to contain DFTD devils in the eastern half of Tasmania. 
These variables were controlled to remove bias between gender and the genetics of eastern 
and north-western devils. 
3.3.1 GC-MS 
Since promising results had been obtained from the pilot study (see chapter 2), these 
samples were analysed using GC-MS. Examples of chromatograms from a non-DFTD and 
DFTD sample can be observed in Figure 3.1. To determine if there was variability between 
the non-DFTD and the DFTD samples, the samples were analysed by PCA. To reduce the 
amount of data prior to PCA analysis a feature selection was conducted using Student’s t-
test. The eleven chromatographic signals with a p value < 0.1 were analysed further with 
PCA since only six signals had p values < 0.05. The PCA plot that shows the first and 
second principal components can be observed in Figure 3.2. The plot can be separated into 
an area of only non-DFTD samples but the DFTD area contained two samples that had 
come from apparent non-DFTD individuals. Continued trapping trips had been undertaken 
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at this location so information was sought to determine if any of the devils that had 
provided these samples later showed signs of DFTD. 
 
Figure 3.1: Comparision of GC-MS chromatograms of a non-DFTD and DFTD serum sample. The 
samples were injected into the GC using a splitless injection for 0.50 min at 230 ˚C. The temperature 
of the column was held at 55 ˚C for 0.70 min and then ramped to 330 ˚C at a rate of 42.40 ˚C/min. The 
column was held at 330 ˚C for 2.10 min. The acquisition of data was initiated 2.20 min into the run. 
Unfortunately, the devil that provided sample 04/1771 (graph ID 16) was not caught again 
so further information on this devil could not be obtained. Interestingly though, two of the 
samples from this set were shown to later develop DFTD. Sample 04/0448 (graph ID 4) 
clustered with the non-DFTD samples in Figure 3.2 but this devil showed signs of DFTD 
when it was trapped again 35 days later. Sample 04/0560 (graph ID 6) which had also been 
part of the pilot study, was diagnosed with DFTD after it was trapped again 69 days later. 
It is interesting that the sample that showed signs 69 days later clustered with the DFTD 
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samples where as the sample from the devil with DFTD signs 35 days later clustered with 
the non-DFTD samples in the PCA plot in Figure 3.2.  There are a couple of hypotheses 
that could explain this. Firstly, it is possible that sample 6 developed visible tumours prior 
to sample 4 but this could not be determined since the devils were only examined if they 
were trapped during trapping expeditions. Secondly, it is possible that the presence of 
these two pre-clinical DFTD samples (samples 4 and 6) in the feature selection step as 
non-DFTD samples may have also influenced the results.  
 
Figure 3.2: Principal component analysis (PCA) of the 11 signals determined to be significantly 
different (p-value < 0.1) between ten apparent non-DFTD serum samples and nine DFTD samples 
analysed by GC-MS.    
To eliminate the influence of the two pre-clinical samples as well as sample 16 on the 
feature selection, these samples were removed and the remaining samples reanalysed. This 
time, feature selection with Student’s t-test was used to determine signals that were 
significantly different from the remaining seven non-DFTD samples and the nine DFTD 
samples. The 19 signals which had p-values < 0.1 from all 19 samples were then analysed 
again with PCA (see Figure 3.3). With the three samples removed from the feature 
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selection, the two pre-clinical samples (samples 4 and 6) clustered with the DFTD 
samples. This exciting result showed that there are serum metabolite differences between 
DFTD and non-DFTD devils that can be observed before observable tumours. Both of the 
pre-clinical samples did not cluster with the DFTD samples in the first PCA (Figure 3.2) 
because including these samples in the feature selection would interfere in the selection of 
metabolites that are different between DFTD and non-DFTD samples. Interestingly, 
sample 16, which was also removed from the feature selection step, still clustered with the 
DFTD samples. It is possible that this devil did have DFTD with no observable tumours 
but this cannot be determined for certain because the individual was not trapped again.    
 
Figure 3.3: Showing the variability of samples without including the pre-clinical samples in the feature 
selection. PCA of the 19 signals determined to be significantly different (p-value < 0.1) between 7 non-
DFTD serum samples and 9 DFTD samples analysed by GC-MS. The two pre-clinical DFTD samples 
along with sample 16 that had clustered with the DFTD samples in Figure 3.2 were not included in the 
feature selection.  
Since good results were obtained with the Bronte Park samples the remaining male 
samples from the pilot study that had not already been included in the Bronte Park set were 
added to the analysis. This was to show if the addition of other devils from around eastern 
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Tasmania could still show metabolite variability between non-DFTD samples and samples 
obtained from devils with DFTD including individuals that developed DFTD in the future 
(pre-clinical). Another feature selection was conducted in the same way as above and 
looked for differences between the 11 DFTD samples and the 11 non-DFTD samples (this 
feature selection did not include the two pre-clinical samples or sample 16 that had 
clustered with the DFTD samples in both of the plots in Figure 3.2 and Figure 3.3). The 17 
signals with p values < 0.05 were analysed further using principal component analysis 
(PCA). The first and third principal components were required in this PCA to adequately 
separate the DFTD and non-DFTD samples (see Figure 3.4). The pre-clinical DFTD 
samples as well as sample 16 still clustered with the DFTD samples. Interestingly, the 
sample that showed clinical signs of DFTD 35 days after the sample had been taken still 
clustered close to the non-DFTD samples as it had done in the two previous PCA plots. 
Even though the majority of samples were obtained from Bronte Park, the samples 
obtained from other areas in eastern Tasmania still separated according to DFTD status in 
the PCA plot. As in these two former plots, the pre-clinical sample that was observed to 
have clinical signs 69 days later (sample 6) was positioned on the opposite side of the non-
DFTD cluster on the PCA plot. As was mentioned above, it is possible that the devil 
developed DFTD tumours earlier than the other pre-clinical sample (sample 4).  
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Figure 3.4: Variability between devil serum samples obtained from male devils in eastern Tasmania. 
This plot shows a principal component analysis using the first and third principal component, of 
DFTD, pre-clinical DFTD and non-DFTD serum samples from male Tasmanian devils analysed by 
GC-MS. The chromatographic data was analysed initially with Student’s t-test to determine 
significantly different peaks between the DFTD and the non-DFTD (not including the potential pre-
clinical samples and sample 16) samples. The 17 signals with a p value < 0.05 along with the 25 samples 
were then analysed via PCA.  
3.3.2 Metabolite Identification 
It is not necessary to identify the metabolites when the data is analysed with multivariate 
pattern analysis to determine the metabolite biomarkers [24]. The identification of these 
metabolites though, could be useful for understanding the disease or in the development of 
a more practical method to analyse samples for the disease. With prior separation, 
metabolites can be tentatively identified from the retention time and the mass spectrum 
using metabolomics libraries or standards [9]. Metabolites can be hard to identify though, 
because the lack of commercially available metabolites limits the number of metabolites 
that are included in metabolomics libraries [25] or as metabolite standards.  
The GC-MS peaks that were determined to be significantly different between the DFTD 
and non-DFTD samples of all the males analysed in this chapter were preliminarily 
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identified using a private metabolite library obtained from a collaboration with the Max 
Planck Institute (Golm Database). The spectra of each of the peaks were compared to the 
spectra in the metabolite database. Some of the metabolites could not be identified with 
enough confidence from the library and these were identified as being unknown. 
Identification was aided using retention indices provided in the Golm Database. To ensure 
that the identified metabolites was appropriate, retention indices values were plotted 
against the retention time along with two known metabolites phosphate and cholesterol 
which eluted at the beginning and end of the chromatogram respectively (see Figure 3.6). 
The metabolite identifications and average abundance of each metabolite are listed in 
Table 3.2. Except for peak 38 the average abundance of each of the metabolites listed in 
Table 3.2 was higher in the DFTD samples than it was in the healthy serum samples. 
Compound 76, which was identified as being an unknown, was around twice as abundant 
in both the DFTD and the pre-clinical samples. Interestingly this peak was on average 
more abundant in the pre-clinical samples than it was in the samples obtained from devils 
with visible tumours. Previous research has also shown changes in the concentration of 
some of the suggested metabolites in Table 3.2 between healthy and cancerous samples 
from animals or humans.  
Glycine has been shown to increase in cells as they become more tumourgenic [118]. This 
work also showed an increase in the concentration of glycine in serum samples from 
DFTD devils both before and after visible signs.   Yang et al. found in their study of the 
central metabolism of human cancer cells that the concentration of Myo-inositol decreased 
in tumour tissues [118]. Myo-inositol though has been shown to be increased in a selection 
of cancers including colon adenocarcinoma, ovarian carcinomas and schwannomas [24]. 
We found that the concentration of this metabolite increased in serum from DFTD devils 
which appear to have developed from a Schwann cell or a precursor of Schwann cells [82]. 
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Erythrose is a type of aldolase and in 1943, research was published that showed that rats 
with tumours had an abundance of aldolase. This has also been shown in human sera from 
cancer patients although the increase in aldolase was not very pronounced [119].  
Table 3.2: Identification of metabolites that were significantly different between DFTD and non-DFTD 
serum samples including fold changes with respect to non-DFTD samples.  
Pk # Identification 
Average fold change 
in pre-clinical 
compared to non-
DFTD 
Average fold 
change in DFTD 
compared to non-
DFTD 
30 Unknown 1.3 1.6 
37 Glycine 1.3 1.3 
38 Unknown 0.9 0.9 
46 Erythrose 1.2 1.3 
55 Aspartic acid 2.3 1.4 
56 Unknown 1.5 1.3 
59 Oxalacetic acid 1.3 1.3 
60 Unknown 1.3 1.4 
62 Oxoproline 1.7 1.7 
64 Ribitol derivitive 1.5 1.5 
65 Unknown 1.4 1.3 
70 Unknown 1.4 1.4 
71 Unknown 1.8 1.6 
73 Inositol-β-glactoside 1.7 2.3 
74 Myo-inositol 1.4 1.3 
76 Unknown 2.3 1.8 
78 Unknown 1.6 1.6 
 
It was promising that some of the identified metabolites or metabolite classes had 
previously been associated with other cancers especially myo-inositol which has 
previously been associated with schwannomas. The identification of metabolites specific 
to DFTD could be used to study the biology of DFTD and the effects it causes to 
Tasmanian devils. These identifications should be confirmed using metabolite standards (if 
available) and then could be used to develop a more targeted metabolomic approach to 
diagnose DFTD in future research. 
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Figure 3.5: The average normalised intensity significantly different metabolites identified with GC-
MS. This graph compares the normalised intensity between DFTD (clear box) and healthy (filled box) 
samples. The error bars are ± one standard deviation from the average. The bottom graph is zoomed 
in to show more detail. 
 
Figure 3.6: Plot of retention time verses retention indices of identified metabolites. The first and last 
data points are phosphate and cholesterol respectively. 
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3.3.3 ESI-MS 
Although compound identification with mass spectrometry is more difficult without the 
information that can be gained though prior separation, analysis time is dramatically 
reduced with the removal of the separation step. These samples were analysed via 
electrospray ionisation - mass spectrometry (ESI-MS) to confirm the results obtained from 
the GC-MS data and determine if a faster technique could be used to diagnose DFTD. 
Examples of chromatograms from a non-DFTD and DFTD sample can be observed in 
Figure 3.7. 
 
Figure 3.7: Comparison of mass spectra from a non-DFTD and a DFTD serum sample analysed in 
positive ion mode via ESI-QTOF-MS. 
A feature selection using Students t-test was again conducted to reduce the amount of data 
prior to analysis by PCA with the XLSTAT software. Since the two pre-DFTD samples 
(sample 4 and 6) and sample 16 continually clustered with the DFTD samples when the 
samples had been analysed by GC-MS, the ESI-MS feature selection step did not include 
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these three samples. Initially only the Bronte Park males were analysed and the PCA plot 
can be observed in Figure 3.8. The Student’s t-test identified 57 signals with p-values < 
0.05 and these signals from each of the 19 samples were analysed with PCA. The 
variability between the non-DFTD and DFTD samples was more pronounced when the 
samples were analysed by ESI-MS than when they were analysed by GC-MS analysis 
(compare plots in Figure 3.3 and Figure 3.8). Encouragingly both of the pre-clinical 
samples (samples 4 and 6 marked with “x” on the plot) still clustered with the DFTD 
samples with this method. Sample 16 clustered with the non-DFTD samples instead of 
with the DFTD samples as it did after GC-MS analysis. There are two hypotheses that 
could explain this. The first possibility is that the GC-MS method is capable of identifying 
DFTD earlier than the ESI-MS method because of the prior separation of metabolites prior 
to MS detection. The second hypothesis is that the ESI-MS method is more accurate at 
diagnosing non-DFTD individuals than the GC-MS method which would suggest that the 
devil that provided sample 16 was in fact non-DFTD. These theories cannot be confirmed 
because the devil was not re-captured. Increasing the sample set could help to examine if 
ESI-MS can identify samples with DFTD earlier than the GC-MS method.   
Since variability between the DFTD and non-DFTD samples was successfully shown with 
the Bronte Park samples analysed by ESI-MS, the remaining male samples from the pilot 
study were also included as they had been with the GC-MS approach. The feature selection 
identified 130 MS signals that had p-values < 0.05 with Student’s t-test. The PCA 
successfully separated the non-DFTD samples from the DFTD samples using the first and 
second principal components (see Figure 3.9). The variability between the DFTD and the 
non-DFTD samples was not as pronounced in this PCA plot as it was in Figure 3.8 when 
only the Bronte Park samples were anlaysed. This could be explained from the increase in 
sample variability by the addition of multiple sampling locations. The pre-clinical samples 
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Figure 3.8: Variability between samples obtained from devils at Bronte Park. This plot shows the 
principal component analysis (PCA) of the 57 signals determined to be significantly different (p-value 
< 0.1) between 7 non-DFTD serum samples and 9 DFTD samples analysed by ESI-MS. The two pre-
clinical DFTD samples along with sample 16 that had clustered with the DFTD samples in Figure 3.2 
were not included in the feature selection. 
were positioned in the DFTD cluster close to the non-DFTD samples whereas sample 16 
remained clustered with the non-DFTD samples. There were other DFTD samples that 
were positioned on the plot close to the pre-clinical samples. Two of these samples came 
from the same devil (samples six and ten; devil A) and were sampled four months apart. 
Samples 9, 8 and 4 were sampled respectively over the course of 50 days from another 
devil (devil B). The samples that were taken later were positioned further to the left on the 
PCA plot. Sample 7 was sampled from the same devil as sample 24 (devil C), 35 days 
later. The positions of samples from devils A, B and C could suggest that the first principal 
component and thus the positions of samples on the PCA plot do coincide with the length 
of time that a devil has had DFTD but this is inconclusive.  
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Figure 3.9: Variability between samples obtained from male devils throughout eastern Tasmania. This 
plot shows the PCA using the first and third principal component, of DFTD, pre-clinical DFTD and 
non-DFTD serum samples from male Tasmanian devils analysed by ESI-MS. The MS data was 
analysed initially with Student’s t-test to determine significantly different peaks between the DFTD 
and the non-DFTD (not including sample 16) samples. The 130 signals with a p value < 0.05 along with 
the 25 samples were then analysed via PCA. 
3.3.4 Method comparison 
The results from the ESI-MS and the GC-MS sets of data showed that there are differences 
in serum metabolite profiles between non-DFTD and DFTD positive devils for a sample of 
wild male devils that were caught over the course of one calendar year from a range of 
geographical areas in the eastern half of Tasmania. There can be many issues when mining 
for potential disease biomarkers in wild animals because of the lack of control such as 
genetics or diet [20, 21] that can affect an individual’s metabolome. This work was able to 
overcome the issues that can be seen with wild animals and successfully distinguish 
between samples taken from DFTD and non-DFTD devils including classifying pre-
clinical samples as DFTD positive by limiting the variability of other factors that can 
affect the metabolome. At present pre-clinical diagnosis cannot be conducted on 
Tasmanian devils for DFTD. Both of these methods show evidence of the ability to 
diagnose DFTD prior to visible tumours by the analysis of serum metabolites. The GC-MS 
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method was capable of obtaining preliminary metabolite identifications. These 
identifications need to be confirmed using metabolite standards. Identifying these 
metabolites could increase the knowledge of components that help to characterise DFTD 
[6] and help to further understand the disease.  
The development of two complementary techniques for DFTD diagnosis is advantageous 
for multiple reasons. If uncertain results are obtained with one of the methods the 
diagnosis could be evaluated using the alternate method. The GC-MS method is able to 
give additional information because of the prior separation of metabolites and production 
of mass fragments allows for identification of the metabolites. The results obtained in this 
study also showed the possibility that prior separation of metabolites before MS detection 
could help diagnose DFTD earlier since sample 16 was only identified as DFTD in the 
GC-MS method. The ESI-MS method could be utilised as a quick screening test for 
DFTD. The isolation of metabolites is identical for both methods so after the metabolites 
have been isolated they can be analysed by either GC-MS or ESI-MS. Since GC-MS could 
potentially show DFTD earlier than the ESI-MS method the GC-MS method could be used 
to just re-analyse the samples classified as non-DFTD to confirm the diagnosis which 
would decrease diagnosis time. The methods discussed here show the potential to test 
individuals for DFTD within a day using a small amount of serum. Currently DFTD 
diagnosis takes a number of days and can only be determined after the presentation of 
visible tumours so both of these methods show improvement on the current DFTD 
diagnostic test.  
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4 Blind Study to Investigate Differences in the 
Metabolome of DFTD and Non-DFTD Devils 
Involved in a DFTD Suppression Trial 
4.1 Introduction 
The major purpose of research into DFTD is to prevent the possible imminent extinction of 
the Tasmanian devil and this has resulted in two major initiatives being undertaken. The 
first project involves the establishment of a captive insurance population. This insurance 
population was obtained in part by capturing Tasmanian devils in DFTD-free areas in 
western Tasmania. This population has been established in numerous wildlife parks and 
zoos across Tasmania and the rest of Australia. The second project involved a suppression 
trial in the Forestier Peninsula in south-eastern Tasmania. This location was chosen 
because the only connection to the mainland of Tasmania is via a bridge over a canal. The 
suppression trial involved capturing and euthanising infectious animals to limit the spread 
of DFTD [86].  
At present all current methods for the diagnosis of DFTD require biopsies of the suspected 
DFTD tumours [82, 85]. This is disadvantageous in the suppression trial because DFTD-
devils can only be identified and removed once they are all ready contagious. Although 
there was no increase in the abundance of DFTD during the suppression trial, the disease 
was not eliminated from the Forestier Peninsula population [120]. As the spread of DFTD 
is by allograft, the visible presence of DFTD tumours required for diagnosis leaves the 
possibility in which the disease can still be spread. The availability of a pre-clinical test 
along with frequent trapping trips could improve the success of this trial by eliminating 
DFTD devils prior to the transmission of the disease to another individual.  
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This chapter builds upon the results of chapter 3 by increasing the number of devils in the 
sample set and using the metabolite profiling methods in a diagnostic manner with blind 
samples. Samples were obtained from male devils trapped in the Forestier Peninsula 
between 2008 - 2010. Concentrating on devils from this specific location removed many of 
the sample variables that would be present in a sample set representing devils from 
throughout the state. Although a pre-clinical test that is suitable for all Tasmanian devils is 
required to help with the establishment of captive insurance populations, the development 
of any pre-clinical diagnostic test for this specific population has direct and immediate 
benefits if implemented to assist in a suppression trial.  In chapter 3, the ESI-MS method 
was shown to give comparable results to the GC-MS analysis in a considerable shorter 
time frame. The ESI-MS method was, therefore, used to examine serum metabolites from 
a set of 97 samples obtained from healthy devils; devils with DFTD; devils with other 
diseases; and devils that later developed DFTD. All of the samples were blind except for 
18 samples that were analysed to train the chemometric algorithms. 
4.2 Methods  
4.2.1 Samples  
A set of 97 Tasmanian devil serum samples was obtained from the Tasmanian Department 
of Primary Industries, Parks, Water and the Environment (DPIPWE) and stored at -80 ˚C. 
The samples were obtained from 59 wild male devils that had been trapped between 2008 
and 2010 on the Forestier Peninsula, south eastern Tasmania, Australia and included 18 
sample replicates. The sample set included 10 known DFTD samples and 8 known healthy 
samples from devils that had not shown any signs of DFTD that were used as a training 
set. The known DFTD samples were labelled as sample 10, 15, 20, 49, 50, 77, 80, 90, 95 
and 100 and the healthy samples were samples 24, 28, 29, 40, 42, 62, 67, and 70. All the 
remaining samples were blind. Quality control samples were prepared from pooled rat 
serum.  
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4.2.2 Reagents 
Methanol (> 99.7 %, isocratic HPLC grade (254 nm)), was obtained from Scharlau 
Chemie S.A., (European Union); a 10 % v/v solution of formic acid was prepared with 
formic acid (98 %, Fluka) and diluted with Milli-Q water (Millipore). 
4.2.3 Sample Preparation 
Each day up to 40 devil samples plus two aliquots of rat serum were prepared and run in 
the same day. The samples were randomised prior to sample preparation. Serum 
metabolites were extracted by mixing 15 µL of serum with 500 µL of cold methanol as 
stated in section 2.2.3 and prepared for ESI-MS analysis according to section 3.2.3. Two 
aliquots of supernatant from each of the prepared rat samples were prepared for quality 
controls.  
4.2.4 Instrumentation 
ESI-MS experiments were conducted using a QTOF Mass spectrometer (Bruker 
micrOTOF-Q II). The samples were randomised again prior to injection into the ESI-MS. 
Prior to every 10 samples a reagent blank and quality control sample was run. Each sample 
or reagent blank in turn was infused into the instrument the same way as stated in section 
2.2.4 and analysed using the same parameters. The average spectrum obtained between 
1.0-2.0 min was then used for further analysis and collected using the same software in the 
same way as stated in section 2.2.4. On each day of analysis the first Tasmanian devil 
sample was run 3 times over the course of the day. Two quality control samples were 
prepared each day and two aliquots were obtained from each of these prepared QC 
samples and run on the instrument in alternating order.  
4.2.5 Data Analysis 
The 18 training set samples undertook automated data reduction to locate sample class-
differentiating metabolites by using two-tailed t-tests to determine differences between the 
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DFTD positive and DFTD negative devils. A p-value ≤ 0.05 was considered statistically 
significant and the significant peaks were then analysed using PCA (XLSTAT Version 
2010.2.01 Copyright Addinsoft 1995-2010). Each peak in the quality control samples were 
examined to see if they were outside an acceptable range determined by the following 
formula: ݂ሺݔሻേ ൌ ݔҧ േ ሺܩ௡ୀ௫ ൈ ߪሻ, where Gn=12 was the Grubbs test value for 12 samples 
which is 2.412.  
4.3 Results 
4.3.1 Quality Controls 
The Grubbs test analysis showed good reproducibility with the QC samples (example 
spectrums can be observed in Figure 2.4, see spectrums for day 1, 2 and 3).  
4.3.2 Identification of Metabolome Differences between DFTD and Non-DFTD 
Serum Samples 
The 18 known samples mentioned in section 4.2.1 formed a training set that was used to 
aid in establishing the DFTD footprint from each individuals metabolite fingerprint. This 
was conducted using Student’s t-test as a feature selection step. The Student’s t-test 
determined 16 peaks to be significantly different between the DFTD positive and DFTD 
negative samples to the 95 % confidence level. The masses are listed below in Table 4.1. 
This is lower than the number identified with the Bronte Park samples (see section 3.3.3) 
which may be because of the increase in sample variability since the samples were not all 
obtained during the one year or the increase in the number of samples which may have led 
to the identification of metabolites more specific to DFTD.  
Table 4.1: List of mass-to-charge ratios determined to be significantly different (p < 0.05) according to 
Student’s t-test. 
134 191 192 200.9 207 519.3 547.4 584.4 
622.4 709.5 818.6 829.7 841.5 885.8 936.7 953.7 
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Figure 4.1: Principal component analysis using the first and second principal components sowing the variability between samples obtained from Forestier. A 
Students t-test was conducted and the 16 peaks that had p-value ≤ 0.05 between the 8 healthy and 10 DFTD samples were used to develop this PCA. The blind 
samples were plotted onto the PCA as supplementary observations. (Replicates were labelled X.1, X.2 and X.3 if they had been analysed on the same day.  
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Principal component analysis (PCA) was then conducted on the 18 training set samples 
with only the peaks that were determined to be significantly different. The analysis was 
then used to plot the remaining 79 samples (see Figure 4.1).  The plot of variables shows 
which of these mass-to-charge ratios contributed most to the variability between the left 
and right side of the plot which corresponds to the non-DFTD and DFTD samples 
respectively (see Figure 4.2). 
 
Figure 4.2: Plot showing the correlation between variables and principal components. It shows the 
importance each variable (m/z) had in the position of each sample on the PCA plot. 
The PCA plot (see Figure 4.1) was separated into three sections, non-DFTD, DFTD and 
uncertain, according to the position of the samples in the training set. These three sections 
were used to predict the DFTD status of all of the blind samples. Once the disease 
diagnosis predictions had been completed the samples were unblinded to determine the 
accuracy of this method in predicting DFTD. The identification for each sample can be 
seen in Table 4.2 and are summarised in   
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Table 4.3. 
. 
Table 4.2: DFTD classifications for all of the unknown Forestier samples obtained using 20 Forestier 
samples for the training set. Samples that were wrongly classified are in italics. Samples run in 
triplicate are labelled X.1, X.2 and X.3, where X is the sample number. 
Sample 
ID 
PCA 
classification 
Prior Clinical 
Diagnosis  
Sample ID 
PCA 
classification 
Prior Clinical 
Diagnosis 
1 DFTD DFTD 30 NON-DFTD DFTD in 12 month 
2 DFTD DFTD 31 NON-DFTD DFTD in 12 month 
3 DFTD DFTD 32 NON-DFTD DFTD in 12 month 
4 DFTD DFTD 33 DFTD DFTD 
5 DFTD DFTD 34 Uncertain DFTD in 6 month 
6 DFTD DFTD 35 NON-DFTD Other disease 
7 DFTD Other disease 35.2 Uncertain Other disease 
8 DFTD DFTD 35.3 NON-DFTD Other disease 
9 Uncertain DFTD 36 DFTD DFTD 
11 DFTD DFTD 36.3 DFTD DFTD 
12 DFTD DFTD 37 DFTD DFTD in 12 month 
13 DFTD DFTD 38 DFTD DFTD in 6 month 
14 Uncertain DFTD 39 NON-DFTD DFTD in 6 month 
16 DFTD DFTD 41 NON-DFTD DFTD in 12 month 
17 NON-DFTD DFTD 44 NON-DFTD DFTD in 6 month 
18 DFTD DFTD in 6 month 44.2 NON-DFTD DFTD in 6 month 
19 DFTD DFTD 44.3 NON-DFTD DFTD in 6 month 
21 DFTD DFTD 45 Uncertain DFTD in 6 month 
22 DFTD DFTD 46 NON-DFTD DFTD in 6 month 
23 Uncertain DFTD 47 NON-DFTD DFTD in 12 month 
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Sample 
ID 
PCA 
classification 
Prior Clinical 
Diagnosis  
Sample ID 
PCA 
classification 
Prior Clinical 
Diagnosis 
25 NON-DFTD DFTD in 6 month 48 DFTD DFTD 
26 NON-DFTD DFTD in 12 month 51 NON-DFTD DFTD in 6 month 
27 DFTD DFTD in 6 month 52 DFTD DFTD 
53 NON-DFTD DFTD in 12 month 75 DFTD DFTD in 1 month 
54 NON-DFTD DFTD in 6 month 76 DFTD DFTD 
55 NON-DFTD DFTD in 12 month 78 DFTD DFTD 
56 NON-DFTD DFTD in 12 month 79 DFTD DFTD in 6 month 
57 DFTD DFTD in 6 month 81 DFTD DFTD in 1 month 
58 Uncertain DFTD 83 DFTD DFTD 
59 NON-DFTD DFTD in 6 month 84 DFTD DFTD 
60 NON-DFTD DFTD in 6 month 85 DFTD DFTD in 6 month 
61 NON-DFTD DFTD in 6 month 86 Uncertain DFTD 
63 NON-DFTD Other disease 88 DFTD DFTD 
64 NON-DFTD DFTD in 6 month 89 Uncertain DFTD in 12 month 
65 NON-DFTD DFTD in 6 month 91 DFTD DFTD in 1 month 
66 NON-DFTD DFTD in 6 month 92 Uncertain DFTD 
68 NON-DFTD DFTD in 12 month 93 DFTD DFTD 
69 DFTD DFTD 94 DFTD DFTD 
71 DFTD DFTD 96 DFTD DFTD 
72 DFTD DFTD in 1 month 97 DFTD DFTD 
73 DFTD DFTD 98 DFTD DFTD 
74 DFTD DFTD 99 NON-DFTD DFTD in 6 month 
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Table 4.3: Summary of DFTD classifications for the unknown Forestier samples using a Forester 
training set (these figures do not include replicates). 
 DFTD status according to ESI-MS method
DFTD Non-DFTD Uncertain 
C
lin
ic
al
ly
 
di
ag
no
se
d 
D
FT
D
 st
at
us
 DFTD 32 1 6 Other disease 1 2 0 
12 month pre-
clinical 1 10 1 
6 month pre-
clinical 6 13 2 
1 month pre-
clinical 4 0 0 
 
All of the blind samples came from devils that had DFTD, other diseases or developed 
DFTD within 12 months, so the accuracy of determining healthy devils could not be 
determined. The only samples obtained from devils that did not show signs of DFTD 
within 12 months had been provided as part of the training set. The latency period of 
DFTD could be anywhere up to 12 months so the samples that have been obtained from 
devils that developed DFTD within 12 months need to be considered as pre-clinical. The 
longest observed latency period for DFTD was observed in a devil that developed DFTD 
10 months after it had been placed into a wildlife park (personal communication from 
Nolan Fox). 
The sensitivity of the results was calculated to be 66 % (defined as  ்௉்௉ାிே , where TP is 
the number of true positives and FN is the number of false negatives. In other words 
sensitivity refers to how accurate the test is at classifying only the diseased samples as 
diseased). The specificity was calculated to be 80 % (defined as ்ே்ேା ி௉, where TN is the 
number of true negatives and FP is the number of false positives. This shows how accurate 
the test is at identifying the non-diseased samples as non-diseased [65]). From the samples 
analysed only 8 samples were classified as uncertain. Only one sample was classed 
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wrongly (sample 17 italicised in Table 4.2). This sample was classed as non-DFTD but 
was obtained from a DFTD-positive devil. One devil that had another disease was classed 
as having DFTD (sample 7). It is possible that this disease was another type of cancer with 
a similar metabolomic footprint to DFTD which could explain the wrong diagnosis. This 
could not be determined because the details of this devils disease were not given. Overall 
the results were promising.  
The sample classed incorrectly, Sample 17, plotted close to the samples determined to be 
uncertain on the PCA plot which suggests that the line separating non-DFTD and uncertain 
should have been further left. This was not done though as it would have changed the 
classification of the non-DFTD samples from the training set to uncertain. It is also 
possible that this sample was an outlier in some other way compared to the DFTD and 
non-DFTD samples in the training set. To investigate the possible differences between 
sample 17 and DFTD samples, the average intensity for each of the significantly different 
mass-to-charge peaks (see Table 4.1) was obtained for the DFTD and the non-DFTD 
samples in the training set. These responses were plotted and compared with sample 17 
(see Figure 4.3). The first five peaks (peaks 134, 191, 192, 200.9 and 207) were 
representative of the non-DFTD samples. All of these peaks except for peak 191 were also 
observed in the comparison of variables and principal components plot (see Figure 4.2) to 
effect the position of samples in the non-DFTD area. Sample 17 also gave a response for 
peaks 829.7 and 841.5 which were not observed at all in the average spectrum for DFTD 
samples. These peaks also were correlated with a negative value for the first principal 
component and representative of the non-DFTD samples. Sample 17 also had responses 
that were more representative of the average DFTD spectrum. For example, a strong 
response was observed with peak 936.7 which was absent in the average non-DFTD 
spectrum and no peak was observed for 622.4 which was also observed in the average 
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DFTD spectrum. The spectrum for 17 was not abnormal (see Figure 4.4) and the decrease 
in intensity in the small mass ions could also be observed in the full spectrums when 
compared to a representative DFTD sample. The increased intensities for the small ions 
were also observed in other DFTD samples. An investigation using tandem mass 
spectrometry to identify the compounds corresponding to these small mass ions as well as 
ion 622.4 and 936.7 could help shed more light on why the DFTD-positive sample 17 was 
classified as non-DFTD in this analysis.  
The replicates of Tasmanian devil samples plotted very close together in the PCA plot 
showed limited variability. The sample with the greatest variability according to the PCA 
plot was sample 36. One of the three replicates of this sample had a corrupt file so only 
two were analysed. They have almost no variability according to the second principal 
component but some variability with the first principal component. They were both still 
significantly positioned correctly with the DFTD samples. The other two devil samples 
(samples 35 and 44) were clustered with limited variability in both the first two principal 
components. Two of the replicates for sample 35 were classified as uncertain and the 
remaining replicate was classified as non-DFTD but all three were still clustered close 
together on the PCA plot suggesting good reproducibility. Each of the replicates for 
sample 44 were positioned very close together and classified as non-DFTD. 
All of the samples that came from devils that showed signs of DFTD one month later were 
classed as DFTD, and all bar one of the samples that came from devils who showed signs 
of DFTD 12 months later were classed as non-DFTD. The six month pre-clinical samples 
were classed as a mixture of DFTD, non-DFTD and uncertain. It is entirely feasible that 
the samples classed as non-DFTD were indeed not infected at the time of sampling and 
contracted the disease after the sampling point. 
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Figure 4.3: Comparing the average significantly different m/z responses (determined using Student’s t-
test) for the DFTD and non-DFTD training set samples with sample 17 that had been wrongly 
classified. 
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Figure 4.4: The mass spectrum of sample 17 compared to a representative spectrum from a DFTD and 
a non-DFTD sample.  
These results are compelling because of their ability to diagnose DFTD up to six months 
before signs of a tumour are present. It is especially promising that all of the devils that 
showed signs of DFTD one month later were identified as having DFTD. Unfortunately, 
because of the contagiousness of this disease, the only samples obtained from healthy 
Tasmanian devils were part of the training set so it is impossible to determine how 
accurate these metabolites are at correctly classifying non-DFTD devils. 
4.4 Summary 
A suppression trial was conducted at Forestier Peninsular in south-eastern Tasmania 
between 2004-2010, which involved the removal of all DFTD devils that were trapped 
during trips occurring 4-5 times a year. The removal of DFTD devils at the Forestier 
Peninsula has recently been shown to not be preventing the spread of DFTD. Lachish et al. 
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suggested that more frequent trapping and the utilisation of a pre-clinical diagnostic test 
could allow DFTD devils to be removed prior to the individual transmitting the disease to 
another devil, would improve the results of this trial [120]. In 2010, field trips were 
increased to every month to decrease the chance of a DFTD-positive devil spreading the 
disease to another individual but the suppression trial was suspended because of the need 
for a pre-clinical diagnostic test.  
These results showed the ability to identify DFTD up to six months prior to the 
presentation of tumours using ESI-MS. Only one DFTD sample was classified wrongly as 
non-DFTD. This technique allows samples to be prepared and analysed in less than hour. 
If the suppression trial was initiated again a sample of serum could be obtained, transferred 
to a laboratory facility and analysed within a day. The individuals diagnosed without 
DFTD could then be released after a limited time in captivity. The removal of pre-clinical 
DFTD devils would likely improve the outcomes of a suppression trial and potentially 
eliminate DFTD in the area. 
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5 Discovery of differences in metabolites between 
DFTD and non-DFTD devils with extensive 
sample variability 
5.1 Introduction 
The overall goal of this work is to develop a pre-clinical diagnostic test that can be used to 
determine DFTD biomarkers and which is not biased towards a particular subset of devils 
such as gender or territory which have been found to alter the metabolites in an individual 
[20, 21]. This chapter describes results from a blind study that contained samples 
representative of the conditions previously mentioned that can affect the metabolome. This 
study looked at a set of 130 serum samples collected between 2005-2009 from male and 
female Tasmanian devils. The devils were obtained throughout Tasmania and also 
included one sample from Badger Island in Bass Straight. The samples came from areas 
where DFTD was prevalent and from DFTD free regions; included devils with other 
known diseases; and also included devils that were known to have DFTD or another 
disease at a later date. Previous sample sets that were restricted to eastern Tasmania had 
shown the ability to determine devils that had DFTD up to six months prior to visible 
tumours (see chapters 2, 3 and 4).  
It was proposed that by using feature selection and multivariate analysis, serum 
metabolites changes specific to DFTD could still be discovered even with the presence of 
other metabolite changing variables such as those mentioned above. The previous chapter 
(Chapter 4) showed the ability to identify DFTD devils using a relatively quick method 
with ESI-MS. The GC-MS method requires more analysis time but also provides a 
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separation dimension which could help to diminish the effects of having increased sample 
variables in this sample set. The discovery of DFTD specific metabolite changes in a 
sample set with this many variables would allow for the ability to diagnose DFTD in all 
Tasmanian devils rather than a subpopulation. Metabolites that show the presence of 
DFTD pre-clinically could aid firstly in obtaining disease free devils for insurance 
populations and secondly to remove DFTD devils before they can spread the disease to 
another individual. Both GC-MS and ESI-MS were used in this study to mine for 
differences between non-DFTD and DFTD samples to determine features that are 
significantly different between non-DFTD samples and, pre-clinical and clinical DFTD 
samples from devils throughout Tasmania.   
5.2 Methods  
5.2.1 Samples 
130 Tasmanian devil serum samples obtained from male and female devils around 
Tasmania were provided by DPIPWE. This set of samples included a training set of 20-30 
samples of which 20 were replicates of 20 of the other 110 samples (see Table 5.1 for a 
summary of the details of each sample and Table A 4 in the appendix for further 
information). A pooled mouse serum sample was used for a quality control. 
5.2.2 Reagents 
≥ 98 % o-methylhydroxylamine hydrochloride and 98 % Formic acid were obtained from 
Fluka, Switzerland; Pyridine, and  N-Methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) 
were obtained from Sigma Aldrich; Methanol (> 99.7%, isocratic HPLC grade (254 nm) 
was obtained from Scharlau Chemie S.A., (made in the European Union); and Millipore 
Milli-Q water. 
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5.2.3 Sample Preparation 
The samples were randomised prior to sample preparation. Metabolites were collected 
from the Tasmanian devil and pooled mouse serum by placing 15 µL of serum into 500 µL 
of cold methanol. The mixtures were vortexed (Ratek VM1 vortex mixer) to mix and then 
incubated at 4 ˚C for at least 20 min to ensure that as much protein as possible had 
precipitated out. The samples were then centrifuged at 14,000 rpm for 5 min (Eppendorf 
bench top centrifuge 5424) and an aliquot of supernatant was obtained and prepared for 
either GC-MS or ESI-MS.  
Gas chromatography – mass spectrometry: Precipitation of proteins and solvent 
evaporation was conducted on one day to decrease sample variability. The metabolites 
were obtained by taking 200 µL of the supernatant from the protein precipitation step and 
evaporated to dryness in a vacuum oven between 50-55 ˚C. The samples were then stored 
at -20 ˚C. Prior to analysis, 10 µL of 40 mg/mL o-methylhydroxylamine hydrochloride in 
pyridine was added to the dried metabolite extracts. The samples were then vortexed to 
mix and then placed on a heating block at 30 ˚C for 60 min. The samples were then 
incubated at room temperature for at least 17 hours. After the incubation, 90 µL of 
MSTFA was added to each sample, vortexed to mix and incubated for a further 30 min at 
37 ˚C on a heating block. This exact procedure was also applied to reagent blanks and 
quality controls (mouse sera extracts).  
Electrospray ionisation – mass spectrometry: A 100 µL aliquot of supernatant for each 
sample and mouse quality control was placed into a tube with 2 µL of a 10 % v/v formic 
acid (in milli-Q water) and 98 µL of methanol to give a 0.1 % acidified solution. Reagent 
blanks were prepared by adding 2 µL of a 10 % v/v formic acid (in milli-Q water) to 198 
µL of methanol. 
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Table 5.1: List of samples 
Sample # Sex DFTD status Other disease information Sample # Sex DFTD status Other disease information 
D1 m DFTD   6 f NON-DFTD   
D2 m DFTD   7 f NON-DFTD Pre-Non-DFTD disease 
D3 m DFTD   8 f DFTD   
D4 f DFTD   9 m DFTD   
D5 m DFTD   10 m DFTD   
D6 f DFTD   11 f NON-DFTD   
D7 m DFTD   12 f NON-DFTD Pre-Non-DFTD disease 
D8 m DFTD   13 f NON-DFTD   
D9 f DFTD   14 f NON-DFTD Pre-Non-DFTD disease 
D10 m DFTD   15 m DFTD   
H11 m NON-DFTD   16 f NON-DFTD   
H12 m NON-DFTD   17 m DFTD   
H13 f NON-DFTD   18 m DFTD   
H14 m NON-DFTD   19 f NON-DFTD   
H15 f NON-DFTD   20 m NON-DFTD Pre-Non-DFTD disease 
H16 m NON-DFTD   21 f DFTD   
H17 f NON-DFTD   22 f NON-DFTD   
H18 f NON-DFTD   23 f NON-DFTD   
H19 m NON-DFTD   24 f NON-DFTD   
H20 f NON-DFTD Another disease  25 m DFTD   
1 m NON-DFTD   26 f DFTD   
2 f DFTD   27 f DFTD   
3 m NON-DFTD   28 m NON-DFTD   
4 f NON-DFTD   29 f DFTD   
5 m NON-DFTD   30 f NON-DFTD Neoplasia 
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Sample # Sex DFTD status Other disease information Sample # Sex DFTD status Other disease information 
31 f NON-DFTD   56 m NON-DFTD Skin inflammation 
32 f DFTD   57 m PRE-DFTD   
33 m NON-DFTD   58 m NON-DFTD   
34 f NON-DFTD   59 m DFTD   
35 f NON-DFTD   60 m NON-DFTD Pre-Non-DFTD disease 
36 m DFTD   61 m DFTD   
37 f NON-DFTD   62 m NON-DFTD Non-DFTD growths 
38 f DFTD   63 m DFTD   
39 m NON-DFTD   64 m DFTD   
40 f PRE-DFTD   65 m DFTD   
41 f NON-DFTD   66 f NON-DFTD   
42 f NON-DFTD   67 f NON-DFTD Neoplasia 
43 m PRE-DFTD   68 m DFTD   
44 f NON-DFTD   69 m NON-DFTD Pre-Non-DFTD disease 
45 m DFTD   70 f DFTD   
46 m DFTD   71 m DFTD   
47 f NON-DFTD   72 f DFTD   
48 m NON-DFTD   73 f DFTD   
49 m NON-DFTD   74 m DFTD   
50 m DFTD   75 m NON-DFTD   
51 m DFTD   76 f DFTD   
52 m NON-DFTD   77 m NON-DFTD   
53 m DFTD   78 f NON-DFTD   
54 f DFTD   79 m NON-DFTD   
55 m NON-DFTD Non-DFTD growths 80 f NON-DFTD   
115 
 
Sample # Sex DFTD status Other disease information Sample # Sex DFTD status Other disease information 
81 m DFTD   96 f NON-DFTD Another disease  
82 m DFTD   97 f PRE-DFTD   
83 f DFTD   98 m NON-DFTD Urinary Infection 
84 m NON-DFTD   99 m DFTD   
85 m DFTD   100 f NON-DFTD  Developed another disease 
86 f PRE-DFTD   101 m NON-DFTD Ulcers 
87 f NON-DFTD Pre-Non-DFTD disease 102 f DFTD   
88 m NON-DFTD Non-DFTD growths 103 f NON-DFTD Pre-non-DFTD growths 
89 f NON-DFTD Alopecia (baldness) 104 m PRE-DFTD   
90 m PRE-DFTD   105 m DFTD   
91 f DFTD   106 m NON-DFTD Non-DFTD growths 
92 f NON-DFTD Neoplasia 107 m DFTD   
93 m NON-DFTD Kidney disease 108 f NON-DFTD Skin lesions 
94 m NON-DFTD Malformation 109 m NON-DFTD   
95 f NON-DFTD Another disease  110 m NON-DFTD   
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5.2.4 Instrumentation 
Gas chromatography – mass spectrometry: The samples were randomised again before 
being analysed by the GC-MS and analysed with an Agilent 6850 GC system connected to 
an Agilent 5975C VLMSD mass spectrometer fitted with a SGE capillary column (part 
number 054702, Scientific Glass Engineering Analytical Sciences (SGE), Ringwood, 
Australia) (59.5 m in length, column thickness 0.25 µm and an internal diameter of 0.25 
µm). 1 µL of sample was injected using splitless injection at 285 ˚C. A temperature 
program of 55.0 ˚C for 6 min and then ramped at a rate of 6.00 ˚/min to 340 oC with an 
isothermal period of 10 min at 340 oC was applied. Helium was used as the carrier gas at a 
flow rate of 1.5 mL/min for 50 min and then increased to 3.0 mL/min at a rate of 0.20 
mL/min. MS detection was initiated 12.00 min into the run. Spectra were collected 
between 40-550 m/z. The spectra were analysed using the GCMS solutions software 
(Version 2.50SU1, Shimadzu 1999-2006). 10 Tasmanian devil serum metabolite extracts 
were run daily. A reagent blank was run in the first and ninth run of the day and a quality 
control was run in the fifth and final run of the day to ensure that variability over the 
course of the day was minimal. 
Electrospray ionisation – mass spectrometry: The instrument was calibrated with sodium 
formate (10 mM sodium hydroxide, 0.1 % formic acid in 1:1 water-isopropanol). Samples 
were analysed using a Bruker micrOTOF-Q II instrument using the same procedure as 
chapter 3 using metabolites obtained from a pooled mouse sample for the quality control.  
5.2.5 Data Analysis 
Gas chromatography – mass spectrometry: The samples were randomised again before 
commencement of data analysis. The base peaks of each separated metabolite in the 
chromatograms of two healthy samples, two DFTD-positive samples and two blind 
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samples was determined and tabulated. The area of the base was then automatically 
tabulated using the GCMS Postrun software (Version 2.50SU1, Shimadzu 1999-2006). 
Obtaining the area of the base peak instead of the total ion chromatogram allowed for more 
accurate comparisons between runs with peaks that overlapped. The peaks from the GC-
MS chromatograms were then normalised by obtaining the ratio of the peak area with the 
sum of all the base peak areas for each individual run. The known DFTD and healthy 
samples were used as a training set to classify the blind samples. The data was analysed by 
principal component analysis (PCA) (XLSTAT Version 2010.2.01 Copyright Addinsoft 
1995-2009). Prior to PCA, a feature selection using Student’s t-test was conducted with 
the training set. Signals that were not significantly different between the healthy and 
DFTD samples (p ≤ 0.05 or ≤ 0.10 as stated) were removed and not considered further. 
Using these significantly different signals, PCA was performed using the known DFTD 
and healthy samples. The blind samples were not involved in the PCA but plotted on the 
PCA plot as supplementary observations. In the PCA, if the first two principal components 
were not successful in separating the non-DFTD samples from the DFTD samples, 
combinations of the first four principal components were evaluated to determine if any of 
those combinations could successfully separate the DFTD samples from the non-DFTD 
samples. 
Electrospray ionisation – mass spectrometry: Data interrogation for ESI-MS experiments 
was performed by chemometric analysis of the extracted spectra (50-1200 m/z). A 
Student’s t-tests to extract ion responses (from the spectra) that were significantly different 
(p ≤ 0.05 or ≤ 0.10 as stated) between a selection of DFTD and non-DFTD samples that 
had been selected as the training set. The significantly different ion responses were then 
analysed further using principal component anlaysis (PCA).  
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5.3 Results and Discussion 
5.3.1 GC-MS 
The known DFTD (samples D1 to D10) and non-DFTD samples (samples H11 to H20) 
were used to conduct the feature selection to select the most significant peaks. The feature 
selection only identified 10 peaks with a p-value ≤ 0.1 so these were used to develop the 
PCA (see Figure 5.1).  
 
Figure 5.1: Principal component analysis of samples in the training set using the first two principal 
components. The chromatographic data of 10 DFTD and 10 non-DFTD samples was analysed with 
Student’s t-test to determine the peaks that were significantly different between these two groups (p ≤ 
0.10). The resulting peaks were then analysed by PCA. 
The PCA showed more variability between the non-DFTD samples than the DFTD 
samples. Even with the loss of information that occurs with feature selections, this process 
of handling data allows for the pre-selection of DFTD specific signals. This pre-selection 
was efficient at selecting the signals that were DFTD specific which was shown by 
increased variability in the non-DFTD samples when compared to the DFTD samples. It 
was also supported by the evidence that the first principal component (labelled F1 on the 
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axes) contributed the greatest to separating the DFTD samples from the non-DFTD 
samples.  
PCA plots that plotted the first principal component against the third and fourth principal 
components were also examined. These plots were not more efficient in separating the 
DFTD and non-DFTD samples (see Figure 5.2) than the plot that separated the samples 
using the first two principal components. 
As previously mentioned, this set of samples contained a number of sample variables that 
were not present in the previously analysed sample sets (see chapters 3 and 4). The 
samples in this blind study were obtained from male and female devils located in eastern 
and north-western populations that have different genetics [4, 87] and come from different 
habitats [121]. To reduce the affect of these added variables an additional five DFTD and 
five non-DFTD samples were added to the training set chosen randomly from the blind 
samples. The DFTD samples that were un-blinded were samples 27, 71, 83, 99 and 107. 
The non-DFTD samples were samples 23, 41, 42, 55 and 92. The increase in the training 
set was done in an attempt to eliminate some of the variability that is observed in the PCA 
plot that could be attributed to some of the sample variables such as sample location and 
gender. A Student’s t-test was conducted with these 30 samples. This test found 5 
metabolite peaks with a value of p ≤ 0.05 and 14 peaks with a value of p ≤ 0.1. Since there 
were only 5 peaks with a p-value ≤ 0.05, the peaks that had a p-value ≤ 0.1 were further 
analysed by PCA. Two dimensional PCA plots using various combinations of the first four 
principal components (PCs) were examined to determine the plot that separated the DFTD 
samples from the non-DFTD samples most efficiently using two dimensional plots. The 
first and second PCs were observed to give the best separation between the DFTD and 
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non-DFTD samples (see Figure 5.3). The addition of more samples in the training set did 
not improve the separation of the DFTD and non-DFTD samples. Unlike in Figure 5.1, 
 
Figure 5.2: Principal component analysis of samples in the training set of the first and third principal 
component (A) and first and fourth principal component (B). The chromatographic data of 10 DFTD 
and 10 non-DFTD samples was analysed with Student’s t-test to determine the peaks that were 
significantly different between these two groups (p ≤ 0.10). The resulting peaks were then analysed by 
PCA. 
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where the first PC had the highest influence in separating the DFTD samples from the non-
DFTD samples, both of the PCs are involved in separating the DFTD and non-DFTD 
samples in Figure 5.3. The two eclipses in Figure 5.3 show the distribution of the DFTD 
and non-DFTD samples. The eclipse showing the distribution of the non-DFTD samples 
overlaps with the eclipse surrounding the DFTD samples as there are four non-DFTD 
samples that clustered in the midst of the DFTD samples. When the sample set was un-
blinded, information on the gender, age and location the animal was caught was obtained. 
These samples came from two females and two males of various ages ranging between one 
to six years old and from four different locations around mainland Tasmania. None of 
these sample variables explained why these four samples may have clustered with the 
DFTD samples. After the un-blinding it was found that three of the samples in the training 
set (samples 55, 92 and H20) had come from devils that had non-DFTD growths. The 
presence of samples from devils with other diseases would hopefully increase the 
specificity that this test could be specific to DFTD and not be indicative of any disease in 
general. These three samples from devils with non-DFTD growths did cluster close to or 
within the DFTD samples which suggests that the metabolites obtained in the feature 
selection show changes that occur with the presence of all abnormal growths not just those 
caused by DFTD. The other three non-DFTD samples (H11, H14 and H15) clustering with 
the DFTD samples in this plot (Figure 5.3) were considered to be healthy when they were 
trapped. Sample H11 was obtained from a three year old male that had been caught at 
West Pencil Pine. He was caught nine months later in the same location and still appeared 
to be DFTD free. The latency period of DFTD is still unknown, but it is believed to be less 
than 12 months so it is unlikely that sample H11 was a pre-clinical DFTD sample. No 
information on the devils that provided sample H14 and H15 was obtained from 
subsequent trapping trips so there is a possibility that these devils had contracted DFTD. 
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Figure 5.3: Principal component analysis of samples in the extended training set. The 
chromatographic data of 15 DFTD and 15 non-DFTD samples was analysed with Student’s t-test to 
determine the peaks that were significantly different between these two groups (p ≤ 0.10). The 
resulting peaks were then analysed by PCA. 
A simple way to eliminate one of the sample variables that could affect the metabolome 
was to analyse each gender separately. Studies on gender differences in species have been 
observed previously. A study by Hines et al. showed increases in the presence of some 
metabolites in mussels (Mytilus galloprovincialis) and found that some metabolites were 
consistently higher in one gender or the other [22]. Another study by Plumb et al. 
investigated differences in the urine from mice between males and females. They analysed 
data from HPLC-ESI-TOF-MS using PCA and the PCA plots showed distinctive 
differences between male and female mice [122]. 
To analyse the males and females separately the training set of 30 that was used above was 
split into males and females and the gender of each sample was obtained. The female 
training set included nine non-DFTD samples (samples H13, H15, H17, H18, H20, 23, 41, 
42 and 92) and five DFTD samples (samples D4, D6, D9, 27 and 83). The male training 
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set included six non-DFTD samples (samples H11, H12, H14, H16, H19 and 55) and ten 
DFTD samples (samples D1, D2, D3, D5, D7, D8, D10, 71, 99, and 107). These samples 
were analysed in the same way. A Student’s t-test was conducted initially to determine 
which peaks had p-values ≤ 0.05 and 0.1. These sets of peaks were then analysed by PCA 
and combinations of the first four principal components were examined to find the 
combination that showed the greatest variability between the DFTD and non-DFTD 
samples.  
The anlaysis of the female samples determined seven peaks that had a p-value ≤ 0.1 from 
Student’s t-test that were analysed further by PCA. The first and third principal 
components showed the most variability between the DFTD and non-DFTD samples (see 
Figure 5.4). The DFTD samples along with sample H15 clustered together. H15 also 
clustered with the DFTD samples in Figure 5.3 where the males and females had been 
analysed together with the 30 sample training set. The rest of the female samples were also 
plotted onto this PCA as supplementary observations (samples that were not involved in 
the development of the PCA) but there was not good separation between the DFTD and 
non-DFTD samples (see Figure 5.5). As mentioned above, when the sample set became 
un-blinded, further information showed that two of the non-DFTD samples in the female 
training set (samples 92 and H20) were obtained from devils that had non-DFTD growths. 
This could explain why these samples were positioned close to the DFTD samples in the 
PCA plot. It is encouraging though that these samples did cluster with the non-DFTD 
observations even though the samples came from devils with non-DFTD disease.  
In the anlaysis of the male samples the feature selection identified 7 peaks that had a p- 
value ≤ 0.05 and 11 peaks that had a p-value ≤ 0.10 from Student’s t-test. The first and 
fourth principal components showed greatest variability between the DFTD and non-
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DFTD samples in both instances but the p ≤ 0.05 peaks showed the most separation 
between the DFTD and non-DFTD training samples which can be observed in Figure 5.6. 
Although sample H14 clustered close to the DFTD samples a line could be drawn that 
separates this sample away from the DFTD samples along with the rest of the non-DFTD 
training samples. The remaining male samples were added to the PCA plot as 
supplementary observations (see Figure 5.7). Only 5 out of the 22 DFTD samples that 
were not part of the training set clustered below the dotted line with the non-DFTD 
training samples but the majority of the non-DFTD samples also plotted above the dotted 
line with the DFTD training samples. 
 
Figure 5.4: Principal component analysis of female training set samples analysed by GC-MS. 9 non-
DFTD and 5 DFTD samples were used in the training set. A Students t-test was conducted and the 
seven peaks that had p ≤ 0.1 were used to develop this PCA. The first and third principal components 
are used.   
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Figure 5.5: Principal component analysis of all female samples analysed by GC-MS. 9 non-DFTD and 5 DFTD samples were used in the training set. A Students 
t-test was conducted and the 7 peaks that had p ≤ 0.1 were used to develop this PCA. The first and third principal components are used.   
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Figure 5.6: Principal component analysis of male training set samples analysed by GC-MS. 6 non-
DFTD and 10 DFTD samples were used in the training set. A Students t-test was conducted and the 7 
peaks that had p ≤ 0.05 were used to develop this PCA. The first and fourth principal component are 
used. 
The feature selection pre-selects the peaks that contribute the greatest in distinguishing 
between DFTD and non-DFTD samples. The PCAs developed with 14 samples for the 
female training set and 16 in the male training set was still unable to successfully 
distinguish between the DFTD and non-DFTD samples when all of the samples were 
added to the PCA plot. The PCA plots that just showed the training set did show enough 
variability between the DFTD and non-DFTD samples to separate these two sets more 
efficiently than when both genders were analysed together. The procedure was more 
successful at identifying differences between the DFTD and non-DFTD samples in the 
male devils. A higher proportion of DFTD samples were included in the male training set 
than in the female training set which may have contributed to the improved separation of 
DFTD and non-DFTD samples in the male PCA plots. 
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Figure 5.7: Principal component analysis plotting all of the male samples analysed by GC-MS. 6 non-DFTD and 10 DFTD samples were used in the training set. 
A Students t-test was conducted and the 7 peaks that had p ≤ 0.05 were used to develop this PCA. The first and fourth principal components are used. 
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Separating the samples according to gender showed greater variability between DFTD and 
non-DFTD samples than the PCA plot including samples of both genders (see Figure 5.3, 
Figure 5.4 and Figure 5.6). The small number of samples in the training set is not efficient 
though to counteract the other variables such as diet; presence of other diseases; and 
sample location that can also affect the presence and abundance of metabolites. Once the 
set was un-blinded a larger training set was used to see if this could improve the results. If 
this was positive it would suggest that there were too many variables in this set for the 
number of samples that was being analysed.  
It was believed that a larger sample set was still required to represent the number of 
sample variables other than gender that were represented in this sample group. The 
training set was increased to include a total of 70 % of the DFTD and healthy samples 
(samples without any disease or that were known to develop another disease later on) from 
the blind set. These were randomly selected to be used along with the original training set 
samples. The samples were also chosen so that equal numbers of DFTD and non-DFTD 
samples were used in the training set. Since looking at each gender separately had 
improved the results with the smaller training sets each gender was still examined 
separately. Overall there were 18 DFTD and 18 non-DFTD samples used in the male 
training set and 15 DFTD and 15 non-DFTD samples used in the female training set. As 
before, a PCA was developed using the peaks identified with p-values ≤ 0.05 and ≤ 0.1 
using Student’s t-test. Combinations of the first four principal components were examined 
to find the plot that showed the highest variability between the DFTD and non-DFTD 
samples. 
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Figure 5.8: Principal component analysis of female training set samples analysed by GC-MS. 70 % of 
the non-DFTD and DFTD (15 non-DFTD samples and 15 DFTD samples) samples were used in the 
training set. A Students t-test was conducted and the 7 peaks that had p ≤ 0.05 were used to develop 
this PCA.  
The 70 % training set that was used with the female samples showed more promise than 
the 70 % male training set. The principal components that showed the greatest variability 
between the DFTD and non-DFTD samples were the first and third that was analysed the 7 
peaks that had a value of p ≤ 0.05 in the Student’s t-test. Although some of the DFTD and 
non-DFTD samples clustered close together, it was possible to obtain a line of separation 
between the DFTD and non-DFTD samples (see Figure 5.8) except for one non-DFTD 
sample, sample 4. No further information was obtained from the devil that provided 
sample 4 so no supported theory on why this sample may have clustered with the DFTD 
samples could be determined except for the same explanation stated above for why four 
non-DFTD samples clustered with the males in the 70 % training set. Sample 92 also 
clustered closer to the DFTD samples than the other non-DFTD samples. This had also 
occurred when the smaller female training set was used (see Figure 5.4). As was 
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mentioned above, this sample had come from a devil that had a non-DFTD growth 
(neoplasia) which could explain the position of this point in the PCA plot. It is possible 
that the metabolites identified in the feature selection could be representative of changes 
that occurs in multiple types of tumours and abnormal growths not just DFTD which 
would explain why observations of samples from devils with non-DFTD growths cluster 
close or along with the DFTD observations. Since the PCA plot shown in Figure 5.8 
showed promise in distinguishing the DFTD samples from the non-DFTD samples the 
remaining samples from the set were added to the PCA plot (see Figure 5.9). Once the 
sample set was un-blinded, it was very promising to see that the only DFTD sample to 
cluster with the non-DFTD sample was a pre-DFTD sample. The other two pre-DFTD 
samples clustered on the DFTD side of the plot. Another promising observation was that 
all of the samples that came from devils with other diseases clustered on the non-DFTD 
side of the plot except for one that came from a devil not with abnormal growths but with 
alopecia (baldness). There were samples that came from devils that later developed a non-
DFTD disease that plotted with the DFTD devils. The “pre-other disease” sample that was 
positioned the furthest away from the non-DFTD section of the plot came from a devil that 
developed non-DFTD growths at a later stage which could explain why it was positioned 
with the DFTD samples. There were 3 samples that came from healthy devils that were not 
part of the training set that clustered amongst the DFTD samples (samples 11, 78 and 80). 
No further information was obtained on these devils so it is uncertain if these devils did 
later develop DFTD or another disease. The results are summarised in Table 5.2. The 
results showed this method to have a sensitivity of 95 % to correctly identify the DFTD 
and pre-DFTD samples and a specificity value of 80 % to correctly identify the healthy 
and devils with other diseases as DFTD-negative.    
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Table 5.2: Summary of the results obtained by analysing the female samples by GC-MS and PCA. 70 
% of the samples were included in the training set. The PCA can be observed in Figure 5.9. 
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DFTD 16 0 
Pre-DFTD 2 1 
Healthy 4 20 
Other Disease 1 4 
Pre-other disease 2 4 
 
A PCA plot of the 70 % training set for the male devils was not as successful at separating 
the non-DFTD samples from the DFTD samples as the initial smaller male training set (see 
Figure 5.10). In the male plot the first two principal components from the PCA that used 
the signals with p-values ≤ 0.1 determined in the t-test showed the greatest variability 
between the DFTD and non-DFTD samples. There was a clear section in the plot that 
showed separation of non-DFTD samples from the DFTD samples in the training set but 
there were still four non-DFTD samples that clustered with the DFTD samples. Since there 
was a definite non-DFTD section on the plot the remaining samples were added to the plot 
as supplementary observations (see Figure 5.11). 2/4 of the non-training healthy (no 
disease) samples clustered within the DFTD section of the plot and 3/13 of the non-
training DFTD samples clustered within the non-DFTD section of the plot. Promisingly all 
of the pre-DFTD samples clustered with the DFTD samples, even though there was not 
complete separation between the non-DFTD and DFTD samples in the training set. Once 
the sample set was un-blinded, no more information was available on the devils that 
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Figure 5.9: Principal component analysis of all female samples analysed by GC-MS. 70 % of the non-DFTD and DFTD (15 non-DFTD samples and 15 DFTD 
samples) samples were used in the training set. A Students t-test was conducted and the 7 peaks that had p ≤ 0.05 were used to develop this PCA. 
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provided the four non-DFTD samples from the training set that clustered within the DFTD 
section of the plot and neither of the devils had appeared to be affected by other diseases at 
the time of sampling. The analysis of the male samples was inferior to the results obtained 
when analysing the female samples. In the female 70 % training set, the DFTD samples 
were obtained from ten different locations around Tasmania whereas in the male training 
70 % training set the samples were obtained from six different locations and two thirds of 
these samples were obtained from only two separate locations, Forestier Peninsula and 
Bangor. This suggests that sample location does increase the variability of the samples and 
should be well represented in the training set as was the case with the females (see Figure 
5.8 and Table 5.3).  If the training set of the males represented samples from more 
locations these results could potentially be improved. A training set more representative of 
the different sampling locations could not be obtained from this set of samples to test this 
because 58 % of all the male DFTD samples in this blind study were obtained from either 
the Forestier Peninsula or Bangor (see Table 5.3) for distribution of samples according to 
sampling location and DFTD status). Samples of non-DFTD samples from these two 
locations were not provided from the Forestier Peninsula and only two were provided from 
Bangor which increased the bias these samples had with the DFTD training samples.  
Only two of the metabolites (peaks 67 and 166) used in the PCA’s to classify DFTD and 
non-DFTD samples were identified as being significant in both the female and male 
samples (see 7.2 Appendix 2: Fold Changes Observed for the Significantly Different Peaks 
for Both Blind Studies,   
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Table A 6) when using 70 % of the samples in the training set. Peak 166 showed < 0.5 fold 
change in pre-DFTD and DFTD females but only in the pre-DFTD males. There was a 
greater abundance of the metabolite peak 67 in the pre-DFTD males and females. The 
selection of different significant peaks between the genders correlates with other research 
that gender can affect the metabolome footprint of a disease [23]. 
Table 5.3: Distribution of sampling locations for the male and female samples also showing the 
distribution of samples obtained from non-DFTD and DFTD devils for each gender.  
Sampling 
Location 
 All 
males 
DFTD 
males 
Non-
DFTD 
males 
All 
females 
DFTD 
females 
Non-
DFTD 
females 
Forestier 9 9 0 2 2 0 
Reedy Marsh 2 2 0 2 2 0 
Buckland 2 2 0 2 1 1 
Bangor 12 10 2 6 4 2 
West Pencil Pine 10 2 8 11 2 9 
Fentonbury 4 2 2 5 2 3 
Coles Bay 5 2 3 2 2 0 
Granville 5 0 5 4 0 4 
Bicheno 3 0 3 0 0 0 
Trowunna 6 0 6 5 0 5 
Mount Pleasant 5 2 3 8 1 7 
Wisedale 1 0 1 3 1 2 
Bronte Park 1 1 0 0 0 0 
Taranna 3 0 3 0 0 0 
Narawntapu 1 1 0 1 0 1 
Marrawah 1 0 1 0 0 0 
Hobart 0 0 0 2 0 2 
Deloraine 0 0 0 1 1 0 
Taroona 0 0 0 1 1 0 
Westbury 0 0 0 1 0 1 
Mole Creek 0 0 0 1 1 0 
Temma 0 0 0 1 0 1 
Alcomie 0 0 0 1 0 1 
Sidmouth 0 0 0 1 0 1 
Total samples 70 33 37 60 20 40 
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Figure 5.10: Principal component analysis of male training set samples analysed by GC-MS. 70 % of the non-DFTD and DFTD (18 non-DFTD samples and 18 
DFTD samples) samples were used in the training set. A Students t-test was conducted and the 17 peaks that had p ≤ 0.1 were analysed with PCA. 
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Figure 5.11: Principal component analysis of all male samples analysed by GC-MS. 70 % of the non-DFTD and DFTD (18 non-DFTD samples and 18 DFTD 
samples) samples were used in the training set. A Students t-test was conducted and the 17 peaks that had p ≤ 0.1 were used to develop this PCA. Samples not 
included in the training set were added as supplementary observations.
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5.3.2 ESI-MS 
The data obtained using the ESI-MS method was analysed by PCA and looked at each 
gender individually since the previous work on the data obtained with GC-MS showed 
superior results when analysing the genders separately with PCA. The mass spectrums of 
these samples gave responses for over 2000 m/z values so Student’s t-test was used to 
conduct a feature selection and decrease the number of peaks that would participate in 
further analysis. Feature selections were conducted with 70 % of DFTD and healthy 
samples. In the females there were less DFTD samples than healthy samples so 70 % of 
DFTD samples were included in the 70 % feature selection (13) with the same number of 
healthy samples. The male set included 15 non-DFTD (healthy) samples and the same 
number of DFTD samples. The samples included in these feature selections were chosen 
randomly using the “random function” in Microsoft Excel. 
5.3.2.1 Females  
The feature selection on the female samples analysed via ESI-MS, determined that 64 
peaks were significantly different (p-value ≤ 0.05) between the DFTD and healthy samples 
in the training set. A PCA was then conducted on all of the samples using these peaks and 
the results are summarised in Table 5.4. This PCA was able to successfully separate the 
DFTD samples from the healthy samples as well as all but one “pre-other disease” 
samples. Information on what disease this “pre-other disease” (sample 87) was not given. 
The sensitivity of this test for the females was 95 % and the specificity was calculated to 
be 72 %. Promisingly the pre-DFTD samples also clustered with the DFTD samples except 
for sample 97. This PCA was not able to separate all of the “other disease” samples from 
the DFTD samples though. Interestingly some of the samples that came from devils with 
other types of cancers/growths (samples 92 and 95) clustered with healthy and DFTD 
samples so the significant peaks obtained from the feature selection were not specific to 
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diagnosing all types of cancer. There were other samples that also came from devils with 
non-DFTD growths (samples 67, 103) that did cluster with the DFTD samples. Samples 
that came from devils with other types of diseases (skin lesions, 108; baldness, 89) also 
clustered with the DFTD devils.  
Table 5.4: Summary of the results obtained by analysing the female samples by ESI-MS and PCA 
using 70 % of the samples in the training set. The PCA can be observed in Figure 5.12. 
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DFTD 17 0 
Pre-DFTD 2 1 
Healthy 4 18 
Other Disease 5 3 
Pre-other disease 1 4 
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Figure 5.12: PCA plot of female samples analysed by ESI-MS. Initially a feature selection was conducted using Student’s t-test and a PCA was conducted using 
the peaks that were found to be significantly different between 70 % of the DFTD and healthy samples to p ≤ 0.05. 
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5.3.2.2 Males 
A PCA analysis of the male samples was conducted using the 103 peaks that had a value 
of p ≤ 0.05 that were determined with Student’s t-test on the training set samples (see 
Figure 5.13). The PCA score plot did not completely separate the healthy samples from the 
DFTD samples when the first principal component was plotted with the second, third or 
fourth PC. The score plot that plotted the first and second principal component gave the 
best separation but this score plot sufficiently separated the majority of the healthy samples 
from the DFTD samples. Since one of the purposes of this test is to ensure that only non-
DFTD devils are placed into insurance populations this is better than DFTD devils 
clustering with healthy samples. Only one of the pre-DFTD samples (sample 104) 
clustered with the DFTD samples. The remaining pre-DFTD samples clustered together in 
the lower right hand side of the plot along with sample 88 which came from a devil that 
had non-DFTD growths. This could be for a couple of reasons, firstly this test may not be 
sensitive enough to detect that these samples were diseased and secondly, it is possible that 
these devils had not developed DFTD at the time of analysis. Interestingly, all of the pre-
other disease and other disease samples clustered with the DFTD samples except for 
sample 88. This suggests that the variability of the metabolites between these samples is 
more apt at showing the presence of disease generally than being specific to DFTD. The 
PCA of the male samples was not as sufficient as separating the DFTD and non-DFTD 
samples as the analysis on the female samples was which, as with the GC-MS results, is 
likely to be because of the bias in sample location for the male DFTD samples (see section 
5.3.1).  
From the metabolites considered to be significantly different using Student’s t-test, only 3 
were the same as those identified in the female samples (see 7.2 Appendix 2: Fold 
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Changes Observed for the Significantly Different Peaks for Both Blind Studies, Table A 
5). This is a similar to the result obtained with analysis via GC-MS (see section 5.3.1). 
Interestingly the 560.3 mass ion was observed to have an average ~2 fold change in female 
pre-DFTD samples but ~ 0.5 fold change compared to non-DFTD samples in pre-DFTD 
males and both male and female DFTD samples. A similar response is observed with the 
799.7 mass ion where the response for DFTD samples is very similar in both male and 
females but no fold change is observed in female pre-DFTD samples but this metabolite is 
down-regulated on average in samples obtained from male pre-DFTD devils. The third 
metabolite ion observed to be significant in both male and female samples from this 
sample set when analysed by ESI-MS was the 948.5 mass ion. Interestingly this metabolite 
was up-regulated in male pre-DFTD and non-DFTD samples but either not present or 
present in low amounts, in the female samples. From all of the metabolites considered to 
be significantly different only one was the same as those identified with in the blind study 
with low sample variability (discussed in chapter 4). These results show that differences in 
gender (as also observed with the GC-MS results) and sampling location can affect a 
disease metabolome as also observed  by Sugimoto and Ward and their respective 
colleagues [23, 101].   
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Figure 5.13: PCA plot of male samples analysed by ESI-MS. Initially a feature selection was conducted using Student’s t-test with 70 % of the healthy samples 
(15 samples) and the same number of DFTD samples. A PCA was then conducted using the peaks that were found to be significantly different between all DFTD 
and healthy samples to p ≤ 0.05. The samples in the bottom right hand corner were considered to be DFTD and the samples above the top line were considered 
to be non-DFTD. Samples positioned between the two lines were classed as uncertain. 
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5.3.3 Comparison of results between ESI-MS and GC-MS 
To compare the methods the predicted DFTD status with each method, when 70 % of the 
samples were included in the training set, was compared for each sample (see Table 5.5 
and Table 5.6). This comparison included the position of the training set samples since the 
training set was chosen randomly for both methods. The GC-MS method showed slightly 
better accuracy that the ESI-MS method which is likely because of the prior separation of 
the metabolites before detection with MS. For the female samples, 82 % were correctly 
identified using the GC-MS method; 75 % using the ESI-MS method; and 64 % of the 
samples were correctly identified with both methods. For the males, 60 % were identified 
using GC-MS; 58 % were correctly classified using the ESI-MS method; and 48 % of the 
samples were identified correctly with both methods. If a DFTD status had been uncertain 
in one of the methods or the methods gave contradicting results the diagnosis was 
determined to be uncertain. There were 17 uncertain results with the females and over all, 
only 3 (5 %) samples were classified wrongly using both methods. In the males, 28 
samples had uncertain results and 7 samples were classified wrongly with both methods. 
As had been seen when looking at the males using the GC-MS and ESI-MS methods, the 
results for the males was inferior to the results obtained for the female samples probably 
because of the bias in sampling locations (see section 5.3.1 and Table 5.3). 
One potential for the practical applications for using both of these methods to test for 
DFTD, would be to use the quicker ESI-MS method to screen for DFTD and then use the 
slower GC-MS method for confirmation or to diagnose the samples that were considered 
uncertain with the ESI-MS method. When looking at the female samples, 6 were 
considered uncertain with the ESI-MS method. All of these via one were correctly 
identified with the GC-MS method. This sample was classified as DFTD positive with the 
GC-MS method. If this method is used to ensure devils entering into insurance populations 
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are DFTD free it would be more important to ensure that there are no false negatives than 
ensuring that all healthy devils are classified as DFTD. The samples classified wrongly 
with the ESI-MS method (7 samples from the female set) were all classified as DFTD 
except for one pre-DFTD sample that was classified as non-DFTD. This sample (sample 
97) was also classified as non-DFTD using the GC-MS method. It is possible that this 
devil had not contracted the disease at the stage of sampling. These results suggest that the 
ESI-MS method would be suitable to initially screen the samples and the GC-MS method 
is suitable to confirm any results considered as uncertain. Further validation though would 
be required before this could be confirmed.
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Table 5.5 Comparison of DFTD diagnosis of female samples between GC-MS and ESI-MS methods.  
Sample Clinical diagnosis GC-MS training GC-MS prediction ESI-MS training (Y/N) ESI-MS prediction Overall result Correct? 
D4 DFTD Yes DFTD yes DFTD DFTD yes 
D6 DFTD Yes DFTD no DFTD DFTD yes 
D9 DFTD Yes DFTD yes DFTD DFTD yes 
H13 Non-DFTD Yes Non-DFTD no Non-DFTD Non-DFTD yes 
H15 Non-DFTD Yes Non-DFTD no Non-DFTD Non-DFTD yes 
H17 Non-DFTD Yes Non-DFTD no DFTD Uncertain no 
H18 Non-DFTD Yes Non-DFTD yes Non-DFTD Non-DFTD yes 
H20 Other Disease Yes Non-DFTD no Non-DFTD Non-DFTD yes 
2 DFTD Yes DFTD yes Uncertain Uncertain no 
4 Non-DFTD Yes DFTD yes Non-DFTD Uncertain no 
6 Non-DFTD No Non-DFTD yes Non-DFTD Non-DFTD yes 
7 Pre-Other Disease No Non-DFTD no Non-DFTD Non-DFTD yes 
8 DFTD Yes DFTD yes DFTD DFTD yes 
11 Non-DFTD No DFTD no Non-DFTD Uncertain no 
12 Pre-Other Disease No Uncertain no Non-DFTD Uncertain no 
14 Pre-Other Disease No DFTD no Non-DFTD Uncertain no 
16 Non-DFTD No Non-DFTD no Uncertain Uncertain no 
19 Non-DFTD No Non-DFTD yes Non-DFTD Non-DFTD yes 
21 DFTD Yes DFTD no DFTD DFTD yes 
22 Non-DFTD Yes Non-DFTD yes Non-DFTD Non-DFTD yes 
23 Non-DFTD Yes Non-DFTD yes Non-DFTD Non-DFTD yes 
24 Non-DFTD No Non-DFTD no DFTD Uncertain no 
26 DFTD Yes DFTD yes DFTD DFTD yes 
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Sample Clinical diagnosis GC-MS training GC-MS prediction ESI-MS training (Y/N) ESI-MS prediction Overall result Correct? 
27 DFTD Yes DFTD yes DFTD DFTD yes 
29 DFTD Yes DFTD yes DFTD DFTD yes 
31 Non-DFTD Yes Non-DFTD no Non-DFTD Non-DFTD yes 
32 DFTD Yes DFTD yes DFTD DFTD yes 
34 Non-DFTD No Non-DFTD yes Non-DFTD Non-DFTD yes 
35 Non-DFTD yes Non-DFTD no DFTD Uncertain no 
37 Non-DFTD no Non-DFTD yes Non-DFTD Non-DFTD yes 
38 DFTD yes DFTD no DFTD DFTD yes 
40 Pre-DFTD no DFTD no DFTD DFTD yes 
41 Non-DFTD yes Non-DFTD no Non-DFTD Non-DFTD yes 
42 Non-DFTD yes Non-DFTD yes Non-DFTD Non-DFTD yes 
44 Non-DFTD yes Non-DFTD yes Non-DFTD Non-DFTD yes 
47 Non-DFTD yes Non-DFTD yes Non-DFTD Non-DFTD yes 
54 DFTD yes DFTD yes DFTD DFTD yes 
67 Other Disease no Non-DFTD no Uncertain Uncertain no 
70 DFTD no DFTD no DFTD DFTD yes 
73 DFTD yes DFTD yes Uncertain Uncertain no 
76 DFTD yes DFTD yes DFTD DFTD yes 
78 Non-DFTD no DFTD yes Uncertain Uncertain no 
80 Non-DFTD no DFTD yes Non-DFTD Uncertain no 
83 DFTD yes DFTD no DFTD DFTD yes 
86 Pre-DFTD no DFTD no DFTD DFTD yes 
87 Pre-Other Disease no Non-DFTD no DFTD Uncertain no 
89 Other Disease no DFTD no DFTD DFTD no 
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Sample Clinical diagnosis GC-MS training GC-MS prediction ESI-MS training (Y/N) ESI-MS prediction Overall result Correct? 
91 DFTD no DFTD yes DFTD DFTD yes 
92 Other Disease yes Uncertain no Non-DFTD Uncertain no 
95 Other Disease no Non-DFTD no Non-DFTD Non-DFTD yes 
96 Other Disease no Non-DFTD no Uncertain Uncertain no 
97 Pre-DFTD no Non-DFTD no Non-DFTD Non-DFTD no 
100 Pre-other Disease no Non-DFTD no Non-DFTD Non-DFTD yes 
102 DFTD no DFTD yes DFTD DFTD yes 
103 Pre-other Disease no DFTD no DFTD DFTD no 
108 Other Disease no Non-DFTD no DFTD Uncertain no 
 
Table 5.6: Comparison of DFTD diagnosis of male samples between GC-MS and ESI-MS methods. 
Sample Clinical diagnosis GC-MS training GC-MS prediction ESI-MS training (Y/N) ESI-MS prediction Overall result Correct? 
D1 DFTD yes DFTD no DFTD DFTD yes 
D2 DFTD yes DFTD no DFTD DFTD yes 
D3 DFTD yes DFTD no DFTD DFTD yes 
D5 DFTD yes DFTD yes DFTD DFTD yes 
D7 DFTD yes DFTD yes DFTD DFTD yes 
D8 DFTD yes DFTD no Non-DFTD Uncertain no 
D10 DFTD yes DFTD yes DFTD DFTD yes 
H11 Non-DFTD yes Non-DFTD Not run - Non-DFTD yes 
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Sample Clinical diagnosis GC-MS training GC-MS prediction ESI-MS training (Y/N) ESI-MS prediction Overall result Correct? 
H12 Non-DFTD yes Non-DFTD no Non-DFTD Non-DFTD yes 
H14 Non-DFTD yes DFTD yes Uncertain Uncertain no 
H16 Non-DFTD yes Non-DFTD yes Non-DFTD Non-DFTD yes 
H19 Non-DFTD yes Non-DFTD no Non-DFTD Non-DFTD yes 
1 Non-DFTD yes DFTD yes Uncertain Uncertain no 
3 Non-DFTD no Non-DFTD yes Uncertain Uncertain no 
5 Non-DFTD yes DFTD no Non-DFTD Uncertain no 
9 DFTD yes DFTD yes DFTD DFTD yes 
10 DFTD no Uncertain no DFTD Uncertain no 
15 DFTD yes DFTD yes DFTD DFTD yes 
17 DFTD no DFTD no Uncertain Uncertain no 
18 DFTD yes DFTD yes DFTD DFTD yes 
25 DFTD yes DFTD yes Uncertain Uncertain no 
28 Non-DFTD yes Non-DFTD yes Non-DFTD Non-DFTD yes 
33 Non-DFTD yes Non-DFTD yes Non-DFTD Non-DFTD yes 
36 DFTD no Non-DFTD no Non-DFTD Non-DFTD no 
39 Non-DFTD no DFTD no Non-DFTD Uncertain no 
43 Pre-DFTD no DFTD no DFTD DFTD yes 
45 DFTD no Uncertain no DFTD Uncertain no 
46 DFTD yes DFTD no Non-DFTD Uncertain no 
48 Non-DFTD yes Non-DFTD yes Non-DFTD Non-DFTD yes 
49 Non-DFTD yes Non-DFTD yes Non-DFTD Non-DFTD yes 
50 DFTD no DFTD no Uncertain Uncertain no 
51 DFTD no DFTD no DFTD DFTD yes 
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Sample Clinical diagnosis GC-MS training GC-MS prediction ESI-MS training (Y/N) ESI-MS prediction Overall result Correct? 
52 Non-DFTD yes Non-DFTD no Uncertain Uncertain no 
55 Non-DFTD yes Non-DFTD yes Uncertain Uncertain no 
56 Other Disease no Non-DFTD no Non-DFTD Non-DFTD yes 
57 Pre-DFTD no DFTD no DFTD DFTD yes 
58 Non-DFTD yes Non-DFTD yes Uncertain Uncertain no 
59 DFTD yes DFTD yes DFTD DFTD yes 
60 Pre-Other Disease no Non-DFTD no Non-DFTD Non-DFTD yes 
61 DFTD yes DFTD yes DFTD DFTD yes 
62 Other Disease no Non-DFTD no Non-DFTD Non-DFTD yes 
63 DFTD no DFTD yes Uncertain Uncertain no 
64 DFTD no Non-DFTD yes Uncertain Uncertain no 
65 DFTD no DFTD yes DFTD DFTD yes 
68 DFTD yes DFTD no DFTD DFTD yes 
69 Pre-Other Disease no DFTD no DFTD DFTD no 
71 DFTD yes DFTD no DFTD DFTD yes 
74 DFTD no Non-DFTD yes Uncertain Uncertain no 
75 Non-DFTD no DFTD yes Uncertain Uncertain no 
77 Non-DFTD yes DFTD no Non-DFTD Uncertain no 
79 Non-DFTD yes Uncertain yes Non-DFTD Uncertain no 
82 DFTD no DFTD no Non-DFTD Uncertain no 
84 Non-DFTD yes Non-DFTD yes Non-DFTD Non-DFTD yes 
85 DFTD no DFTD yes DFTD DFTD yes 
88 Other Disease no DFTD no Uncertain Uncertain no 
90 Pre-DFTD no DFTD no Uncertain Uncertain no 
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Sample Clinical diagnosis GC-MS training GC-MS prediction ESI-MS training (Y/N) ESI-MS prediction Overall result Correct? 
93 Other Disease no DFTD no DFTD DFTD no 
94 Other Disease no DFTD no DFTD DFTD no 
98 Other Disease no DFTD no DFTD DFTD no 
99 DFTD yes Uncertain no Non-DFTD Uncertain no 
101 Other Disease no DFTD no DFTD DFTD no 
104 Pre-DFTD no DFTD no DFTD DFTD yes 
105 DFTD no Uncertain no Uncertain Uncertain no 
106 Other Disease no DFTD no Uncertain Uncertain no 
107 DFTD yes DFTD no Non-DFTD Uncertain no 
109 Non-DFTD yes Non-DFTD yes Non-DFTD Non-DFTD yes 
110 Non-DFTD no Non-DFTD yes Non-DFTD Non-DFTD yes 
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5.4 Summary 
These results highlighted how different sample variables such as gender and sampling 
location (habitat), can cause interferences in predicting disease specific metabolite 
biomarkers. This was shown by the PCA plots that were developed with ≤ 30 samples in 
the training set that were not efficient at distinguishing between the DFTD samples the 
non-DFTD samples that were not part of the training set. The inferior results obtained with 
the male samples also highlighted problems with sample variability potentially because of 
the bias in sampling locations of the DFTD samples.   
The removal of some of the variability between samples improved the results. This was 
shown by the dividing the samples according to gender. With the larger training set that 
contained 70 % of the healthy and DFTD samples the female PCA plots were quite 
proficient at separating the DFTD and non-DFTD samples. The females provided more 
promising results than the males with sensitivities of 95 % with both the GC-MS and the 
ESI-MS method. This may have been because of the lack of variability in the sampling 
locations of the samples obtained from DFTD-positive males in this sample set. The 
results highlighted the need to ensure that the many variables that can affect an 
individual’s metabolome are well represented in the set of samples used as the training set 
in biomarker discovery. A broader set of male samples is needed to try and improve the 
results obtained from this gender. Especially since better sensitivity and specificity was 
obtained with the females using this sample set than that obtained from the samples 
examined in chapter 4 which had less variability because of the restricted sampling area.  
Overall this set of samples was too small for the number of variables to be able to identify 
metabolomic differences between all of the DFTD and non-DFTD samples. The results 
also highlighted that the presence of other diseases can be wrongly diagnosed as having 
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DFTD when examining the metabolites identified in the Student’s t-test. The results 
discussed in this chapter were comparable to results obtained by Stentiford and co-workers 
who found greater differences in age and sampling location than disease in liver fish. They 
were able to diagnose 7 out of 10 fish that had liver tumours when looking at peptides [8, 
101]. Further work is needed to look at the identified metabolites more closely to 
determine if these metabolites are specific to DFTD or are just changed because the 
presence of cancer or other diseases.  
The techniques discussed in this chapter showed good sensitivity and specificity at 
correctly classifying non-DFTD and DFTD female devils. Both methods provided a 
sensitivity of 95 % and specificities of 80 and 72 % for the GC-MS and ESI-MS methods 
respectively. As discussed in section 5.3.3 there is a viable potential in using the quicker 
ESI-MS method as a quick screening method and the GC-MS method to confirm uncertain 
diagnoses.  
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6 Summary and Conclusions 
6.1 Discussion of Techniques 
The aim of this research was to develop a screening test for DFTD that was firstly 
applicable for sampling wild Tasmanian devils and secondly did not require a biopsy of 
the suspected DFTD tumour. Three different mass spectrometry methods (capillary 
electrophoresis – mass spectrometry (CE-MS), gas chromatography – mass spectrometry 
(GC-MS) and electrospray ionisation – mass spectrometry (ESI-MS)) were investigated to 
mine for disease metabolite biomarkers using non-targeted approaches. All three methods 
involved the injection of roughly equivalent volumes of serum considering the different 
sample preparation steps and dilutions conducted prior to injection. CE-MS and GC-MS 
involve the separation of metabolites prior to detection with mass spectrometry. The CE-
MS method was not as sensitive or reproducible as the other two methods and therefore 
not investigated further. Both the ESI-MS method and GC-MS method, when analysed 
with a feature selection step followed by principal component analysis (PCA), were able to 
distinguish differences in the serum metabolites from devils with DFTD up to six months 
prior to visible tumours. This positive result obtained from two complimentary techniques 
supported the hypothesis that differences in the serum metabolome can be observed 
between DFTD-positive and DFTD-negative devils prior to visible manifestation of 
tumours around the face and mouth of diseased Tasmanian devils.  
In the case of the ESI-MS method, the removal of a separation step decreased the analysis 
time for the sample. The preparation of samples for the ESI-MS method could be 
completed in less than 30 min and analysed within five min including pre and post 
instrument washings. Prior to GC-MS analysis the metabolites needed to be derivatised in 
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two steps. The first reaction with o-methylhydroxylamine hydrochloride was conducted 
either for at least 17 hours or for 90 min prior to the addition of MSTFA which was 
incubated further prior to sample injection. Each sample run then took between 10 to 60 
min depending upon the length of the column. Even though the preparation and analysis 
time for the GC-MS method was considerably longer, prior separation of metabolites 
allowed the collection of further information by separating the metabolites by chemical 
type.  
Encouragingly some of the metabolites identified had previously been associated with 
cancer. The most interesting of these was the observed increase in myo-inositol which has 
been previously associated with schwannomas [24]. This result supports the evidence 
presented by Murchison et al. that suggests that DFTD may be Schwann cell in origin 
[82]. The preliminary identification of these metabolites could aid in understanding more 
about DFTD and the discovery of potential treatment strategies.  
There were two reasons for the development of a pre-clinical diagnostic test. Firstly, to 
ensure that devils entering into insurance populations were DFTD-free to decrease 
quarantine time and secondly to remove DFTD-positive devils in the wild before the 
display of tumours to eliminate or at least reduce the spread of the disease to other devils. 
It is beneficial to lean on the side of caution in the first instance to ensure that no DFTD 
devils enter into the insurance populations. On the other hand the genetic diversity of 
Tasmanian devils is quite low so the removal of healthy devils from wild populations 
because of lack of specificity in the diagnosis is not advisable. 
After validation it would be possible to use this test to diagnose DFTD in wild devils since 
serum samples can be obtained during routine trapping trips of wild populations. The 
sample preparation method to obtain metabolites from the serum samples are obtained 
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identically for both the ESI-MS and GC-MS method. This allows for simultaneous 
analysis of samples using both of the developed methods. A pre-clinical metabolite 
biomarker diagnostic test for DFTD could be used to confirm diagnosis of DFTD to 
eliminate the removal of healthy devils from a wild population. The shorter, ESI-MS 
method could be developed further to ensure that no DFTD devils are wrongly classified 
as having DFTD. The devils could be held for short periods of time and then released back 
in the wild after the analysis of the sample. In turn the GC-MS method could be further 
developed as a highly sensitive technique to ensure that only DFTD devils are diagnosed 
as DFTD-positive. This proposition is plausible since the size and geography of Tasmania 
would allow for samples to be obtained; delivered to a lab; and analysed within 24 hours.  
Currently, there are also portable GC-MS instruments on the market. The GC-MS method 
could be modified for a portable instrument so that samples could be analysed at a base 
camp on the field. The devils are also micro-chipped on initial capture so it is possible to 
obtain a blood sample, test for the disease and then remove the devil on subsequent trips if 
a positive DFTD diagnosis is obtained. These latter two options are more plausible 
because of the cost and effort that would be required to temporarily hold animals during 
the time necessary to transport the samples back to the laboratory and analyse for DFTD.  
6.2 Discussion of Sampling 
Prior to routine testing of devils for DFTD, a potential diagnostic test will need appropriate 
validation. The methods developed here could be validated for use or the metabolites 
identified with the GC-MS method could be used to develop a more targeted approach for 
a diagnostic test. The validated diagnostic test will be required to be effective to test all 
Tasmanian devils including individuals from DFTD and non-DFTD areas and diagnose 
DFTD pre-clinically. To aid in this, samples for this study were obtained from wild devils 
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trapped throughout Tasmania. The spread of DFTD is very extensive in eastern Tasmania 
and almost non-existent in the majority of north-western and western Tasmania. 
Unfortunately, there are other variables that are also different between these two 
subpopulations of devils that can affect an individual’s metabolome which include habitat, 
diet and genetics as well as the presence of other diseases.  
There were challenges in selecting appropriate samples to be included in the sample sets 
because of the variables between north-western and eastern devils. To effectively 
determine metabolite biomarkers specific to DFTD, ideally the non-DFTD and DFTD 
samples needed to both include samples from western and eastern Tasmania. 
Unfortunately, there are very limited devils that will remain DFTD free for 12 months in 
eastern Tasmania and limited DFTD positive devils in the western half of Tasmania. The 
presence and rate of spread of DFTD appears to be dependent upon the variability of the 
MHC protein found on the surface of cells that inform an individual’s immune system of 
invading cells from other individuals from the same or different species. The Tasmanian 
devils from north-western and western Tasmania appear to express a different combination 
of the MHC proteins than their compatriots in eastern Tasmania which is believed to 
explain the absence of DFTD in western Tasmania. 
The results in chapter 5 illustrated the importance of appropriately handling sample 
variables. When the samples were separated by gender enough variability could be 
observed between the non-DFTD and DFTD female samples. When additional samples 
were added to the female training set both the GC-MS and the ESI-MS methods had 
sensitivities of 95 % and specificities > 70 %.  In the case of the male samples, the 
distinction between non-DFTD and DFTD devils was not observed as it had been with the 
females because of the bias in sample location of the DFTD samples. This highlighted the 
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importance of ensuring that the training set is well representative of as many metabolite 
varying variables as possible in both the DFTD and non-DFTD set of samples. The spread 
of this disease makes this a difficult requirement to obtain. The training set for the males 
had 18 non-DFTD and 18 DFTD devils where as the training set for the females had 15 of 
each. The feature selection step does aid in pre-selecting only the metabolites that are 
DFTD specific. Gender was also observed to affect the metabolites that are significantly 
different between non-DFTD and DFTD samples. From the ESI-MS metabolites identified 
as significant, only 3 were identified in both the male and female samples from the blind 
state wide study sample set. The fold differences between non-DFTD and pre-DFTD and 
non-DFTD and DFTD samples were also not the same with both genders. The metabolites 
observed using the GC-MS method only identified two metabolites that were significantly 
different with both genders although the fold changes with this method were similar for 
both male and female samples. The results for the females in Chapter 5 suggests that with 
careful training set selection that was representative of as many sampling locations as 
possible a training set of around 40 could be used to mine for significant metabolites that 
differ between DFTD and non-DFTD devils if the genders are examined separately.  
6.3 Applicability as a Pre-Clinical Diagnostic Test for DFTD 
The success of many potential intervention projects to combat DFTD is dependent upon 
the development of a diagnostic test that has the ability to diagnose all wild devils with or 
without signs of DFTD.  
The initial work involved in this project showed variability between devils without DFTD 
and those with DFTD including samples obtained from devils 69 days prior to clinical 
signs. This result showed the potential to use metabolomics to diagnoses diseases in wild 
populations which can be difficult because of uncontrolled variables such as diet or when 
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the individual last ate. The techniques discussed in this project showed the ability to detect 
differences between DFTD and non-DFTD devils up to six months prior to the 
presentation of visible facial tumours even with sample sets of increased variability (see 
chapters 4 and 5). With the correct validation these techniques could be used on any devil 
to ensure that devils entering into insurance populations are DFTD-free and to help form 
wild populations of DFTD-free devils in eastern Tasmania through the re-location of 
DFTD devils in areas such as the Forrester Peninsula. Further research should examine the 
accuracy of diagnosing DFTD between one to six months pre-clinical. If all devils that 
show signs of DFTD three or four months after the initial trapping, quarantine times for 
devils entering into insurance populations could be reduced.  
In the case of suppression trials, trapping frequencies could be reduced from once a month 
to every three months. Removing DFTD devils prior to identifiable tumours should 
decrease the rate of spread for this contagious disease. The ability to reduce trapping 
frequencies will also dramatically reduce the cost of a suppression trial. Tasmanian devils 
have low genetic diversity which follows the island founder effect but there are differences 
in the genetics between the northwest and eastern devils [4]. Many of the devils that have 
been placed into the captive insurance populations come from north-western populations 
since these populations are predominantly DFTD-free but this limits the range of genetic 
diversity. The success of a suppression trial in eastern Tasmanian could establish a 
population of wild DFTD-free east-coast devils which will help to sustain the genetic 
diversity of this unique and valuable carnivorous marsupial.  
The techniques developed here could also be used for biomarker discovery for conditions 
and diseases in humans and other types of wildlife. The identification of diseases in early 
stages, as in the case of this work, could help to eliminate the spread of contagious 
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diseases or aid in early diagnosis and thus better outcomes for diseased individuals by 
providing options for early treatment. Confirmation of metabolite identification could also 
help shed light on the biology DFTD to help develop treatment strategies for this disease.   
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7 Appendices 
7.1 Appendix 1: Sample sets 
7.1.1 Pilot Set 
Table A 1: Set of samples obtained for a pilot study to determine the feasibility of discovering 
metabolite differences between DFTD and non-DFTD Tasmanian devils. 
Sample # Microchip # Location DFTD status Sex  Age 
04/0560 982009101334983 Bronte Park DFTD 69 days later M 3 
04/0603 982009101328318 Bronte Park Non-DFTD F 3 
04/0605 982009101682197 Bronte Park DFTD F 3 
04/0735 982009101449680 Bronte Park DFTD M 3 
04/0960 985120016080819 National Park Non-DFTD M 3 
04/1021 Unknown National Park Non-DFTD F 4 
04/2058 985120016023130 Mount William DFTD F 3 
04/2062 985120016063210 Mount William Non-DFTD M 1 
04/2064 985120016051065 Mount William DFTD M 4 
04/2065 985120016102779 Mount William Non-DFTD F 3 
04/3000 985120016084089 Fentonbury DFTD F ? 
04/3003 985120016105311 Fentonbury Non-DFTD F 4 
04/3008 985120015622584 Fentonbury DFTD M 4 
04/3011 985120016101849 Fentonbury Non-DFTD M 4 
04/3176 985120015992482 St Helens Non-DFTD F 3 
04/3201 985120016101940 St Helens Non-DFTD M 3 
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7.1.2 Set 1 
Table A 2: Samples obtained from male devils at Bronte Park during 2004.  
Sample 
# Microchip # Location DFTD Status Sex Age 
04/0446 982009101663132 Bronte Park DFTD Male 3 
04/0448 982009101564196 Bronte Park DFTD 35 days later Male ? 
04/0720 982009101357889 Bronte Park Non-DFTD Male 3 
04/0728 982009101162213 Bronte Park Non-DFTD Male ? 
04/0731 982009101382207 Bronte Park Non-DFTD Male ? 
04/1167 985120016021605 Bronte Park Non-DFTD Male 2 
04/1771 985120016684224 Bronte Park Non-DFTD Male 2 
04/0451 982009101449680 Bronte Park DFTD Male 3 
04/0602 982009101538392 Bronte Park DFTD Male 3 
04/0725 982009101564196 Bronte Park DFTD Male 3 
04/1769 982009101357889 Bronte Park DFTD Male 3 
04/0284 982009101449680 Bronte Park DFTD Male ? 
04/0722 Unknown Bronte Park Non-DFTD Male 3 
04/0735 982009101449680 Bronte Park DFTD Male 3 
04/1849 985120015506893 Bronte Park Non-DFTD Male 1 
04/1852 985120015994043 Bronte Park Non-DFTD Male 2 
04/1853 982009101538392 Bronte Park Non-DFTD Male 3 
04/0276 982009101382207 Bronte Park Non-DFTD Male 4 
04/0560 982009101334983 Bronte Park DFTD 69 days later Male 3 
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7.1.3 Blind Study samples obtained from the Suppression Trial 
Table A 3: Details of serum samples obtained from devils located at the site of the suppression trial at Forestier Peninsula including government accession 
numbers microchip numbers and DFTD status.  
Sample 
ID Accession # Microchip # DFTD Status 
Sample 
ID Accession # Microchip # DFTD Status 
1 08/0134 982009104349396 DFTD 22 08/3904 982009104327264 DFTD 
2 08/0177 982009104246774 DFTD 23 08/4046 982009104931509 DFTD 
3 08/0178 982009104877244 DFTD 24 09/0235 985154000001083 Healthy 
4 08/0741 982009104326821 DFTD 25 09/1418 982009104914402 6 month pre-clinical 
5 08/1046 982009104272295 DFTD 26 09/1430 982009104925396 12 month pre-clinical 
6 08/1047 982009104833287 DFTD 27 09/1438 982009104907340 6 month pre-clinical 
7 08/1072 982009104246128 Other disease 28 09/1439 982009104720533 Healthy 
8 08/1130 982009104254912 DFTD 29 09/1440 982009104884473 Healthy 
9 08/2378 982009104809064 DFTD 30 09/1441 982009105175668 12 month pre-clinical 
10 08/2379 982009104877259 DFTD 31 09/1443 982009104929919 12 month pre-clinical 
11 08/2385 982009104836888 DFTD 32 09/1444 982009105195643 12 month pre-clinical 
12 08/2386 982009104811311 DFTD 33 09/1448 982009104965330 DFTD 
13 08/2380 982009104248590 DFTD 34 09/1449 982009104815996 6 month pre-clinical 
14 08/2480 982009104834357 DFTD 35 09/1451 982009104925128 Other disease 
15 08/3673 982009104810858 DFTD 36 09/1478 982009104857449 DFTD 
16 08/3594 982009105181458 DFTD 37 09/1494 982009104876128 12 month pre-clinical 
17 08/3595 982009102344207 DFTD 38 09/2535 982009104840088 6 month pre-clinical 
18 08/3605 982009104328024 6 month pre-clinical 39 09/2536 982009104975946 6 month pre-clinical 
19 08/3695 982009104815960 DFTD 40 09/2538 982009104907551 Healthy 
20 08/4006 982009104931509 DFTD 41 09/2539 982009104725775 12 month pre-clinical 
21 08/3727 982009100741969 DFTD 42 09/2540 982009104884473 Healthy 
43 09/2543 982009104720533 Healthy 69 09/4408 982009104914402 DFTD 
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Sample 
ID Accession # Microchip # DFTD Status 
Sample 
ID Accession # Microchip # DFTD Status 
44 09/2532 982009104879401 6 month pre-clinical 70 09/4436 982009106092189 Healthy 
45 09/2533 982009105195643 6 month pre-clinical 71 09/4440 982009104243151 DFTD 
46 09/2531 982009104858662 6 month pre-clinical 72 10/0148 982009104975946 1 month pre-clinical 
47 09/2545 985154000001106 12 month pre-clinical 73 10/0150 982009104858662 DFTD 
48 09/2549 982009104940952 DFTD 74 10/0135 982009104789723 DFTD 
49 09/2554 982009104863462 DFTD 75 10/0147 982009104879401 1 month pre-clinical 
50 09/2561 982009104271638 DFTD 76 10/0129 982009105195643 DFTD 
51 09/2573 982009104849679 6 month pre-clinical 77 10/0134 982009104840088 DFTD 
52 09/2578 982009104995020 DFTD 78 10/0130 982009104849679 DFTD 
53 09/2597 982009104929919 12 month pre-clinical 79 10/0156 982009106039877 6 month pre-clinical 
54 09/2601 982009104914402 6 month pre-clinical 80 10/0157 982009104943898 DFTD 
55 09/2602 982009104932691 12 month pre-clinical 81 10/0148 982009104975946 1 month pre-clinical 
56 09/2605 982009104919715 12 month pre-clinical 82 09/4345 982009104884473 Healthy 
57 09/2603 982009104906424 6 month pre-clinical 83 08/2480 982009104834357 DFTD 
58 09/2615 982009104940952 DFTD 84 10/0129 982009105195643 DFTD 
59 09/4338 982009104902572 6 month pre-clinical 85 10/0156 982009106039877 6 month pre-clinical 
60 09/4339 982009104348760 7 month pre-clinical 86 09/2615 982009104940952 DFTD 
61 09/4343 982009104840088 8 month pre-clinical 87 10/0157 982009104943898 DFTD 
62 09/4345 982009104884473 Healthy 88 10/0150 982009104858662 DFTD 
63 09/4346 982009106601685 Other disease 89 09/1494 982009104876128 12 month pre-clinical 
64 09/4347 982009104789723 6 month pre-clinical 90 09/1478 982009104857449 DFTD 
65 09/4348 982009104943898 6 month pre-clinical 91 10/0147 982009104879401 1 month pre-clinical 
66 09/4349 982009104858662 6 month pre-clinical 92 10/0135 982009104789723 DFTD 
67 09/4351 982009104720533 Healthy 93 10/0134 982009104840088 DFTD 
68 09/4407 982009104925396 12 month pre-clinical 94 10/0130 982009104849679 DFTD 
95 08/3695 982009104815960 DFTD 98 08/1130 982009104254912 DFTD 
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Sample 
ID Accession # Microchip # DFTD Status 
Sample 
ID Accession # Microchip # DFTD Status 
96 08/2379 982009104877259 DFTD 99 09/1449 982009104815996 6 month pre-clinical 
97 08/0741 982009104326821 DFTD 100 08/3727 982009100741969 DFTD 
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7.1.4 Blind State Wide Study Sample Set 
Table A 4: List of samples obtained from Tasmanian devils throughout Tasmania  included in a blind study with no control of metabolite affecting sample 
variables. Details of government accession numbers, devil microchip numbers, sampling location, gender, age and disease status are listed. 
Sample # Accession # Microchip # Sampling Location Sex Age DFTD status 
Other Disease 
Information 
D1 06/2022 982009100819644 Forestier m 3 DFTD   
D2 06/2023 982009104356213 Forestier m 3 DFTD   
D3 06/2024 982009104252965 Forestier m 2 DFTD   
D4 06/2026 985120016101456 Forestier f 2 DFTD   
D5 06/2027 985120016108883 Forestier m 2 DFTD   
D6 07/1872 982009102626938 Reedy Marsh f N/A DFTD   
D7 07/1875 982009102327363 Reedy Marsh m 4 DFTD   
D8 06/2673   982009104842051   Buckland m 1 DFTD   
D9 07/0189 982009100873904 Coles Bay f 2 DFTD   
D10 07/1490 982009102731064 Bangor m 4 DFTD   
H11 07/1531 982009104868089 West Pencil Pine m 3 Non-DFTD   
H12 07/1237 982009105190043 Fentonbury m 1 Non-DFTD   
H13 07/1279 985120016097550 Mount Pleasant f 4 Non-DFTD   
H14 07/1323 982009104335482 Coles Bay m 1 Non-DFTD   
H15 07/1366 982009102229973 Granville f 4 Non-DFTD   
H16 07/1367 982009104358597 Granville m 2 Non-DFTD   
H17 07/1368 982009102725368 Granville f 4 Non-DFTD   
H18 06/2057 982009102432250 Bangor f 3 Non-DFTD   
H19 08/0153 982009104859118 Bicheno m 1 Non-DFTD   
H20 09/0402 982009100786171 Mount Pleasant f 6 Other disease Not Specified 
1 06/3112 000682FBF5 Trowunna m 2 Non-DFTD   
2 06/2177    982009102645810 MTP f 2 DFTD   
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Sample # Accession # Microchip # Sampling Location Sex Age DFTD status 
Other Disease 
Information 
3 06/3115 00065ED672 Trowunna m N/A Non-DFTD   
4 06/2057 982009102432250 Bangor f 3 Non-DFTD   
5 06/3145 00062D5B41 Trowunna m 4 Non-DFTD   
6 06/3144 982009100795775 Trowunna f 3 Non-DFTD   
7 05/1879 00065D83FA Trowunna f NA Pre-other disease Pre-Non-DFTD disease 
8 05/0051  N/A Deloraine f N/A DFTD   
9 06/2023 982009104356213 Forestier m 3 DFTD   
10 06/2022 982009100819644 Forestier m 3 DFTD   
11 06/3113 00068351D8 Trowunna f 2 Non-DFTD   
12 06/3448 982009100786171 Mount Pleasant f N/A Pre-other disease Pre-Non-DFTD disease 
13 06/3114 00065DC74E Trowunna f 2 Non-DFTD   
14 06/3451 982009100852046 Mount Pleasant f 3 Pre-other disease Pre-Non-DFTD disease 
15 06/2109 985120015995993 Forestier m 3 DFTD   
16 05/3164 985100010685532 Taroona f 4 Non-DFTD   
17 06/2027 985120016108883 Forestier m 2 DFTD   
18 06/2024 982009104252965 Forestier m 2 DFTD   
19 07/0298 982009104863314 Wisedale f 1 Non-DFTD   
20 06/1005 982009100819358 Granville m 4 Pre-other disease Pre-Non-DFTD disease 
21 07/1315 982009100818058 Fentonbury f 3 DFTD   
22 06/2672 982009104881249 Buckland f 1 Non-DFTD   
23 07/1240 982009104809696 Fentonbury f 1 Non-DFTD   
24 06/3447 985120016024404   Mount Pleasant f 3 Non-DFTD   
25 06/2401 982009100371954   Mount Pleasant m 3 DFTD   
26 06/2026 985120016101456 Forestier f 2 DFTD   
27 06/2671 982009102220925 Buckland f 3 DFTD   
28 07/1531 982009104868089 West Pencil Pine m 3 Non-DFTD   
29 07/0187 982009102287979 Fentonbury f 2 DFTD   
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Sample # Accession # Microchip # Sampling Location Sex Age DFTD status 
Other Disease 
Information 
30 07/0374 00065D83FA Trowunna f 5 Other disease Neoplasia 
31 07/0295 982009104272592   Westbury f 2 Non-DFTD   
32 07/0817 00065DC9C5 Mole Creek f 6 DFTD   
33 07/0300 982009104817698 Wisedale m 1 Non-DFTD   
34 07/0301 982009104246213 Wisedale f 4 Non-DFTD   
35 07/0711 982009105197308 Temma f 3 Non-DFTD   
36 07/0192 982009100873958  Coles Bay m 2 DFTD   
37 07/1366 982009102229973 Granville f 4 Non-DFTD   
38 07/0189 982009100873904 Coles Bay f 2 DFTD   
39 07/1367 982009104358597 Granville m 2 Non-DFTD   
40 07/1316 982009100831798   Fentonbury f 3 Pre-DFTD   
41 07/1279 985120016097550 Mount Pleasant f 4 Non-DFTD   
42 07/1241 982009104841310 Fentonbury f 1 Non-DFTD   
43 07/1285 985120016101682 Mount Pleasant m N/A Pre-DFTD   
44 07/1368 982009102725368 Granville f 4 Non-DFTD   
45 06/2449 982009104234181   Bangor m 3 DFTD   
46 06/2673   982009104842051   Buckland m 1 DFTD   
47 07/0473 982009104967035 West Pencil Pine f 2 Non-DFTD   
48 07/0479 982009104350998   West Pencil Pine m 5 Non-DFTD   
49 07/1369 982009100816855 Granville m 3 Non-DFTD   
50 07/1324 982009102247939 Coles Bay m 2 DFTD   
51 06/1785 985120016101682 Mount Pleasant m 4 DFTD   
52 07/1323 982009104335482 Coles Bay m 1 Non-DFTD   
53 07/1875 982009102327363 Reedy Marsh m 4 DFTD   
54 07/1253 985120016064617 Bangor f 4 DFTD   
55 07/1372 982009100819358 Granville m 5 Other disease Non-DFTD growths 
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Sample # Accession # Microchip # Sampling Location Sex Age DFTD status 
Other Disease 
Information 
56 07/1534 982009104354989 West Pencil Pine m 5 Other disease Skin inflamation 
57 07/1286 982009100371954 Mount Pleasant m N/A Pre-DFTD   
58 07/0474 982009104862874   West Pencil Pine m 5 Non-DFTD   
59 07/1856   982009100819338 Bangor m 2 DFTD   
60 07/0481 982009104354989 West Pencil Pine m 5 Pre-other disease Pre-Non-DFTD disease 
61 07/1855 982009100895084 Bangor m 2 DFTD   
62 07/1540 982009104960787   West Pencil Pine m 5 Other disease Non-DFTD growths 
63 07/1238 982009100917481 Fentonbury m 2 DFTD   
64 07/1492 982009100747693 Bangor m N/A DFTD   
65 07/2258 982009100754517 Bangor m 2 DFTD   
66 07/0478 982009104976856 West Pencil Pine f 4 Non-DFTD   
67 07/2124 982009101687230 Narawntapu f 6 Other disease Neoplasia 
68 07/1490 982009102731064 Bangor m 4 DFTD   
69 07/1914 982009105007128 Taranna m 1 Pre-other disease Pre-Non-DFTD disease 
70 07/1212 982009102751068 Bangor f 3 DFTD   
71 07/2259 982009100906846   Bangor m 2 DFTD   
72 07/1213 982009100834894 Bangor f 2 DFTD   
73 07/2257 982009100847763   Bangor f 2 DFTD   
74 07/0500 982009100662150   Bronte Park m 2 DFTD   
75 07/0477 982009104833285 West Pencil Pine m 5 Non-DFTD   
76 07/1872 982009102626938 Reedy Marsh f N/A DFTD   
77 07/1325 982009105363992 Coles Bay m 1 Non-DFTD   
78 07/0476 982009104832117 West Pencil Pine f 3 Non-DFTD   
79 07/1878 00065D7157 Taranna m 5 Non-DFTD   
80 07/0480 982009104253340   West Pencil Pine f 5 Non-DFTD   
81 07/1239 982009105165660 Fentonbury m 2 DFTD   
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Sample # Accession # Microchip # Sampling Location Sex Age DFTD status 
Other Disease 
Information 
82 07/1489 982009102757183   Bangor m N/A DFTD   
83 07/1714 982009104267602   Wisedale f 3 DFTD   
84 07/1237 982009105190043 Fentonbury m 1 Non-DFTD   
85 07/3341 982009104859904 Narawntapu m 3 DFTD   
86 07/0488 982009104269739 West Pencil Pine f 3 Pre-DFTD   
87 07/0490 982009104357109 West Pencil Pine f 2 Pre-other disease Pre-Non-DFTD disease 
88 08/0266 982009104880604 Marrawah m 5 Other disease Non-DFTD growths 
89 08/4048 N/A Alcomie f 4 Other disease Alopecia (baldness) 
90 07/1478 000658C2A0 Trowunna m 4 Pre-DFTD   
91 07/0486 982009104869208 West Pencil Pine f 4 DFTD   
92 09/1583 982009104250147 West Pencil Pine f 4 Other disease Neoplasia 
93 07/3448 982009105007128 Taranna m 1 Other disease Kidney disease 
94 09/0193 985154000001207 Trowunna m 1 Other disease Malformation 
95 09/0402 982009100786171 Mount Pleasant f 6 Other disease   
96 09/0991 00068B7E56 Hobart f 3 Other disease   
97 09/1612 982009104269739 West Pencil Pine f 5 Pre-DFTD   
98 09/1069 982009104984790   Mount Pleasant m 3 Other disease Urinary Infection 
99 08/1620 982009105145532 West Pencil Pine m 2 DFTD   
100 08/3764 982009104250147 West Pencil Pine f 4 Pre-other disease   
101 09/1446 982009104905221   Bangor m 1 Other disease Ulcers 
102 07/0487 982009104968776 West Pencil Pine f 5 DFTD   
103 09/1278 985154000001173 Sidmouth f 4 Pre-other disease Pre-non-DFTD growths 
104 06/3122 000658C2A0 Trowunna m 3 Pre-DFTD   
105 08/0134 982009104349396   Bangor m 2 DFTD   
106 09/1451 982009104925128 Bangor m 2 Other disease Non-DFTD growths 
107 07/1537 982009104815428 West Pencil Pine m 5 DFTD   
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Sample # Accession # Microchip # Sampling Location Sex Age DFTD status 
Other Disease 
Information 
108 09/0992 982009104357109 Hobart f 4 Other disease Skin lesions 
109 08/0153 982009104859118 Bicheno m 1 Non-DFTD   
110 08/0153 982009104859118 Bicheno m 1 Non-DFTD   
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7.2 Appendix 2: Fold Changes Observed for the Significantly Different 
Peaks for Both Blind Studies 
Table A 5: Fold changes between DFTD and non-DFTD samples of significantly different peaks analysed 
by ESI-MS in both of the blind studies (see chapters 4 and 5). These peaks were determined using 
Student’s t-test (p ≤ 0.05) and then used to classify DFTD status using PCA. 
ESI-Metabolite male Forestier male whole state female whole state 
pre-DFTD DFTD pre-DFTD DFTD pre-DFTD DFTD 
134 1.5 3.7 - - - - 
135 - - 0.6 0.7 - - 
150 - - - - 1.8 1.9 
151 - - 0.5 0.6 - - 
164.9 - - - - 10.0 6.4 
165 - - - - 2.2 2.1 
191 1.2 1.8 - - - - 
192 1.7 8.0 - - Only in DFTD (av 2.3) 
193 - - 0.2 0.5 - - 
200.9 2.9 4.0 - - - - 
205.1 - - - - 2.6 2.7 
207 1.0 3.1 - - - - 
221.2 - - - - 1.4 1.4 
222.2 - - - - 2.0 1.5 
244.2 - - - - 3.0 2.8 
250.9 - - 0.7 0.7 - - 
252.9 - - 0.2 0.5 - - 
261 - - 0.7 0.8 - - 
266.2 - - - - 0.9 1.3 
267.2 - - - - 0.0 1.9 
271 - - 0.5 0.8 - - 
274.9 - - 2.6 2.3 - - 
287 - - - - 5.4 6.0 
304.3 - - - - 1.1 1.5 
308.9 - - 0.7 0.6 - - 
310.9 - - 0.8 0.5 - - 
323.2 - - - - 1.5 0.0 
329.2 - - - - 1.1 1.3 
332.3 - - - - 2.1 1.7 
332.9 - - 6.2 7.6 - - 
334.9 - - 4.7 5.6 - - 
362.3 - - - - 1.5 1.4 
370.3 - - 0.3 0.3 - - 
370.4 - - 1.1 1.6 - - 
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ESI-Metabolite male Forestier male whole state female whole state 
pre-DFTD DFTD pre-DFTD DFTD pre-DFTD DFTD 
371.2 - - - - 1.2 1.3 
384.1 - - 1.2 1.4 - - 
387.2 - - - - 1.1 1.9 
392.8 - - 1.4 1.5 - - 
400.8 - - 1.8 1.9 - - 
408.3 - - - - 1.4 1.3 
433.3 - - 0.0 0.0 - - 
441.3 - - - - 0.0 3.0 
490.3 - - 0.3 0.2 - - 
512.3 - - 1.0 0.1 - - 
516.3 - - 0.9 0.4 - - 
519.3 1.1 0.8 - - - - 
522.4 - - 0.3 0.7 - - 
524.4 - - 0.2 0.7 - - 
532.9 - - - - 1.0 1.2 
534.3 - - 1.0 0.7 - - 
540.4 - - - - 1.9 2.0 
540.9 - - - - 1.3 1.8 
542.3 - - 0.7 0.8 - - 
544.3 - - 0.6 0.5 - - 
547.4 0.6 0.5 - - - - 
556.8 - - 0.8 0.1 - - 
560.3 - - 0.6 0.4 1.9 0.5 
563.9 - - 1.4 0.3 - - 
564.3 - - 0.0 0.5 - - 
566.3 - - - - 1.0 0.7 
569.4 - - 0.6 0.4 - - 
570.4 - - 1.1 0.8 - - 
572.4 - - 1.2 0.3 - - 
582.7 - - - - 0.0 5.8 
584.4 1.7 2.1 - - - - 
585.9 - - 1.3 0.4 - - 
586.3 - - - - 0.0 0.2 
586.9 - - 1.2 0.2 - - 
589.5 - - 0.7 0.8 - - 
590.3 - - - - 0.0 0.2 
591.5 - - 0.3 0.7 - - 
592.5 - - 0.0 0.7 - - 
592.9 - - 1.1 0.6 - - 
593.9 - - 1.8 0.1 - - 
600.9 - - 1.4 0.2 - - 
602.3 - - 0.4 0.5 - - 
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ESI-Metabolite male Forestier male whole state female whole state 
pre-DFTD DFTD pre-DFTD DFTD pre-DFTD DFTD 
604.3 - - 0.2 0.5 - - 
605.5 - - 0.8 0.7 - - 
606.9 - - - - 1.2 1.2 
607.9 - - 1.2 0.6 - - 
614.4 - - 1.2 0.8 - - 
615.9 - - 1.7 0.3 - - 
619.5 - - 0.6 0.8 - - 
620.5 - - 0.4 0.6 - - 
621.9 - - 1.2 0.2 - - 
622.4 1.8 0.1 - - - - 
630.9 - - 2.8 0.0 - - 
631.5 - - 0.7 0.8 - - 
639.4 - - 0.5 0.4 - - 
643.9 - - 1.4 0.3 - - 
644.9 - - 1.4 0.4 - - 
658.4 - - 1.0 0.8 - - 
658.6 - - 0.4 0.2 - - 
659.9 - - 1.3 0.4 - - 
663.5 - - - - 1.5 1.3 
665.5 - - 1.1 0.8 - - 
666.5 - - 1.1 0.9 - - 
668.5 - - - - 0.0 0.3 
669.6 - - 1.2 1.6 - - 
670.6 - - 1.2 1.6 - - 
671.6 - - - - 1.1 0.7 
672.6 - - - - 1.1 0.7 
672.9 - - - - 0.9 1.3 
677.6 - - - - 1.2 1.5 
680.4 - - 1.4 0.3 - - 
683.5 - - - - 1.2 1.4 
695.6 - - - - 1.1 0.8 
696.6 - - - - 1.0 0.8 
697.6 - - - - 1.1 0.8 
698.6 - - - - 1.0 0.9 
702.9 - - 1.1 0.6 - - 
709.5 1.0 0.5 - - - - 
709.9 - - 0.8 0.0 - - 
710.9 - - 1.5 0.4 - - 
717.9 - - - - 0.0 5.8 
730.6 - - - - 0.0 8.8 
731 - - - - 1.2 1.3 
732.9 - - 1.9 0.2 - - 
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ESI-Metabolite male Forestier male whole state female whole state 
pre-DFTD DFTD pre-DFTD DFTD pre-DFTD DFTD 
739 - - - - 1.2 1.2 
740 - - 1.7 0.4 - - 
747 - - 1.2 0.7 - - 
748.6 - - 0.5 0.5 - - 
756.6 - - - - 1.3 0.9 
761 - - - - 1.3 1.3 
762 - - 2.0 0.5 - - 
763.6 - - - - 1.1 0.9 
765.5 - - 1.6 1.1 - - 
765.6 - - 0.9 0.8 - - 
791 - - 1.5 0.6 - - 
799.7 - - 0.3 0.8 1.0 0.7 
804.6 - - - - 1.2 0.9 
805.6 - - - - 1.2 0.9 
806 - - 1.4 0.4 - - 
806.6 - - - - 1.0 0.8 
807.6 - - - - 1.0 0.8 
809.6 - - - - 1.1 0.8 
818.6 0.5 0.8 - - - - 
827 - - - - 0.0 3.2 
827.7 - - 0.4 0.8 - - 
829.7 0.7 0.2 0.4 0.8 - - 
834.6 - - - - 1.1 0.8 
841.5 0.7 0.1 - - - - 
843.7 - - 0.4 1.0 - - 
844.7 - - 0.1 0.8 - - 
850.6 - - 1.1 0.4 - - 
857.7 - - 0.5 0.6 - - 
859.6 - - 7.0 2.3 - - 
860.6 - - 1.3 1.3 - - 
862.6 - - 2.1 4.2 - - 
864 - - 3.6 0.0 - - 
869.7 - - 0.5 0.7 - - 
871.7 - - 0.5 0.8 - - 
872.7 - - 0.5 0.9 - - 
885.8 0.5 0.3 - - - - 
886.6 - - 7.8 2.8 - - 
890.6 - - - - 1.4 0.8 
892.6 - - 0.0 0.2 - - 
904.8 - - 3.0 1.5 - - 
936.7 2.6 3.3 - - - - 
948.5 - - 1.2 1.7 0.0 0.0 
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ESI-Metabolite male Forestier male whole state female whole state 
pre-DFTD DFTD pre-DFTD DFTD pre-DFTD DFTD 
953.7 2.1 4.0 - - - - 
965.8 - - - - 1.7 1.3 
997.7 - - - - 1.4 1.4 
1003.7 - - 1.3 0.3 - - 
1005.7 - - 1.4 0.3 - - 
1011.9 - - - - 1.2 1.7 
1012.9 - - - - 1.1 1.7 
1013.7 - - - - 1.3 1.3 
1016.7 - - 1.6 0.5 - - 
1030.7 - - 1.4 0.7 - - 
1040.9 - - 0.7 0.6 - - 
1045.9 - - 0.9 0.3 - - 
1048.9 - - 0.9 0.7 - - 
1057.7 - - - - 1.3 1.3 
1063.9 - - - - 0.9 1.9 
1074.7 - - 1.1 0.7 - - 
1076.7 - - 2.0 0.2 - - 
1077.7 - - 2.2 0.1 - - 
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Table A 6: Fold changes between DFTD and non-DFTD samples of significantly different peaks analysed 
by GC-MS in the blind study with extensive sample variability (see chapter 5). These peaks were 
determined using Student’s t-test (p ≤ 0.05 for the females and p ≤ 0.1 for the males) and then used to 
classify DFTD status using PCA. 
GC-MS metabolite male whole state female whole state 
Peak # Migration time (min) Base peak (m/z) pre-DFTD DFTD pre-DFTD DFTD 
4 13.2 175 0.9 0.9 - - 
12 14.1 104 1.3 1.2 - - 
34 16.1 103 3.5 1.7 - - 
35 16.3 147 0.7 0.7 - - 
41 17.05 147 1.3 1.3 - - 
53 18.6 145 - - 0.8 0.7 
56 19 100 1.9 1.3 - - 
57 19.1 147 2.2 1.4 - - 
67 20.4 147 1.0 0.9 1.3 0.7 
68 20.6 147 - - 0.4 0.2 
80 22.1 85 - - 0.9 1.3 
81 22.35 147 0.7 1.0 - - 
84 23 204 - - 2.6 2.1 
116 28.1 115 0.6 0.6 - - 
136 32.1 319 1.4 1.3 - - 
137 32.4 147 1.6 1.3 - - 
143 33.7 204 2.6 1.6 - - 
151 35.1 299 1.1 0.9 - - 
156 37.8 327 1.1 0.9 - - 
166 43.4 361 0.4 0.9 0.3 0.4 
167 43.8 361 0.2 0.8 - - 
170 45.2 91 - - 0.7 0.3 
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